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 Abstract  
The treatment of 1,3-dienes with singlet oxygen (1O2) to give endoperoxides represents a potent, 
chemo- and regioselective method for the introduction of oxygen functionality. Additionally, these 
endoperoxides products can be further utilized in the synthesis of added value compounds, as well 
as complex natural products. In the thesis a new method for the synthesis of acyclic 1,3-dienes is 
presented. Furthermore, both acyclic and cyclic 1,3-dienes are used in the synthesis of natural 
products using singlet oxygen (1O2) addition as a core strategy.  
A new approach for the synthesis of range of 1,3-dienes from aryl boronic acids 2 and substituted 
propargyl alcohols 1 via a palladium catalyzed has been developed. This reaction uses a base-free, 
Suzuki-Miyaura coupling followed by an unprecedented isomerization sequence and gives a wide 
range of cyclic and acyclic of 1,3- diene compounds 4 with varying aryl groups in good isolated 
chemical yields. 
This reaction involves initial formation of an allene 3 as intermediate which then undergoes ready 
rearrangement by way of a palladium hydride intermediate, which results from the interaction of 
palladium (0) and boric acid. To ascertain mechanistic conformation of this rearrangement the 
intermediary allenes were isolated and exposed to palladium (0) and boric acid. Additionally, 
direct injection ESI-MS was utilized to observe an intermediate palladium allyl complex; which 
can only occur form the addition of palladium-hydride to the allene. Furthermore, a range of stable 
allenes were then isomerized to 1,3-dienes by using the boric acid and a palladium (0) catalytic 
system. 
 
Scheme 1: Synthesis of 1,3-dienes 
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The synthetic utility of this reaction was applied by developing a convenient route to resveratrol 
6 from 1,3-diene 5. Additionally, we then utilized the addition of singlet oxygen to 5 and were 
then able to convert the resultant endoperoxide 7 to moracin M (8). 
 
Scheme 2: Synthesis of Natural Products Resveratrol and Moracin M 
Additionally, treatment of bicyclic 1,3-dienes 9 with singlet oxygen to give bicyclic endoperoxides 
10 was examined as a method to deliver the core structure of the xanthanolide class of natural 
products. The xanthanolide skeleton, particularly xanthatin which is a potent anti-inflammatory 
natural product, contain a trans-fused ring system and can be obtained from the treatment of 10 
with a malonate nucleophile via Korn Blum DeLaMare rearrangement. Significant progress 
toward the total synthesis of xanthatin 12 was made, and we were able to obtain the advanced 
precursor 11, which is only 11-steps from 9 to xanthatin 12. 
 
Scheme 3: Synthesis of natural product xanthanolides.  
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Abbreviations 
AA Arachidonic acid 
Ac Acetyl 
aq. Aqueous 
Bn Benzyl 
br Broad 
BuLi Butyllithium 
Cat. Catalytic 
COX Cyclooxygenase 
d Doublet 
DCC N,N'-Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEPT Distortionless enhancement by polarization transfer 
DMAP 4-Dimethylaminopyridine 
DIBAL (DIBAH) (DIBAH) Diisobutylaluminum Hydride 
DIAD Diisopropyl azodicarboxylate 
Diglime Bis(2-methoxyethyl) ether 
DIPA Diisopropanolamine 
DMP Dess-Martin periodinan 
EI Electron Ionisation 
Et Ethyl 
Equiv. Equivalents 
GC-MS Gas Chromatography–Mass Spectrometry 
H Hour 
HMDS Hexamethyldisilazide 
HMPA, HMP Hexamethylphosphorictriamide 
Hz Hertz 
IR Infra-red 
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LAH Lithium aluminium hydride 
LOX Lipoxygenase 
LDA Lithium Diisopropylamide 
J Coupling Constant 
MAPH Methyl Aluminum bis(2,6- diphenyl phenoxide) 
MB Methyl blue 
MCPBA   meta-Chloroperoxybenzoic Acid 
min. Minutes 
MOM                                      Methoxymethyl 
m/z Mass to Charge Ratio 
NMR Nuclear Magnetic Resonance 
NMO N-Methylmorpholine N-oxide 
PdCl2(COD) Dichloro (1,5-cyclooctadiene) palladium(II) 
PEG 400 Poly ethylene glycol 400 
ppm Parts per million 
PPTS Pyridinium p-Toluenesulfonate   
q Quartet 
r.t. Room Temperature 
s Singlet 
T Triplet 
TBAF Tetra-n-butylammonium fluoride 
TBSOTE t-Butyldimethylsilyl trifluoromethanesulfonate 
TDA-1 Tris[2-(2-methoxyethoxy)ethyl]amine 
TBDPS t-Butyldiphenylsilyl (alcohol protection 
TBSCl t-Butyldimethylsilyl Chloride 
TMSCl Chlorotrimethylsilane 
TPAP Tetra-n-propylammonium Perruthenate 
TPP    meso-Tetraphenylporphyrin 
TBDPSCl t-Butyldiphenylsilyl Chloride 
THF Tetrahydrofuran 
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TLC Thin Layer Chromatography 
TMS Tetramethylsilane 
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1. Introduction  
1.1 Singlet Oxygen Background: 
Oxygen is one of the most important elements in life, it forms 21% of the air1 in the atmosphere, 
89% of weight of the water of rivers, seas and oceans. In addition, all living organisms utilize 
oxygen either by respiration or to produce energy. By mass, oxygen is the third most abundant 
element in the universe, after hydrogen and helium. Oxygen’s reactivity come from its unpaired 
valence electrons in an otherwise stable molecule which make it able to be a strong oxidant and 
easily reduced.  
According to the molecular orbital theory, oxygen can exist in three forms in terms of the 
configuration of antibonding electrons (figure 1).2  
 
Figure 1: MO diagram of three forms of oxygen. 
Figure 1 shows three forms of energy level of the molecule of oxygen, first 1Δg both electrons 
paired in one orbital leaving other vacant, this oxygen molecule is the more stable singlet state, 
1Ʃg+ is the second (and less stable) singlet state, 3Ʃg- triplet or regular oxygen state.  
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The first is the singlet oxygen species 1Δg form lies 94.7 kJ (7882 cm-1, 1269 nm) in energy above 
the triplet ground state. The second state 1Ʃg+ lies 158 kJ (13120 cm-1, 762 nm) in energy above 
the triplet ground state. Because of the second form state is highest energy than other so, it is less 
stable, and has very short life time compare with the first form 1Δg.,3 therefore the first form is the 
important state of singlet oxygen because it has enough time to oxygenate compounds. Also, the 
diagram shows that the first and second states are diamagnetic while the third is paramagnetic 
furthermore, they have different chemical properties.  
Singlet oxygen was produced by using photosensitization and first reported in 1964 by Foote – 
Wexler reaction for its ability to oxidize organic and biological compound or to be used in 
synthesis4. 
Although, singlet oxygen can be produced in different ways, it has become an important reaction 
in organic synthesis as it can readily undergo addition to alkenes via a number of pathways 
including [4+2]-, [2+2]- and the ene-reaction. Furthermore, because singlet oxygen can be 
generated biomimetically, the synthetic organic chemist has utilised it to imitate the natural 
reaction, the analytical chemist to count their effect in the environment, the biochemist because 
singlet oxygen can be produced from the light-harvesting chlorophyll molecules, and the physics 
to study the stability of substance and many other branch of sciences.5  
1.1.1 Singlet oxygen formation and reaction 
Singlet oxygen reaction is an oxidation reaction using excited single molecular oxygen to make 
carbon-oxygen and heteroatom-oxygen bonds.  
There are two ways to produce singlet oxygen 1O2 in solution (Scheme 4). 
Thermal process or dark singlet oxygenation (Scheme 4A).6 This route is undertaken without using 
light to form the singlet molecular of oxygen. Example of this route is using hydrogen peroxide 
with NaOCl or the use of peroxides [arene endoperoxides; hydrotrioxides; potassium 
monoperoxysulfate (KHSO5); dimethyldioxirane; ozone/heterocyclic adducts with pyrroles, 
oxazoles, and imidazoles; or triphenylphosphite ozonide (cyclo-(PhO)3PO3)].
6 
12 | P a g e  
 
 
The photosynthesis production of the singlet oxygen (scheme 4B).4 This route is done by using 
visible light, oxygen and a sensitizer. Because this route uses natural source of oxygen and readily 
available visible light it is attractive to the organic chemists, as it is biomimetic as well as green;  
A           H2O2       +    NaOCl   →    1O2   + NaCl + H2O 
B           Sens(cat.)         +   hv       →    Sens*   +  3O2  →    1O2  + Sens(cat.) 
                                         Scheme 4: Generation of Singlet Oxygen 
A sensitizer is usually an organic dye that has a large de-localized π systems and can be excited 
by visible light first, this can ionize the oxygen molecule or form singlet oxygen (type II scheme 
5).  
 
Scheme 5: Type I and II photosensitized oxidation 
The singlet oxygen process is accompanied with trace amount of oxygen radical (type I) which is 
responsible for photo-bleaching when its exposed for irradiation for extended time periods in a 
homogeneous solution (scheme 5). 
With reference of singlet oxygen reaction experiments, it was noted that the rate of the reaction 
increases at low temperature whereas, halogenated and deuterated solvents make the reaction 
slower but with increased yields.7 Table 1 shows the life time of singlet oxygen in different 
solvents. 
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Table 1: life time of singlet oxygen in different solvents8 
Solvent 
 
1O2-Lifetime 
(μs) 
Solvent 
 
1O2-Lifetime 
(μs) 
H2O 3.1 D2O 68 
CH3OH 9.1 CD3OD 270 
C6H6 30 C6D6 681 
C6F14 68000 C6F6 21000 
(CH3)2CO 51 (CD3)2CO 992 
CHCl3 229 CDCl3 7000 
C6H5CH3 29 air 86000 
CH3CN 61 CFCl3 1000 
CCl4 59000 CH2Cl2 101 
Table 1 gives a comparison between deuterated and non-deuterated solvents and their singlet 
oxygen life time in addition, fluorinated solvent and CCl4 are also included. There is a factor called 
vibrational frequencies related with the electronic transition energy between the singlet oxygen 
and the solvent. The high value of vibrational frequencies is found in molecules having hydrogen 
atoms bonded strongly to another atom such as O-H, S-H, N-H, C-H. According to this information 
H2O has a high vibrational frequency and very low singlet oxygen life time and is a good quencher. 
Whereas D2O has 20 times more life time. The same situation occurs when we exchange C-H with 
C-F. Also CCl4 have long life time can be described by the low vibrational frequencies and low 
quenching rate. 8-9   
, 13s, tetraphenyl porphyrin (TPP) sensitizers used in organic synthesiThere are three common 
10, 5 (figure 2). 15and methylene blue (MB)  14rose Bengal (RB)  
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Figure 2: structures of sensitizer 
The wavelength range of visible light is between 380 – 750 nm, and every sensitizer dye has a 
specific range of wavelength in which it can be excited. Methylene blue has strong absorption 
between 550 – 700 nm, rose Bengal absorbs in the green region of visible light 480 – 550 nm, 
whereas tetraphenyl porphyrin has the ability to absorb several wavelengths from ultraviolet to 
     11visible light. 
Singlet oxygen reacts with a range of double bond compounds to give various oxygenated 
hydrocarbons. Scheme 65,12-13 shows that 1O2 can form endoperoxide 16 when added to 1,3-diene 
via a [2+4]-cycloaddition, dioxetane 17 through a [2+2]-cycloaddition, hydroperoxides 18 and 19 
when reacted with alkenes and phenols, sulfoxides 20 when reacted with sulfides and phosphine 
oxides 21 when reacted with phosphines.     
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Scheme 6: Synthetic utility of 1O2 for generating oxygenated hydrocarbon5,12 -13  
Two classes of singlet oxygen reaction are generally important in organic chemistry, firstly 
addition to alkenes similar to the Alder-Ene reaction, giving allylic hydroperoxides and [2+2]-
cycloaddition to form dioxetanes. Secondly, [4+2]-addition to the 1,3-diene giving endoperoxides 
similar to the Diels-Alder reaction. Other classes of oxidation of certain heteroatoms by singlet 
oxygen are of somewhat less in generality. 
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Many reports have been published about study the mechanism of [2+2]-addition concerned about 
the intermediate and the relation of the stereochemistry of the substance with the rate of the 
reaction. In addition, the selectivity of the reaction. In general, three intermediates have been 
proposed per-epoxide A, a diradical and zwitterionic intermediates B, and transition state C (figure 
3). 
 
Figure 3: Intermediates of ene reaction mechanism 
Using computational and experimental research, one result of B3LYP study on cis-2-butene 
revealed that the reaction contains a valley–ridge inflection (VRI). Two transition state have a 
relation with VRI to give allylic hydroperoxide products. The VRI give evidence of the peroxide 
species (scheme 7).4   
 
Scheme 7: Mechanism of ene reaction 
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At this point we can say that ene-addition has polar transition state 23 and 25 and could prefer 
polar protic solvents compared to the [4+2]-cycloaddition. An investigate done by Griesbeck in 
2014 to test the effect of solvent and whether preference for the ene reaction or [4+2]-cycloaddition 
to substituted 1,3 dienes while he study the gem effect to functionalize dienes.14   
 
Scheme 8: solvent effect 
Scheme 8 shows the reaction of singlet oxygen with diene 28 forming hydroperoxide 29 and 
endoperoxide 30. When CCl4 was used as a solvent in the reaction gave 46% of the hydroperoxide 
29 and 56% of the endoperoxide 30. The result show that the best solvent to push the reaction 
toward 29 was ethanol while the best solvent to form 30 was CCl4 and CHCl3, respectively. This 
result can be used as evidence that [4+2]-singlet oxygen cycloaddition prefers a nonpolar solvent 
whereas the ene-addition prefers polar solvent. Furthermore, it is not only solvent have an effect, 
the stereochemistry and the substituent groups play a pivotal role in addition of singlet oxygen in 
the reaction pathway. 
 The mechanism of [4+2]-cycloaddition was assumed to follow the classical Diels Alder reaction 
(scheme 9). The first encounter between the excited singlet oxygen and the cis-diene 31 leads to 
exciplex formation. This mechanism was reversible and the product could undergo retro-[4+2] 
(scheme 9). This mechanism occurs as a suprafacial process (the bond forming interaction occurs 
on the same face of a π-system).14 
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Scheme 9: [4 + 2] Mechanism 
Endoperoxide are also known as 1,4-epiperoxides or dioxapropellanes. Endoperoxides are a six-
member rings and are one of the most important products of the cycloaddition [4+2]-addition of 
singlet oxygen to the 1,3-dienes or arenes. These compounds have chemical and biological activity 
so, it can have reacted easily to give many important compounds natural and unnatural products.15 
Scheme 10 shows some general reaction of endoperoxide 33. Exposing endoperoxide 33 to 
reduction conditions (palladium or nickel with two moles of hydrogen) affords 1,4-diols 34 
whereas, exposing it to one mole of hydrogen with nickel will give the 1,4-diol with double bond 
intact 35. When one mole of hydrogen with palladium is used chemoselectice reduction of the 
double bond is observed and the endoperoxide stays intact to give 36. Treatment with ozone and 
peroxyacetic acid will furnish a peroxidic dicarboxylic acid 38 which decomposes in the presence 
of palladium acetate to 1,1-dimethylacetonyl acetone 39.16 Furthermore, addition of ethyl or 
methyl malonate in presence of sodium alkoxide to endoperoxide will afford bicyclic 
butyrolactone 40, via a initial Korn Blum DeLaMare rearrangement by using cyclohepta or 
cycloocta dienes.17 In addition, Kimber and co-worker reported in 2018 that dehydration of 
endoperoxide 41 can be undertaken by applying  Appel reaction conditions to afford the furan 42 
(scheme 11).18- 19  
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          Scheme 10: Reactions of endoperoxides  
 
Scheme 11: Dehydration of endoperoxide 
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Endoperoxides are formed in various organisms from plants to humans and bacteria. For example, 
artemisinin 43 is a unique sesquiterpene lactone with an unusual endoperoxide structure extracted 
from the Chinese medicinal plant Artemisia annua, and is used as an effective anti-malarial drug, 
20 in addition steperoxide A 44 was recently extracted from higher fungi ( mushroom)21 and 
reported in 2010 by Liu and co-worker (figure 4).  
 
Figure 4: Natural endoperoxide. 
However, the synthesis of suitably substituted endoperoxides is predicated on access to the 1,3-
diene precursors. Therefore, in the next section we will cover recent examples of 1,3-diene 
synthesise from the literature. 
1.2. Review of the synthesis of 1,3-Dienes. 
Reactions that create a new carbon bonds are an important and vital area of organic synthesis. Of 
interest within the synthesis of 1,3-dienes, as they are key precursors in a number staple chemical 
transformation, such as the Diels-Alder reaction and the addition of 1O2 to give endoperoxides. 
There are a numerous of methods for the synthesis of 1,3-dienes and all could not possibly be 
covered in full here, and we direct the reader some excellent reviews;22 however, the next section 
will catalogue some of the recent advances in their synthesis. 
In 1985 Katz and co-worker23 reported  a conjugated diene can be simply prepared by enyne 
metathesis by bond reorganization24 of alkene and an alkyne to form 1,3-dienes, and this could be 
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accomplished in both intra- and intermolecularly (for cycloisomerization can provide five-
membered dienes)25 in presence of metal carbene catalyst (scheme 12).26  
 
Scheme 12: Enyne metathesis 
Conjugated 1,3-dienes can be prepared by cross-coupling reactions. For example, a Heck reaction 
was used to form range of 1,3-dienes in 2008 by Santelli and co-workers27 by vinylation of vinyl 
bromides 50 using [Pd(ƞ3-C3H5) Cl]2 / cis,cis,cis-1,2,3,4-tetrakis [(diphenylphosphino) methyl] 
cyclopentane (Tedicyp) as the catalyst with a base in DMF (scheme 13).  
 
Scheme 13: Vinylation of vinyl bromides. 
In 2006, a Heck reaction was used to prepare 1,3-dienes 55 by cross coupling of nonactive vinyl 
tosylates or phosphate 53 with an alkene carrying electron-withdrawing groups (electron-
deficient alkenes) 54 in the presence of palladium complex [PdCl2(cod)] (scheme 14).
28 
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Scheme 14: Heck coupling with a nonactivated vinyl tosylate 
In 2013, White and co-workers29 used oxidative Heck reaction (using PdII instead of Pd0 and 
boronic acids or boronic esters instead of halides) for formation of complex 1,3-dienes and 
polyenes 58 in good yields and excellent selectivity from nonactive terminal olefins 56 with vinyl 
boronic esters or acids 57 in the presence of PdII/sulfoxide as a catalyst in DMF and 2,6-Me2-BQ 
(scheme 15). 
                                  
Scheme 15: oxidative Heck reaction to 1,3-dienes 
In 2014 Wang and co-workers30 reported an oxidative cross-coupling palladium-catalyzed of vinyl 
boronic acids 60 and cyclic α-diazo carbonyl compounds 59 in presence of a base and 
benzoquinone to furnish a conjugated carbonyl 1,3-dienes such as 61 in poor to good isolated 
yields (scheme 16). 
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Scheme 16: Oxidative cross-coupling of vinyl boronic acids 
In 2005 Molander and co-workers31 reported a stereoselective synthesis of conjugated 1,3-dienes 
via a Suzuki-Miyaura Cross-Coupling of potassium alkenyl trifluoroborates 62 with alkenyl 
bromides 63 in presence of palladium catalyst (scheme 17). 
 
Scheme 17: Synthesis of 1,3-dienes via a Suzuki-Miyaura reaction. 
In addition, conjugated 1,3-dienes can be prepared by olefination aldehydes. In 2011 Somfai and 
co-workers prepared 1,3-dienes from base free addition of 1,3-bis(silyl) propenes to aldehydes in 
presence of a Lewis Acid as a promoting agent in poor to excellent yield (scheme 18).32 
 
Scheme 18: Olefination of aldehydes to 1,3-dienes 
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In 2012, Pospisil and co-workers developed a modification of Julia–Kocienski olefination reaction 
by using cation-specific chelating agents to create a new double bond from the reaction of phenyl 
sulfones with aldehydes (scheme 19).33  
 
Scheme 19: Modification of Julia–Kocienski olefination reaction 
Also, He and co-workers in 2010 reported a base free salt Wittig olefination between allylic 
carbonate and aldehydes in presence of triphenyl or butyl phosphine (scheme 20).34 
 
Scheme 20: Base free salt Wittig olefination 
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1.3. Synthesis of natural product compounds 
1.3.1 Moracin M 
1.3.1.1. Background 
Moracin M is a benzofuran isolated from the root bark of Morus alba also known as white 
mulberry. It is a fast-growing, small to medium-sized mulberry tree which grows to 10–20 m tall, 
in the north of China. The root bark of the plant was used widely in traditional Chinese medicine 
as anti-asthmatic and anti-tussive.35 
Moracin M is one of 26 benzofuran compounds (moracin A-Z) extracted from Moraceae family 
plants. Kyeong Lee36 in 2015 his review illustrated the structure of the moracins (A – Z) and their 
structural relationships. In the center of the cycle the structure of 2-phenyl benzofuran compound 
as the basic scaffold of moracins compounds is shown (figure 5). Also, the figure shows there are 
four general structure starting from moracin A to moracin D through to moracin M to moracin P. 
 
Figure 5: Representation of all the moracin36 
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1.3.1.2. Isolation of Moracin M    
Phytoalexins are a large group of chemical compounds including several classes such as 
terpenoids, glycosteroids and alkaloids. The plants use phytoalexins as a medicine against 
infection in case of microbial infection. An extraction of infected mulberry (Morus alba linne) led 
to the identification and isolation of moracin A as a first phytoalexin found in the family of 
Moraceae.37  There are several reports on the extraction of moracin compounds (A- Z) using 
different solvents (methanol, acetone, ethanol) to extract different infected or uninfected tissue 
from diverse mulberry plants.   
For example, to extract moracin M, 1 kg of dried powder of root bark of Morus alba plant was 
extracted with 95% ethanol for 48 hours, followed by removal of the solvent under reduced 
pressure. The residue was then suspended in water and extracted with petroleum ether first then 
further extracted again with ethyl acetate. Then ethyl acetate layer was dried, the solvent removed 
under reduced pressure, and finally column chromatography was used to purify the crude, to get 
just 25 mg of moracin M (8) and 10 mg of moracin C (74) (figure 6).38 
 
Figure 6: Chemical structure of moracin M and moracin C 
1.3.1.3. Biological activity of Moracin M 
Natural product compounds have been used as traditional medicine for the treatment of various 
diseases and illnesses. Diseases and illnesses can classify more precisely than before, so study of 
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the biological activity of compounds is important to find a relation between the structure and the 
biological activity of natural product compounds. 
1. Anti-microbial activity 
Moracin M has weak activity against nine kinds of bacteria in a study of 2005, where three  
moracin compounds C, M, and P were examined (table 2).39 
* (MIC, µg/ml) 75and  8, ial activity of the compounds 74AntimicrobTable 2:  
Comp. MSSA 
FDA209 
MSSA 
smith 
MRSA 
K3 
MRSA 
ST28 
M. 
luteus 
B. 
subtilis 
E. 
Coli 
K. 
pneumoniae 
P. 
aeruginosa 
74 (C) 6.25 12.5 12.5 12.5 12.5 3.13 >100 25 >100 
8 (M) 12.5 25 25 25 25 100 >100 100 >100 
75 (P) 50 100 100 100 100 100 >100 100 >100 
AMOX 0.10 0.10 25 50 0.025 0.10 3.13 100 N100 
VAN 0.39 1.56 1.56 0.78 1.56 0.39 N100 N100 N100 
 
* MRSA is Methicillin resistant St. aureus, MSSA is methicillin sensitive St. aureus 
Micrococcus (M.), Bacillus (B.), Escherichia (E.), Klebsiella (K.), Pseudomonas (P.). Positive 
controls used were amoxicillin (AMOX) and vancomycin (VAN). 
Table 2 shows three moracins compounds (C, M, P) with two antibiotics as a reference against 
nine kinds of bacteria. The numbers in the table represent the minimum inhibitory concentration 
(MIC) so, the lowest number is the better inhibiter against bacteria whereas, the highest number is 
the worst inhibiter. According to this information can easily see that the best inhibiter is moracin 
C and poorest inhibitor is moracin P; moracin M demonstrated a weak activity with comparisons 
of other antibiotics. If we compare the structures of these three compounds we can presume that 
the isopentenyl group in para position of the 2-aryl in moracin C is the significance part for 
antimicrobial activity. 
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Later in 2009 there was a study testing six moracin compunds (Q, T, R, U, C and M,) (figure 7) 
against the antibiotic gentamycin as a reference. This study used firstly MIC (minimum inhibition 
concentration) and secondly MMC (minimum microbial concentration) against three group of 
microorganisms gram-negative bacteria, gram-positive bacteria and fungi.40  
In this study, the best inhibition is moracin T showing MIC (5 µg/ml) against Escherichia coli, 
Shigella dysenteriae, Pseudomonas aeruginosa, from gram-negative bacteria and Salmonella 
typhi, Bacillus cereus from gram-positive bacteria. If we compare the result of moracin T with the 
reference antibiotic gentamycin we found that moracin T gave MIC (139 µg/ml) and (39 µg/ml) 
against: Citrobacter freundii and Klebsiella pneumoniae respectively while, gentamycin gave MIC 
(5 and 10 µg/ml) respectively. Furthermore, moracin T performed better than gentamycin against 
Candida albicans and Microsporum audouinii fungi. Moracin M showed weak activity against 
macrobacteria and fungi (Table 3). 
 Table 3: Antimicrobial activity of various moracins in minimal inhibition concentrations 
(MIC) (µg/ml). * 
Comp. Gram-negative bacteria Gram- positive bacteria Fungi 
Cf Ec Sd Pa Kp St Bc Sa Sf Ca Ma 
74 (C) 156 39 5 10 312 10 78 78 39 78 78 
8 (M) 312 78 78 156 312 78 - - 78 - 78 
67 (Q) - 156 - 625 156 - - 156 - 156 - 
77 (R) - 78 78 10 312 156 156 312 156 - 312 
78 (T) 156 5 5 5 39 5 5 10 10 10 39 
79 (U) 312 10 78 625 156 39 10 156 20 312 78 
Gentamycin 5 5 5 5 10 5 5 10 10 nt nt 
*(-): MIC ˃ (625 µg/ml); (nt) not tested; a Microorganisms: Cf: Citrobacter freundii, Ec: 
Escherichia coli, Sd: Shigella dysenteriae; Pa: Pseudomonas aeruginosa, Kp: Klebsiella 
pneumoniae, St: Salmonella typhi, Bc: Bacillus cereus, Sa: Staphylococcus aureus, Sf: 
Streptococcus faecalis, Ca: Candida albicans, Ma: Microsporum audouinii. 
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Figure 7: Structure of Moracin Q, T, R, U, C, M, S 
To conclude, the relation of activity of moracin T with his structure, moracin T has an additional 
methoxy groups and isopentenyl group attached to benzofuran unit so, existence of ether and 
isopentenyl groups in addition of three hydroxyl groups could be make the moracins compounds 
more active against macrobacteria and fungi. Figure 7 shows three compounds of moracins (M, C, 
T) their functional groups colored red to illustrate the increase of activity from weak moracin M 
to medium moracin C to strong moracin T with the relation of their structure against 
microorganisms. 
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2. Anticancer Activity  
Hypoxia is a low level of oxygen in tissues of human bodies, and this phenomenon can promote 
tumor progression. There is a factor called hypoxia inducible factor HIF-1, wich is a transcription 
factor that will respond to a decrease in available oxygen in the cellular environment. In normoxia 
there are two subunit HIF-1α and HIF-1β whereas under hypoxia condition these two subunits 
dimerize.41 
A study in 2009 tested a number of moracins compounds and their in vitro inhibition activity 
against HIF-1 transcriptional activity. Moracin O, P, Q show a potent inhibitor effect as a hypoxia 
response element HRE (hypoxia response elements) without cytotoxicity, whereas moracin M 
showed no activity (table 4) .42 
Table 4: IC50 Values (μM) of moracins O, P, Q, M on the Inhibition of HIF-1 Activity, 
VEGFa Secretion, and Cell Viability 
Compound HIF-1 IC50 nM VEGF IC50 µM Cell viability 
moracin O (80) 0.14b ± 0.02 7.22 ± 2.13 >30 µM 
moracin P (75) 0.65 ± 0.13 10.6 ± 2.46 >30 µM 
moracin Q (76) 5.88 ± 0.54 9.28 ± 1.34 >30 µM 
moracin M (8) nab na >30 µM 
a: vascular endothelial growth factor is a part of system to restore the oxygen. b: na = not active. 
The three active compounds moracin (O, P and Q) have cyclic oxygen ring fused to benzofuran 
group with two methyl group while moracin M does not. 
3. Anti-diabetes 
Hypoglycemic effects (low blood sugar) occurs when the blood sugar (glucose) fall below the 
normal range level. A study in 2009 extracted moracin M from a natural source (root bark of Morus 
alba L.) and tested in hypoglycemic effects on alloxan-diabetic mice. This study used gliclazide 
as a reference. This is used to increase the amount of the insulin in the body. Table 5 shows that 
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moracin M in a dose of 100 mg/kg can make the fasting blood glucose level have a decreasing 
tendency.43 
Table 5: Effect of moracin M on plasma glucose of alloxan-diabetic mice.  
Comp. Dose (mg/kg) Number of mice Fasting blood 
glucose 
levels (mmol/L) 
Moracin M (8) 50 
100 
10 
10 
20.08±5.86 
18.52±6.61 
Gliclazide 50 10 15.63±5.90 
4. Phosphodiesterase inhibitors 
Phosphodiesterase (PDEs) is an enzyme that breaks a phosphodiester bond that makes up the 
backbone of the strands of nucleic acid. Inhibitors of PDEs can prolong or enhance the effects of 
physiological processes mediated by cyclic nucleotides 3,5-adenine monophosphate cAMP or 
cyclic guanosine monophosphate cGMP by inhibition of their degradation by PDEs. The 
phosphodiesterase-4 (PDE4) enzymes hydrolyzing cAMP to 5-AMP. It performs as key regulators 
in many biological processes such as cell division, smooth muscle contractility and platelet 
aggregation. Phosphodiesterase-4 (PDE4) has been known to be a promising mark for the 
treatment of asthma.44- 45 
In 2012 a study tested moracin M (8) and moracin C (74) against four kinds of PDEs using 
roflumilast as a reference which is used as a drug that acts as a selective, long-acting inhibitor of 
the enzyme phosphodiesterase (table 6).38 
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Table 6: Phosphodiesterase inhibitor activity of 74 and 8. 
Comp. IC50 in µM 
PDE4D2 PDE4B2 PDE5A1 PDE9A2 
Moracin C (74) 26.0 18.1 >50 >100 
Moracin M (8) 2.9 4.5 >40 >100 
roflumilast 0.46 0.67   
 Table 6 shows in vitro inhibition of moracin M are 2.9, 4.5, >40, >100 against PDE4D2, PDE4B2, 
PDE5A1, PDE9A2, respectively. Comparing these results with the reference roflumilast leads to 
the conclusion that Moracin M has strong inhibition against PDE4D2 and PDE4B2 while, moracin 
C gives a moderate inhibition activity. 
5. Anti-inflammatory activity 
Anti-inflammatory agents have the ability to reduce or remove the swelling of inflammation. 
Inflammation is a biological response to something harmful or irritating to the body, so 
inflammation is a part of immunity system trying to heal the body. In general the inflammatory 
pathways consist of four steps starting with inducers for example tissue damage or infection then, 
sensors that discover the damage or infection then, mediators that induced by the sensors for 
example plasma proteases or iNOS production and finally, the target tissues that affected by 
inflammatory mediators.46-47  
A study in 2010 tested anti-inflammatory activity of moracin M and C against the release of β-
glucuronidase from rat PMNs induced by PAF. This study used ginkgolide B as a reference 
positive control. The result showed that both moracin M and C exhibit a strong activity against the 
target substance (table 7).48 
 
 
 
33 | P a g e  
 
 
Table 7: anti-inflammatory activity for moracin M and Ca 
Comp. Inhibition ratios 
Moracin C (74) 100% 
Moracin M (8) 54% 
Ginkgolide B  58% 
a: Compounds were active with inhibitory ratios more than 50% at a concentration of 10−5 M. 
A recent study in 2018 tested the effect of moracin M (8) to inhibit the lipopolysaccharide (LPS) 
by treated nucleus pulposus cell (NPGs) in intervertebral disc. LPS is a large molecule consisting 
of lipid and poly polysaccharide and is found in the outer membrane of gram negative bacteria and 
this molecule responsible for inducing inflammation. The study found that moracin M (8) can 
significantly inhibit LPS-induced inflammation at different concentration.49 
1.3.1.4. Previous Synthesis of Moracin M 
As we know the family of moracins compounds include 26 isolated compounds (A to Z). Moracin 
M (8) structure is regarded as a base for the synthesis of other family compounds, and therefore, 
there are several reported total synthesise of moracin M. 
In 1987 moracin M (8) was synthesised as basic skeleton in overall 44%, so it could be readily 
modified to give another moracin compounds. The key step of this approach was a palladium 
catalyzed cross coupling reaction between 81 (prepared by 4 steps to form unstable oil used 
directly without purification) and 82 (prepared by 2 steps in 57%) to give the 2-phenylbenzofuran 
substituted compound 54 in a good yield. then moracin (M 8) can be formed by deprotection of 83 
with tetra butyl ammonium fluoride in THF (scheme 21).36,50  
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Scheme 21: Synthesis of moracin M (39) by palladium cross coupling reaction 
In 2005 moracin M (8) was prepared by conversion of 3-phenylcoumarin 84 into 2- 
phenylbezofuran 86 through the diol compound 85 as a key reaction. The loss of the carbon unit 
was achieved by reducing the coumarin compound 84 by LiAlH4 to 85 then oxidized it using DDQ 
to give 86. The final step was the deprotection of the hydroxy groups to get moracin M (8) (scheme 
22).51 
 
Scheme 22: Synthesis of moracin M in 2005. 
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In 2011 moracin M (8) was prepared via singlet oxygen reaction. In this route trans-resveratrol 6 
was used as starting material. The oxidation of resveratrol with 1O2 gave the desired endoperoxide 
87, as well as significant amounts of the [2+2]-addition product that subsequently fragmented to 
give 89 and 90. This is presumably due to the electron rich double-bond within 6. The [4+2]-
addition product 87 then tautomerize to the observed endoperoxide 88. Finally dehydration of 88 
accomplished by heating in CD3CN at 80 ºC leading to the formation moracin M (8) overall yield 
23% (scheme 23).52  
 
Scheme 23: Synthesis of moracin M in 2011. 
In 2012 moracin M (8) was prepared in 2-steps. Firstly, the regioselective reaction between phenol 
91 and α-bromoketone 92 in presence of neutral alumina (Al2O3 + K2CO3) furnished the 2-
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substituted benzofuran 93. Deprotection of the ether groups by BBr3 then gave moracin M (8) 
overall yield 7% (scheme 24).53 
 
Scheme 24: Synthesis of moracin M (44) in 2012 
In 2014 moracin M (8) was prepared in overall yield 9% by using a palladium catalyzed 
Sonogashira cross coupling reaction. The reaction started with acetylation of 94 to reduce the 
electron density of the halogen in 95 to accelerate the cross-coupling reaction with aryl acetylene 
96, giving 97 in 63%. The deacetylation of 97 under base condition led to the formation of the 2-
arylbenzofuran 93, and then demethylation of the resulting compound gave moracin M (8) in 25% 
(scheme 25).54 
 
Scheme 25: Using Sonogashira palladium cross coupling in synthesis Moracin M 
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In 2015 moracin M (8) was prepared from 3-carbonyl-2-arylbenzofuran 98 which was prepared 
from the (E)-2-(2-bromophenyl)-3-phenylacrylic acid 97 by reaction with copper acetate catalyst. 
The decarboxylation of 98 afforded 93 which was demethylated using AlCl3 to give moracin M 
(8) in overall yield 73% (scheme 26).55 
 
Scheme 26: Moracin M synthesis from 3-substituted 2 phenylbenzofuran. 
In 2016 Chen et al. prepared Moracin M (8) overall yield 37% by optimized a coupling/cyclization 
reaction between ortho-indophenols 99 ( prepared in 50%) and terminal alkynes 100 with copper 
(I) as a catalyst to furnish the 2-arylbenzofurans 86 in 80% yield; 86 was subsequently deprotected 
in 93% to give moracin M (8) (scheme 27).56 
 
Scheme 27: Synthesis of moracin M 
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According to the overall yields of previous synthesis ways of moracin M, Yong Zou  and co-
workers was prepared moracin M in the better overall yields 73%, whereas in 2012 was prepared 
in 7%, other ways were located between these two percentage. 
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1.4.Synthesis of Xanthanolides 
1.4.1. Introduction  
Sesquiterpenoids are a class of terpenes that consist of three isoprene units and often have 
the molecular formula C15H24 and form a major collection of natural terpenoids, that cover 
thousands of compounds and with over 100 skeletal varieties. Large numbers of sesquiterpenoids 
exist in plants in their lactonised form. Sesquiterpenoid lactones are mainly specific to the 
Asteraceae family, but can exist occasionally in other plant families. They have been labeled as 
the energetic workings of several medicinal plants used in traditional medicine and are known to 
express a wide variety of biological and pharmacological activities, such as anti-inflammatory, 
cytotoxic, anti-proliferative and anti-microbial activities, and special effects on the central nervous 
and cardiovascular systems. Furthermore, some of them have allergenic potency57,58,59. 
The xanthanolides represent a large class (120+ members) of sesquiterpenoid natural product that 
display a diverse range of biological profiles and they commonly contain cis- or trans-fused 
butyrolactones show in figure 8. Xanthanolides are bicyclic sesquiterpene lactones, in which a 
five-membered ɤ-butyrolactone ring is fused to a seven membered carbocycle. There are around 
101 natural xanthanolides compounds and most of them follow the monomeric form, but dimeric 
forms do exist.60 Their structures vary in term of the number and positions of their oxygen 
functions and the stereochemistry at C-7 and C-8. Large numbers of them have a side chain for 
four carbons long at C-1, that can be saturated or unsaturated at positions C-2 and C-3. This chain 
is often substituted with one or two functional groups, mostly keto and/or hydroxyl groups, as well 
as an acetyl moiety.60       
                                                                                                                              
Figure 8: Xanthanolide skeleton. 
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Xanthanolides occur in only a few species of the Asteraceae family. In the middle of the last 
century the first isolation of a xanthanolides resulted in the isolation of xanthatin and xanthainin 
from the aerial part of Xanthium pennsylvanicum61. Later, these compounds have successively 
been isolated by several research groups from diverse plants, e.g. xanthinin from Xanthium 
orientale and Xanthium italicum and xanthatin from Pulicaria crispa, Xanthium italicum, 
Xanthium orientale, Xanthium spinosum and Xanthium strumarium.62 The richest source of 
xanthanolides is Xanthium strumarium; many groups have considered this plant and isolated 26 
xanthanolides thus far (figure 9).60 
 
Figure 9: Xanthanolides. 
1.4.2.Biological activity of xanthanolides 
The structure–activity correlation studies of xanthanolides have shown that the activities are 
referred chemically by α, β-unsaturated carbonyl structures, for example an α-methylene-ɤ-
lactone, an α, β -unsaturated cyclopentenone or a conjugated ester. These kinds of compounds 
react with nucleophiles, particularly cysteine sulfhydryl groups, by a Michael-addition. The thiol 
group, for instance cysteine residues in proteins, seem to be the primary targets of sesquiterpene 
lactones, inhibiting a diversity of cellular functions, which directs the cells into apoptosis. 
Moreover, DNA has also been shown to be a target molecule of sesquiterpene lactones; therefore, 
DNA alkylation is a potential molecular basis of cytotoxicity for these compounds.63 The variances 
in activity between lactones compounds maybe due to the different numbers of alkylating 
structural elements. On the other hand, other factors, such as lipophilicity, the molecular geometry 
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and the chemical environment or the target sulfhydryl, may also effect the activity of 
xanthanolides.64-65 
1. Anti-inflammatory activity 
In 2008, Yoon isolated xanthatin, xanthinosin, obtained from the ethyl acetate extract of X. 
strumarium as inhibitors of NO production in LPS-activated microglial BV-2 cells (this is a type 
of cell that are the resident macrophages of the brain and spinal cord, and thus act as the first and 
main form of active immune defense in the central nervous system). The a-methylene–α-lactone 
ring was recognized as the crucial moiety for their biological activity. 
They impact their activity through the inhibition of I-kB-α degradation, NF-jB activation, and 
subsequent suppression of iNOS and COX-2 expression. These results imply that X. strumarium 
may be useful for the treatment of neuro-inflammatory diseases through reduce regulation of 
662.-such inflammatory enzymes as iNOS and COX 
2. Anti –Cancer activity 
Because many herbal medicines are sources of potential drugs for cancer therapy and therefore 
significant research has been done to find the active substituents. These researches showed that 
xanthatin (figure 9) had significant inhibitory effects on tumor proliferation and could promote 
apoptosis in B16-F10 cells (cells used for tumor formation) both in vitro and in vivo (figure 10). 
This study used Taxol, the well-known anti-cancer agent, as the positive control Taxol has been 
commonly known as an antitumor component from the extract of old Chinese medicine, which has 
great medicinal significance. The stereochemistry of chiral centers for xanthatin 12 was confirmed 
by using NOESY experiment and 1H NMR spectroscopy data (figure 9).67 
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Figure 10. Cytotoxic effects of xanthatin on melanoma B16-F10 cell proliferation. Data are 
presented in three independent experiments. Significance: *p < 0.05, **p < 0.01, ***p < 
0.001 vs. the negative control 
Figure 10 shows the effect of xanthatin in deferent concentration to reduce the cell viability of 
melanoma cell after 12 and 24 hours by using Taxol as a reference. The results show that xanthatin 
gives a more potent activity than Taxol in all concentrations. For example, at (40 µM) of xanthatin 
the cell viability was 32% after 12 hours and 18% after 24 hours whereas, Taxol shows 35% and 
17%, respectively.  
3. Antimicrobial activity 
Most xanthanolid compounds show significant activity against the Gram-positive Bacterium 
Staphylococcus aureus, Candida albicans, Candida glabrata and Aspergillus fumigatus, 
antifungal activity. It has also shown anti-malarial activity against the chloroquine-resistant 
Plasmodium falciparum strain K1, Trypanosoma brucei rhodesiense and Leishmania donovani.68, 
60 
4. Antitumor activity  
The chloroform extracts of the leaves of Xanthium italicum underwent bioassay-guided 
fractionation and the isolated xanthanolides compounds were then assessed for their 
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antiproliferative activity against human cervix adenocarcinoma (HeLa), skin carcinoma (A431) 
and breast adenocarcinoma (MCF7) cells. All of them displayed tumour cell growth-inhibitory 
activities. These result showed that the most active compound was xanthatin.69  
1.4.3 Previous Synthesis of Xanthanolides 
The amount of research activity concerning α-substituted-γ-butyrolactones and xanthanolides has 
increased dramatically in recent years. A review of xanthanolides synthesis show that the earliest 
total synthesis of xanthanolides was by Evans and Morken in 200570 when they prepared 11, 13-
dihydroxanthatin whereas, sundiversifolide first prepared by Shishido and co-worker 2007.71 After 
that Shindo and co-worker in 201072 and 201373 reported formal synthesis converging with a key 
intermediate of Shindo and co-workers in 2012.74 This is a summary of recent routes followed. 
1. Asymmetric Synthesis of (-)-Dihydroxanthatin by the Stereoselective Oshima-Utimoto 
Reaction. 
In 2005 Evans and Morken70 used the catalytic stereoselective Oshima-Utimoto reaction to 
construct the five-membered oxacycles from simple starting materials and this was employed for 
the preparation of the lactone group in the asymmetric synthesis of (-)-11α,13-dihydroxanthatin. 
The allylic alcohol 103 was converted to tetrahydrofuran 104 by the catalytic Oshima-Utimoto 
reaction (scheme 28). Compound 105 was produced after seven steps includes homologation by a 
hydroboration/oxidation/olefination sequence. Molecular modeling (MM2) recommended that the 
favorite alkylation product might be better accessed from a substrate with a minimal dihedral angle 
between the C-4 and C-5 substituents on the tetrahydrofuran, and consequently, the alkylation was 
postponed until after ring closing metathesis 107. Finally, cross metathesis with methyl vinyl 
ketone completed the synthesis by affording 108 in 66% yield. In this route 108 was prepared by 
19 steps in 1% overall yield. 
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Scheme 28: Synthesis of Xanthanolides. 
2. Total Synthesis of (+)-Sundiversifolide.71  
In 2007 Shindo and his group reported the first enantioselective total synthesis of (+)-
sundiversifolide starting with 4-pental 109 to prepare compound 111 by reacting compound 110 
under Aldol conditions (scheme 29). The diene 111 was used to constructed 112 through a ring-
closing metathesis reaction (RCM). The bicyclic ketone 113 afforded, via Claisen-type [3,3]-
sigmatropic rearrangement, 112 followed by an iodo-lactonization reaction. Finally, (+)-
sundiversifolide 114 was produced by Wittig-type olefination reduction sequence reaction of 
ketone 113. In this route the target 114 was prepared by 15 steps in 41% in overall yield. 
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Scheme 29: Synthesis of (+)-Sundiversifolid. 
3. By Wagner–Meerwein-type dyotropic rearrangement of β-lactones.74 
A key step of this suggested preparation was a rearrangement (115 to 116), which involves 
concurrent migration of two vicinal σ-bonds (one C-O bond and one C-C bond), was used to 
produce the ring enlarged γ-butyrolactones product. This method was applied in a well-organized 
preparation of many xanthanolide natural products. Scheme 30 shows the synthesis of a number 
of xanthane-type sesquiterpenoides involving the intermediate 116. The desired compound was 
then obtained by the EtAlCl2-mediated dyotropic rearrangement of 115. The high chemo-, regio- 
and stereoselectivity of this key transformation can be rationalized by considering the transition 
state TS-2 (scheme 30). The intermediate was converted to xanthatin 12 and 11,13-
dihydroxanthatin 108 in 2- and 3-steps, respectively. It’s useful to note that this route of synthesis 
just delivered 116 in 25% as overall yield in 4 steps without synthesis the target xanthatin.  
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Scheme 30: Synthesis of the key intermediate. 
4. Synthesis via intramolecular acylation and Wittig-lactonization. 72 
In this approach, the seven-membered carbocycle was prepared by an intramolecular acylation and 
a one-pot Wittig-lactonization as the key steps. This synthesis afforded a useful intermediate 
having a bicyclic 5,7-fused ring system for the synthesis of the xanthanolides (scheme 31). This 
scope of synthesis includes 28 steps to xanthatin made the overall yields very low 4% despite the 
high yield of the key step 91%. 
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Scheme 31: Synthesis of the key intermediate for the xanthanolides. 
5. Asymmetric total syntheses of xanthatin and 11,13-dihydroxanthatin using a 
stereocontrolled conjugate allylation to γ-butenolide.73 
Shindo and co-workers improved their previous route for synthesis of xanthanolides from 28-steps 
to 14-steps. In the earlier work, the cis-fused γ-butyrolactone was used as a common chiral building 
block, furthermore in the previous route many unrequired steps were necessary to convert the cis-
fused bicyclic lactone into the trans-fused lactone. The key point of this route plan was the 
improvement of a straight and general synthetic route for the stereoselective manufacture of a 
series of trans-fused xanthanolides. This synthetic route offers a general approach to the 
xanthanolides and other natural products having the trans-fused γ-butyrolactone (scheme 32). 
Scheme 8 shows that the γ-butenolide 121 is important to produce 128 (key intermediate) by the 
conjugate allylation of the optically active γ-butenolide 121, because this conjugate reaction was 
expected to proceed from the opposite face of the side chain in 121. Compound 126 has good 
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overall yield without any epimerization at the C-10 position. Compound 128 was obtained after 
ring closing metathesis of the enyne 126 using the Grubbs catalyst to give the seven-membered 
carbocycle 128 in 85% yields. Finally, by using the Hoveyda catalyst (A), the two products can be 
easily obtained to create the target compounds. The overall yields of this scope were 14%.  
 
 
Scheme 32: Total synthesis of Xanthanolides. 
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2. Aims of the project 
The overall aim of this project was to utilise endoperoxides, which can be conveniently accessed 
by the addition of 1O2 to 1,3-dienes, in the synthesis of natural products, such as the xanthanolides. 
However, the synthesis of endoperoxides is predicated on access to suitably substituted 1,3-dienes, 
and as such the first part of the thesis will describe the detection and optimization of a novel allene 
to acyclic 1,3-diene rearrangement, catalyzed by a unique palladium-hydride complex derived 
from palladium (0) and boric acid. The rearrangement was discovered serendipitously and 
warranted investigation within the scope of the project. Furthermore, we will be able to apply this 
unique rearrangement together with 1O2 oxidation to the synthesis of moracin M. 
The second section describes work towards the total synthesis of xanthanolides, once again using 
endoperoxides derived from cyclic 1,3-dienes. The previous section has already highlighted the 
importance of xanthanolides, and our own group recently reported an enantioselective approach to 
trans-fused bicyclic butyrolactones, such as 130 and 132 which utilized a desymmetrisation of 
readily available endoperoxides 129 (Scheme 33). 17 While enantioselective routes toward cis-
fused butyrolactones exist, general synthetic routes toward trans-fused butyrolactones are rarer; 
e.g. in Shishido’s first asymmetric synthesis of the anti-inflammatory natural product xanthatin,75 
they had to convert a key cis-lactone precursor into the trans-lactone using a 3-step procedure 
which included a Mitsunobu inversion of a crucial hydroxyl group.71 
 
Scheme 33: Kimber group approach to trans-fused butyrolactones. 
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In this research programme, intend to utilise this general asymmetric approach to trans-fused γ-
butyrolactones to synthesise appreciable amounts of the anti-inflammatory, xanthatin (figure 11), 
12 for biological evaluation. Importantly, the synthetic approach was to be (a) enantioselective; 
(b) modular, and (c) flexible. This will ultimately allow us to systematically vary the substitution 
on the xanthatin skeleton. Also planned to attempt to access intermediate 133 and synthesise other 
members of this family of natural products via the known key intermediate 134. The anti-
inflammatory activity of the synthetic xanthatin and its analogues were to be eventually evaluated 
using the existing collaborators 
 
Figure 11. Targets within this research programme 
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3. Result and Discussion 
3.1. Synthesis of acyclic 1,3-dienes 
3.1.1. Base Free Cross-Coupling Reaction to 1,3-Dienes 
One of the more prominent tactics is the use of Pd(0)-catalyzed nucleophilic addition to activated 
propargylic substrates followed by cross-coupling of the palladium (II) intermediate with an 
appropriate coupling partner. One of the issues with this approach is the lack of examples within 
the literature incorporating cross coupling in base free conditions with readily available boronic 
acids via the Suzuki-Miyuara (SM) reaction 76. 
With reference to SM-cross coupling reaction, envisaged using propargyl alcohols to react with 
boronic acid via palladium mediated to get the required allenes; however, found that when reaction 
was performed along with the allene and significant amount of the 1,3-diene was observed. 
the initial detection of this transformation occurred when 135 was exposed to the adapted 
conditions of Yoshida and co-workers77 (scheme 34) where extended heating of this reaction led 
the allene 136 as well as  significant amounts of the 1,3-diene 137, in an isolated yield of 40%. 
                      
Scheme 34: Unexpected formation of 1,3-diene 137. 
In the crude 1H NMR spectrum found three signals that had the same integration instead of one for 
allene 136 around 6 ppm. After that found that 1,3-diene 137 was the only structure that  could fit 
this spectrum. The purification of the crude product and the isolation of both allene and diene 
prove that the extending heating of this reaction gives 137 as an additional result. The spectrum 
52 | P a g e  
 
 
(figure 12) clearly shows the first evidence of 137 with three signals belong to the conjugated 
double bonds in compound 137.   
 
 
Figure 12: 1HNMR for 136 in the top and 137 in the bottom. 
The use of a base free SM-reaction to generate the allene had previously been reported by 
Yoshida;77 however, there is no mention of the identification of the 1,3-diene products within this 
report. Therefore, given this novel transformation, make set out to optimize the formation of the 
1,3-diene as shown below in (table 8).  Specifically, examined reaction temperature, solvent and 
equivalent number of boronic acid, and importantly time. 
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Table 8. Optimization for the formation 1,3-Diene 137 in (scheme 34).a 
entry PhB(OH)2. 
equiv. 
Solvent Temp. [°C] Conversionb [%] 
1 3 THF Reflux 5 
2 3 CH3CN 75 0 
3 3 PhMe 75 0 
4 3 1,4-dioxane Reflux 45 
5 3 1,4-dioxane 75 85 [78]c 
6 3 1,4-dioxane 66 15 
7 2 1,4-dioxane 75 45 
8 1 1,4-dioxane 75 20 
aReactions were performed under an N2 atmosphere at 0.5 M for 16 h, unless otherwise stated. 
bDetermined by 1H NMR spectroscopy. 
cIsolated yield. 
In entry 1, 3.0 equiv. of the boronic acid with THF as the solvent at 66 °C gave only minimal 
amounts of the desired 1,3-diene. In entries 2 and 3 the solvent and temperature changed by using 
acetonitrile and toluene, respectively, and this gave none of the 1,3-diene. In entries 4-6 we 
selected 1,4-dioxane as the solvent and varied the temperature. At reflux in dioxane obtained the 
1,3-diene in 45% conversion (entry 4); at 75 °C obtained the 1,3-diene in 85% conversion, and in 
an isolated yield of 78% (entry 5); and at 60 °C only obtained the 1,3-diene in a poor 15% 
conversion. The number of equivalents of boronic acid was also probed (entry 7 and 8) with 2 
equiv giving 137 in get 45% conversion, and 1 equiv. giving 137 in only 20% conversion, this is 
in constrast to the report of Yoshida and co-workers who found 2 equiv. to be favorable. Therefore, 
according to the result of the optimization in (Table 7) we found that the ideal condition was in 
(entry 5) 3 equiv. of boronic acid, 1,4-dioxane as a solvent at 75 °C for 16 hours in presence of 5 
mol% Pd(PPh3)4 as a catalyst. 
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After optimization of the new condition we now applied these to determine the scope of this new 
transformation, and this was undertaken firstly with several boronic acids and one propargyl 
alcohol 135 (table 9). 
Table 9.  Variation of the Arylboronic Acida 
 
entry 
 
1,3-diene product 
Compound 
number 
Yield [%]b 
1 
 
 
137 78 
2 
 
 
138 99 
3 
  
139 87 
4 
 
 
140 60 
5 
  
141 94 
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aReactions were performed under a N2 atmosphere at 0.5 M in 1,4-dioxane, with 5 mol % of 
Pd(PPh3)4 for 16 h, unless otherwise stated. 
bIsolated yields unless otherwise stated.  
cDetermined by 1H NMR spectroscopy. 
Table 9 shows ten examples cyclic diene prepared from cyclohexyl propargyl alcohol with 
different aryl boric acids. Entry 1 the diene 137 was prepared from phenyl boronic acid in good 
yield 78%. Electron-rich boronic acids all participated in the transformation with moderate to high 
isolated yield (entries 2−4). The sterically bulky 1-naphthylboronic acid perform well, giving the 
1,3-diene 141 in an excellent 94% yield (entry 5), as did 3,4-dimethoxyphenylboronic acid, which 
gave the 1,3-diene 142 in 57% yield with 29% of unpredicted diene 143 (see experimental data) 
6 
 
                
142 57 
143 29 
7 
 
 
144 62 
8 
 
 
145 70 
9 
 
 
146 66 
10 
 
 
147 >5c 
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(entry 6). The 3,5-dimethoxyphenylboronic acid gave 144 in 62% isolated yield (entry 7). A 
boronic acid containing an electron-withdrawing group (CO2Et) was tolerated under the reaction 
conditions, giving the 1,3-diene 145 in 70% yield (entry 8). A heterocyclic boronic acid was also 
acceptable in these reaction conditions, with 2-furanylboronic acid giving 146 in 66% isolated 
yield (entries 9); however, 4-bromophenylboronic acid gave limited amounts of the 1,3-diene, with 
a significant amount of starting alkyne and polymeric material being detected (entry 10). 
Next, the examination variation of the alkyne coupling partner in this transformation (Table 10).  
Table 10. Variation of the Propargyl Alcohola 
 
Entry Propargyl alcohol 1,3- diene product 
Compound 
number, 
substitutes 
Yield 
[%]b 
1 
 
 
149: R = H 61 
2 150: R = Me 67 
3 
 151: R 
=OMe 
78 
4c 
 
 
153 80 
5c 
 
 
155 75 
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6c 
 
 
5 43 
7c 
 
158: R= p-
OMe 
67 
8c 
159: R= m-
OMe 
80 
9 
 
 
 
161: R=H 85 
10 
162: R=Me 47 
163: R=OMe 98 
11 
12 
   
165 74 
13 
  
 
167 55 
14 
 
168 73 
15 
 
 
170 64 
aReactions were performed under a N2 atmosphere at 0.5 M in 1,4-dioxane, with 5 mol % of 
Pd(PPh3)4 for 16 h, unless otherwise stated.  
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bIsolated yields unless otherwise stated. c Isolated as a mixture of E- and Z-isomers in 
approximately 85:15 ratio. 
cPropargyl Alcohol prepared under Grignard reaction condition between the cycloketon and 
ethynyl Magnesium bromide.78  
Cyclopentyl propargyl alcohol 148 performed well with phenyl, 4-methyl, and 4- methoxyboronic 
acids giving the 1,3-dienes 149, 150, 151 in 61%, 67% and 78% isolated yields, respectively 
(entries 1−3). Furthermore, cycloheptyl- 152 and cyclooctyl- 154 also participated as expected to 
give 1,3-dienes 153 and 155, in yields of 80% and 75%, respectively (entries 4 and 5). 
The 1,4-dioxaspiro-protected propargyl alcohol 156, when coupled with 3,5-dimethoxyphenyl 
boronic acid, 4- methoxyphenyl boronic acid and 3-methoxyphenyl boronic acid gave the 1,3-
dienes 157, 158 and 159 in a moderate to good yields of 47%, 67% and 80%, respectively 
demonstrating that the reaction is tolerant of acid sensitive functional groups (entry 6-8). The 
acyclic propargyl alcohols 2-methyl-3-butyn-2-ol 160, when exposed to phenylboronic acid, gave 
1,3-diene 161 in 85% yield, while 4-tolylboronic acid and 4-methoxyboronic acid gave 1,3-diene 
162 and 163 in a modest 47% to high isolated yield 98% (entries 9-11). Similarly, 2-phenyl-3-
butyn-2-ol 164 gave the 1,3-diene 165 in 74% isolated yield when exposed to phenylboronic acid 
(entry 12). In entry 13, we used 3-methyl-1-pentyn-3-ol 166 with 3-methyphenylboronic acid, 
yielding the 1,3-diene 167 (isolated as a mixture of E- and Z-isomer in an approximately 85:15 
ratio) as the predominant product in 55% yield, while the same propargyl alcohol 166 with 4-
tolylboronic acid gave 1,3- diene 168 in 73% isolated yield. The prevalence of this 1,3-diene 168 
in this example is presumably due to the formation of the tri-substituted alkene as the 
thermodynamic product. Finally, 19-norethistrone 169 was exposed to the reaction conditions with 
3-methylphenylboronic acid, yielding the 1,3-diene 170 in 64% yield, therefore giving an ideal 
handle for further functionalization of this important steroid (entry 15). 
However, when we used ortho-substituted phenylboronic acid, for example reaction of 3- 
methylpent-1-yn-3-ol 166 with 2-methyl phenylboronic acid 171 under the optimized conditions 
we obtained compound 172 (Scheme 35). The structure of 172 confirmed by 1HNMR spectrum by 
miss the signal at 5.9 belong to the second double bond of the diene. 
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Scheme 35: Unpredictable result of diene synthesis. 
After our successful optimization and scope investigation of this the new route for the preparation 
1,3-diene, we next investigated the relationship between the allene and 1,3-dienes. Plausibly, the 
1,3-diene can result from the rearrangement of an intermediary allene to give the 1,3-diene.  
To determine that this process is two-step, i.e. conversion of the propargyl alcohol to the allene 
followed by rearrangement to its 1,3-diene, the reaction was carried on formation of allene 173, 
which was firstly isolated in 89% yield as shown in (Scheme 36). 
 
Scheme 36: The two step of diene synthesis. 
With 173 in hand we then exposed it to reaction conditions to promote the formation of 1,3- diene 
165 (Table 11). The exposure of 173 to 5 mol % of Pd0 gave no conversion, with only the starting 
allene being detected (entry 1). Again, exposure of 173 to phenyboronic acid gave none of the 
desired 1,3-diene (entry 2). Phenylboronic acid in the presence of Pd0 did give a small conversion 
to the diene 165, but with significant degradation of the allene and addition products79 being 
observed (entry 3). In the acid mediated rearrangement of allenes, reported by Sanz and co-
workers,80 pTSA was used to facilitate the rearrangement of the allene. To investigate this, 165 
was exposed to 1 equiv of B(OH)3, the only other significantly acidic byproduct of the 
Suzuki−Miyaura reaction, but this failed to deliver the 1,3-diene (entry 4). This is unsurprising 
given the pKa of boric acid compared to pTSA. However, when 173 was exposed to Pd0 and 1 
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equiv of B(OH)3, conversion to the 1,3- diene was significant, giving 165 in 92% conversion 
presumably via the formation of a H−PdII-OB(OH)2 complex (entry 5). Yamamoto and co-
workers79 have reported a similar hydroalkoxylation/isomerization of allenes and alkynes using 
analogous H−PdII−OBz and H−PdII−OAc complexes, but with limited selectivity and scope. 
Therefore, we exposed allene 165 to H−PdII−OBz, derived from Pd0 and BzOH, and this gave the 
1,3-diene 165, but with a significant hydroalkoxylation by-product (entry 6). 
Table 11 Allene Isomerization 
Entry Additiveb Catalystc Productd [%] 173                    productd[%] 165 
1 - Pd(PPh3)4 90 - 
2 PhB(OH)2 - 90 - 
3 PhB(OH)2 Pd(PPh3)4 52 15 
4 B(OH)3 - 90 - 
5 B(OH)3 Pd(PPh3)
 
4 5<  92[86]e 
6 BzOH Pd(PPh3)4 5<  60e 
aReactions were performed under an N2 atmosphere at 0.5 M in 1,4-dioxane for 16 h unless 
otherwise stated. 
b100 mol %. 
c5 mol %. 
dDetermined by 1H NMR spectrums.  
eIsolated yield. 
Using the results in (Table 10) together with the well understood mechanism for the formation of 
the allene77, leaded to propose a plausible mechanism for the formation of the 1,3-diene (Scheme 
37). Activation of 174 via a proton or the Lewis acidic boronic acid delivers 175, which in the 
presence of Pd0 undergoes nucleophilic addition to give the allenylpalladium species 176, followed 
by a subsequent SM-coupling to deliver the intermediate allene 178. We then propose, based on 
the results within (Table 10), that the boric acid oxidizes the resultant Pd0 to give the PdII species 
H−PdII−OB(OH)2 179. Allene 178 can then undergo hydropalladation with 183 to deliver either 
180 or 181 with 180 experiencing a dehydropalladation to regenerate the allene 178. However, 
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unlike 180, 181 can undergo two possible dehydropalladations, either regenerating the allene 178 
or, more significantly, delivering the observed 1,3-diene 182. 
 
Scheme 37: Proposed Mechanism for the Formation 1,3-Dienes from Propargyl Alcohols 
and Boronic Acids under Palladium Mediated Catalysis 
Our proposed H−PdII−OB(OH)2 complex parallels the related complexes (e.g., H−PdII− 
OBz and H−PdII−OAc) as reported by Yamamoto (scheme38),79 but demonstrates a 
different reactivity. The latter complex when reacted with allenes gives the 
hydroalkoxylation product, presumably due to the nucleophilicity of the benzoate conjugate 
base whereas, the former H−PdII−OB(OH)2 complex gives predominantly the rearranged 
1,3-diene product. 
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Scheme 38: Yamamoto’s mechanism 
We disclosed these results in July 201681, but a similar reaction was subsequently disclosed 
in September 2016 by Sherburn and co-workers leading to substituted 1,3-dienes by using 
propargylic diols with boronic acids in presence of palladium zero (Scheme 39).82  
 
Scheme 39: Cross-Couplings of Propargylic Diols 
3.2. Isomerization of unactivited Allenes to 1,3- Dienes 
With reference to our synthesis of natural products using endoperoxides, the convenient starting 
material should be the cyclo-dienes (seven or eight-member ring) via ring closing diene metathesis. 
Finding ways to prepare the 1,3-dienes could increase choice in the preparation of different 
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substitute xanthanolides and in relatively few steps. Ostensibly, the rearrangement of alkyl-
substituted allene represents an atom efficient method for the synthesis of dienes via a 1,3-
hydrogen migratory process. This type of 1,3-hydrogen migration route, either acid catalysed or 
thermal, is commonly found in activated allenes such as the allenamide series elegantly described 
by Hsung.83 However, such transformations on inactivated allenes have been infrequent within the 
literature, and commonly undertaken at high temperature or under metal catalysed conditions. 
Allenes and diene have become an increasingly important structural motif in organic synthesis. 
This is due, in part, to their occurrence in natural products and drug candidates, their unique axially 
chirality, and their underlying potential in regio- and stereo-specific carbon-carbon and carbon-
heteroatom bond forming reactions. As a consequence, concise and technically simple synthetic 
methods for their construction have been much sought after and have led to various approaches 
being divulged (Scheme 40).84 
3.2.1 Review of Isomerization of unactivated Allenes to 1,3- Dienes 
A limited number of methods have been reported for the successful isomerization of unactivated 
allenes to 1,3-dienes and these can be grouped into acidic catalyzed, thermal, and finally metal 
catalyzed methods. 
1. Acid catalyzed isomerization.  
In the presences of an acid unactivated allenes can be isomerization to 1,3 dienes via a series 
tautomerizations and proton shifts. This was first reported in 1960 by Thomas and co-worker85 
where they studied the orientation of the addition of hydrogen chloride to aliphatic allenic 
hydrocarbon, and that the addition of hydrogen chloride to 3-methyl-1,2-butadiene at -78 oC in 
presence of bismuth trichloride gave the rearranged 1,3-diene. 
In 1985 Wenkert and co-workers studied the synthesis of allenes by nickel-catalyzed Grignard 
reactions with silylpropargyl alcohols and found that when exposed to acid the prepared allenes 
rearranged to conjugated dienes in high yield (Scheme 40).86 It is useful to mention that just two 
example of isomerization were used basic alumina was used in purification. 
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Scheme 40: Hydrochloric acid to isomerization allenes  
In 2010 Sanz and co-workers 80 used a Bronsted acid to isomerization allene 194 to diene 195 by 
using PTSA as acid catalyst in high yield (scheme 41). 
 
Scheme 41: Bronsted acid to isomerization allenes 
 
In addition, they found that the diene 199 could be prepared directly in a one pot reaction under 
the same condition of the preparation of allene 198 by just extending the heating and they proved 
the suggested mechanism by isolated the intermediate allene 198 (Scheme 42).  
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Scheme 42: Isomerization of allene. 
2. Metal Catalyzed Isomerization. 
In 1998 Yamamoto79 found that aliphatic and α-aryl substituted allenes were isomerized to 1,3-
dienes in modest yield. This was a by-product of a hydrocarboxylation of allenes in the presences 
of palladium catalyst and carboxylic acid (scheme 43). 
 
Scheme 43: Formation and isomerization allene with Palladium catalyst 
In 2004 Yoshida and Ihara found allenic alcohols with aryl- or alkenyl-boronic acids in the 
presence of palladium (0) could be coupled with boronic acid aryl or alkenyl groups to give 
various substituted 1,3-dienes (Scheme 44).87 
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Scheme 44: Rearrangement of allenic alcohols. 
In 2012 Liu and co-worker 84 reported a gold catalyzed isomerization of unactivated allenes to 1,3-
dienes with nitrosobenzene. The proposed mechanism84 shows that the role of nitrosobenzene is to 
facilitate the proton transfer by the electrophilic addition at its nitrogen and this will increase the 
nucleophilicity of the oxygen (scheme 45). 
 
Scheme 45: Isomerization allene with gold catalyst. 
Later in 2014 Widenhoefer and co-worker88 used a cationic gold (I) complex to form gold π- 
tetramethylallene complex 211 (scheme 46). Which could be subsequently converted to 1,3-
diene 212. 
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Scheme 46: Diene from gold π- tetramethylallene complex  
 
3. Thermal rearrangement of allenes. 
In 1966 Paulson and co-worker89 reported that the cyclopropane allene 213 could be converted to 
the 1,3-dienes 214 and 216 at a range of different temperature between 360 to 460 0C. 
Compounds 214 and 215 were formed at 360 0C whereas, 216 needed 460 0C to form (Scheme 
47). 
 
Scheme 47: Thermal rearrangement  
In 1970 Bloch and co-worker90 due to continued interest in cyclopropane allenes reported the 
conversion of cyclopropane allene 217 to diene 218 at 320 0C under vacuum in 30% yield in 
three minutes (Scheme 48). 
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Scheme 48: conversion of cyclopropane allene to diene 
In addition, in 1971 Patrick and co-worker91 reported stereoselective thermal rearrangement of  
cyclopropane allene 219 to diene 220 at 170 0C or at 130 0C in mesitylene solution without 
mentioned the yield percentage (Scheme 49). 
 
Scheme 49: Rearrangement of cyclopropane allene in mesitylene solution 
In 1989 Meier and co-worker92 reported that when exposed cyclo-allene 221 was exposed to a 
high temperature, the allene could undergo a facile rearrangement to the 1,3-diene 222 in 62% 
(scheme 50). 
 
Scheme 50: Thermal rearrangement of allene 
3.2.2 Synthesis of Allenes 
Having developed a method for the direct conversion of propargyl alcohols to 1,3-dienes, as well 
as identifying that the 1,3-diene plausibly results from the rearrangement of an intermediary allene, 
we set about examine further the allene to 1,3-diene transformation. This would be for preparative 
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purposes as well as a further examination of the mechanism for this rearrangement, Initially this 
would require the synthesis of a range of inactivated allenes, which would then be exposed to our 
Pd(0) / B(OH)3 conditions described in section 3.1.1. 
Firstly, optimized the allene synthesis using the Yoshida77 reaction conditions using phenyl 
boronic acid 223 and propargyl alcohol 164 (scheme 51) and (table 12). 
 
Scheme 51. Synthesis of allene 
Table (12) optimization of Allene synthesis reaction  
Entry Partner Amount 
equiv. 
Catalyst Amount 
mol % 
Solvent Conversionb 
[%]c 
1 PhB(OH)2 1.05 Pd(PPh3)4 5.0 THF 22 
2 PhB(OH)2 3.15 Pd(PPh3)4 5.0 THF 48 
3 PhB(OH)2 2.10 Pd(PPh3)4 5.0 THF 30 
4 (PhBO)3 1.05 Pd(PPh3)4 5.0 THF 70 [66] 
5d PhB(OH)2 3.15 Pd(PPh3)4 5.0 THF 91 [78] 
6 PhBF3K 1.05 Pd(PPh3)4 5.0 THF - 
7 PhB(OH)2 3.15 - - THF - 
8d PhB(OH)2 3.15 Pd(PPh3)4 5.0 PhMe 27 
9d PhB(OH)2 3.15 Pd(PPh3)4 5.0 DME 30 
10d PhB(OH)2 3.15 Pd(PPh3)4 5.0 1,4-
dioxane 
86 [82] 
11d PhB(OH)2 3.15 Pd(PPh3)4 5.0 DMF - 
12d PhB(OH)2 3.15 Pd(dba)2 + 
2PPh3 
5.0 1,4-
dioxane 
77 
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13d PhB(OH)2 3.15 Pd(dba)2 + 
(±)-BINAP 
5.0 1,4-
dioxane 
75 
14d PhB(OH)2 3.15 Pd(PPh3)4 2.5 1,4-
dioxane 
62 
15d PhB(OH)2 3.15 Pd(PPh3)4 10.0 1,4-
dioxane 
82 
aAll reactions were performed at 70 ˚C on 1.00 mmol of the alkyne at 0.2 mM unless otherwise 
stated. 
bConversion determined by 1H NMR using trimethoxybenzene as internal standard.  
cIsolated yield.  
dAddition of 4Å molecular sieves. 
We began the study by treating alkyne 164 with phenylboronic acid 223 in the presence of a 
palladium catalyst as shown in (scheme 52) and (table 11). We initially treated 164 with 1.05 
equiv. of 223 in refluxing THF with 5 mol% Pd(PPh3)4 which the yielded in allene 173 in 
promising 22% conversion (entry 1). Variation of the equivalents of boronic acid was then 
performed (entries 2 and 3) which indicated that 3.15 equivalents of boronic acid gave a modest 
increase to 48% conversion. Pleasingly, when 1.05 equivalents of triphenylboroxine was used, in 
place of boronic acid, this conversion then increased to 70% (entry 4). Therefore, the inclusion of 
4Å sieves when using 3.15 equivalents of boronic acid was then trialed which led to an 72% 
conversion to the desired allene, which was subsequently isolated in 78% yield (entry 5). 
Potassium trifluorophenylborate failed to yield the desired allene 173 with only starting material 
being observed (entry 6). A screen of solvents established 1,4-dioxane, in the presence of 4Å 
sieves, as a superior solvent system to undertake the transformation leading to an improved 
formation of the allene in 86% conversion and 82% isolated yield (entry 10). Replacing the Pd(0) 
source from Pd(PPh3)4 to Pd.dba2 with both PPh3 and (±)-BINAP resulted in formation of the 
allene, albeit in slightly reduced conversions (entries 12 and 13). Finally, a variation of the catalysts 
loading using Pd(PPh3)4 was performed indicating 5 mol% of Pd(0) to be optimal for this 
transformation (entries 14 and 15). 
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With optimal conditions achieved we were able establish the scope of this transformation and we 
applied these conditions to different propargyl alcohols with different boronic acids (scheme 52) 
and (table 13). 
  
Scheme 52: General condition of allenes synthesis 
Table 13 allenes synthesis 
Entry 
Propargyl 
alcohol 
ArB(OH)2 Allene product 
Comp. 
No. 
Yield 
[%] 
1 
 
  
173 91 
2 
  
226 84 
3 
 
  
136 71 
4 
 
 
227 64 
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5 
 
 
228 60 
6 
  
229 63 
7 
  
230 45 
8 
  
231 19 
9 
 
 
232 68 
10 
 
 
 
233 43 
11 
  
234 55 
12 
 
 
 
 
236 44 
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13 
 
 
 
237 60 
14 
  
238 68 
15 
  
239 38 
16 
  
240 32 
17 
 
 
241 55 
18 
 
 
242 72 
19 
  
243 35 
20 
 
 
244 24 
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21 
 
  
245 58 
22 
 
 
246 62 
23 
  
247 72 
24 
  
248 32 
25 
 
  
249 45 
26 
 
  
250 56 
27 
  
 
 
252 92 
Table 13 shows allenes compounds resulted by the reaction between different propargyl alcohols 
and various boronic acids. These resultant compounds were confirmed by spectroscopic methods 
(IR, 1H NMR, 13C NMR) and by physical properties. Allenes can be recognized by their infrared 
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spectra by their specific absorption belonging to the bonding with their sp carbon from 1925 to 
1980 cm-1 depending on the substituent group. Furthermore, most allenes give signals in 1H NMR 
spectra between (6.80 - 5.80) ppm belong to the hydrogen atom attached to the sp2-hybridized 
carbon and a unique 13C NMR signal around 200 belonging to the sp- hybridized carbon of the 
allene unit. 
The percentage yield of the resultant compounds varied from 24% to 92%. The percentage varies 
according to many factors, the pKa of the boronic acids, for example. The phenyl boronic acid93 
is pKa = 8.9, whereas, 2-methyl phenyl boronic acid94 has pKa = 9.7. This information means the 
acidity of phenyl boronic acid is larger than others. So, in table 12 the percentage of the result 
compounds 173 and 238 (entries 1 and 14) were larger than compounds 226 and 237 (entries 2 and 
13), same can be said on compound 136 (entries 3) compare with compounds 227 and 228 (entries 
4 and 5). But this rule was not all time works for example 4-bromophenyl boronic acid93 pKa = 
8.6 and the percentage of the result was 19% (entry 8). 
Furthermore, the ring strain of the cyclic substances also affects the percentage of the result, bonds 
in cyclopentane offer little conformation flexibility than the ideal bond angles in cyclohexane, 
cycloheptane and cyclooctane compounds. Ring strain shown in compound 247 (entry 5) has a 
larger percentage than compound 233 (entry 10) both have same boronic acid also (entry 25 and 
26) have 45% and 56% yields respectively.  
in addition, internal alkyne 251 give diene 252 in 92% whereas external alkyne 160 give diene 243 
in 35% by using same boronic acids 
3.2.3 Rearrangement of unactivated allenes to 1,3 dienes 
After the initial optimization of isomerization of 173 to diene 165 in section 3.1., the investigation 
of the allene to 1,3-diene isomerization with regard to temperature and time using allene 229 
(scheme 53 and table 14). 
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Scheme 53: optimization reaction 
Table 14. Optimization condition for rearrangement of allene 229 to 1,3-diene 140 
Entry Temp (°C) Time (h) Observed product 
f140                             253 
1 75 8 66 - 
2 75 24 90 [70] b - 
3 RT 24 55 - 
4 90 24 c60 - 
5d 75 24 35 45 
6e 75 4.5 ˃5 40 
aReactions were performed under an N2 or argon atmosphere with the allene (1 equiv), Pd(PPh3)4 
(10 mol%), B(OH)3 (200 mol%) in 1,4-dioxane unless otherwise stated. 
b Isolated yields.  
cDegradation.  
d100 mol% B(OH)3.  
eBzOH (100 mol %) instead of B(OH)3.  
f determined by HNMR conversion.  
Table 14 show six variations of factors of the reaction in (scheme 53), the first one was to leave 
the reaction for 8 h at 75 °C by using 0.1 equivalent of Pd0 and 2 equivalents of boric acid to get 
66% of the desired product (entry 1) whereas, entry 2 had the same condition except leaving the 
reaction for 24 h to get 90% of the diene 140. We now fixed the time of the reaction at 24 h and 
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changed the temperature to room temperature (entry 3) and to 90 0C (entry 4) to get 55% and 60%, 
respectively of the desired 1,3 dienes. In (entry 5) we decrease the amount of boric acid by half 
and keep the other conditions as (entry 2), and the amount of the resultant 1,3-diene decrease to 
35% and we noticed a new compound 253 in 45% as undesired product. Finally, (entry 6) the boric 
acid was replaced with one equivalent of benzoic acid because it was used to generate a H-PdII-
OBz complex before,95 and in this entry we observed a trace amount of the 1,3 dienes (˃5) with 
40% of the undesired product 253. Table 13 shows that entry 2 give the best conversion (90%) and 
therefore, we used these conditions to treat several allenes from (table 13) with (10 mol%) of 
Pd(PPh3)4 and 2 equivalents of boric acid in 1,4- dioxane under 75 
°C for 24 h (scheme 54 and 
table 15). 
 
Scheme 54: General Conditions of Allene to Diene Rearrangement  
Table 15: rearrangement of allenes to 1,3-dienes. 
Allenes  1,3- Dienes 
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248 
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Table 15 shows the scope of the rearrangement with a variety of allenes from (table 12). The 
cyclohexyl allenes group rearranged to the corresponding dienes in moderate to isolated yields 
giving the 1,3-dienes products 140, 137, 1138, 146 with one exception of naphthyl allene which 
was failed to furnish its 1,3-diene 141. In addition, 146 was prepared in moderate yield by exposing 
the crude of the allene to the rearrangement condition due to their allenes rapid decomposition 
upon standing. The cyclopentyl, cycloheptyl and cyclooctyl allenes 149, 256, 257 could be 
rearranged in excellent isolated yields giving 98%, 98%, and 89% repectively. The acyclic allenes 
could also be rearranged to their 1,3-dienes products 258, 162, 259, 260, 261, and 163, respectively 
due to their difference of the activity of the aryl groups which was the electron rich corresponding 
allene gave 51% of diene 258 whereas, the performance of relatively electron poor corresponding 
allene that gave the anticipated 1,3-diene 261 in 98% yield. This later result suggests to the both 
electron-rich and electron-deficient aryl allenes perform well in this rearrangement in contrast to 
the acid mediated processes in direct preparation of 1,3-diene for example product 140 prepared 
by direct procedure in 60% whereas rearranged in 76% in addition compound 145 prepared in 70% 
where as a product 261 which is has same aryl group rearranged in 98%. The 1,1-dimethyl diaryl 
allene 252 could also be rearranged under these conditions, giving its 1,3-diene 262 as a 1:1 
mixture of E/Z geometric isomers and in an isolated yield of 67%. 
The 1-aryl-3-methyl-1,2-pentadiene 247 was rearranged to corresponding dienes 167, 263, and 
264 in excellent yield of 94% as a total percentage of three products. The thermodynamically stable 
E,E-1,3-diene 147 formed  58% of the total whereas 263 and 264 was isolated as a mixture (2 : 1) 
respectively of 36% for both product, the stereochemistry of the compounds was confirmed by the 
NOE study, in addition the 3,5-dimethyl-1,2-pentadiene 248 was rearranged to the corresponding 
1,3-dienes 265, 266, and 267 in 97% as a total percentage result and we were able to isolate 265 
in 52% yield, whereas the 266 and 267 remained as a mixture in 45% isolated yield.   
3.3 Mechanism of the rearrangement 
With scope of the rearrangement determined, the mechanism of this rearrangement deserved 
further attention. In section 3.1.1., we had already demonstrated that Pd(0) and boric acid was vital 
for the rearrangement. the identification any key palladium allyl intermediates that may provide 
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further evidence for our mechanism shown in section 3.1.1. 
To achieve this, we turned to in situ monitoring of the rearrangement by way of ESI-MS and the 
use of direct sample loop injection.  In most cases the organometallic intermediates could appear 
at different time and be consumed rapidly throughout the chemical reactions. To detect these 
intermediates mass spectrometry (MS) has been used as a molecule analysis since development of 
the electrospray ionization (ESI) techniques. ESI-MS (electrospray ionization mass spectrometry) 
is analytical technique used to find the mass of the compounds according of their mass / charge 
(m/z) ratio. After injected the compounds of our interest in a continues fluid stream firstly, the 
ionization part of the devise ionized the compound into positive or negative charge by using high 
voltage field this technical required a low concentration of the compound in the solution (10-3 to 
10-6 M). At this part the molecules hold same charge of the field are encouraging to migrate to the 
second part of the device whereas, the different charge molecules are set down. The second step is 
started when ions reaches to the mass analyzer detector according to their mass and charge. After 
this step the analyzer generate signals belong to the mass of these ions and these signals recorded 
by a computer system. The computer has a specific software can convert these signals to useable 
graph as a mass spectrum showing the relative abundance of the signals versus m/z.96 
ESI-MS was first reported in 1984 for small molecules ions by John Fenn and co-workers97 who 
won the Nobel prize in 2002 for his work in mass spectrometry. This techniques was use as a tool 
to prove the mechanism for some name reactions since it has been clearly demonstrated used for 
example in 2004 to probe the intermediates of the mechanisms the Heck98 and Baylis-Hillman99 
reactions. 
More relevant to our study, in 2005 Ma and co-workers probed the mechanism of the addition of 
organoboronic acids to terminal allenes in presence of palladium (0) catalyst (scheme 55).100 
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Scheme 55: Addition of organoboronic acids to terminal allene  
In thus study they were able to positively identify key complexes supporting their postulated 
mechanism (scheme 56).100  After running the reaction, a sample of 20 µL after 3 minutes was 
diluted with 80 µL of methanol and injected into the ESI unit of the mass spectrometer. The spectra 
accurately indicated of existence of intermediate ions 271 and 272.  After 2 hours another sample 
was tested to detect and characterized the ions 271 and 274 which was suggested formed during 
the ESI process including elimination of H+.  
 
Scheme 56: Proposed mechanism of palladium catalyzed addition 
To probe the mechanism of our rearrangement of inactivated allenes to 1,3- dienes, our general 
proposed mechanism is illustrated in (scheme 57). 
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 Scheme 57: general plausible mechanism for Pdo/B(OH)3 mediate allene to 1,3-diene 
The mechanism started by the reported oxidation of the Pd0 by boric acid to form hydropalladium 
species 275 H-PdII-OB(OH)2
81 after that the hydropalladium complex adds to the allene unit 276 
to form the π-allylpalladium complex 277, after that hydropalladium complex 278  undergoes β-
hydride elimination to give the 1,3-diene and to form 275 again.95, 101  
The method we used for ESI-MS analysis was to setup the reaction with a continuous loop 
injection, as this enabled us to do multiple measurements at nominated times quickly and without 
diluting the sample with methanol. We selected to two arylallenes 229 and 241 as substrates under 
the same rearrangement condition, where the substitution on the aryl ring on each allene was 
selected to ensure adequate ionization, via the use of a protonatable group. However, to reduce the 
electron-donating ability of each allene, and to impede any adventitious protonation, a meta-
substitution pattern was also selected. Firstly, the rearrangement of allene 229 was monitored by 
direct sample loop and flow injection analysis by ESI-HRMS. After 10 minutes, we were able to 
83 | P a g e  
 
 
intercept, detect, and characterize a number of significant palladium complexes. Two distinct 
complexes can be observed which correspond well to the π-allylpalladium complex 277 described 
in (Scheme 58), complex 280 where one phosphine is attached to the Pd centre (m/z 585.1378; 
calcd for [C33H34OP
108Pd]+: m/z 585.1386) and complex 281 (m/z 323.0467; calcd for 
[C15H19O
108Pd]+: m/z 323.0470) where there are no phosphines attached to the Pd centre (Scheme 
58). To further support the formation of the π-allylpalladium complex 277 shown in (Scheme 59), 
allene 24 was also analysed where an ion corresponding to complex 282 where one phosphine is 
attached to the Pd centre (m/z 545.1072; calcd for [C30H30OP
108Pd]+: m/z 545.1072) was observed 
(Scheme 59). 
 
 
Scheme 58: The detected palladium complexes by direct sample loop 
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Scheme 59: Further support of detected palladium complexes  
The result of MS study gave accurate and strong evidence of formation of π-allylpalladium 
complex and this can only have resulted from the addition of PdII to the allene as described by 
Yamamoto in 2001 (scheme 60),95 and applied by Ma and co-worker; but in their reactions case 
they used a terminal allene and proposed the intermediate terminal allene, respectively.  
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Scheme 60: Yamamotos proposed mechanism 
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3.4 Synthesis of natural products compounds  
Having developed a novel method for the isomerization of unactivated allenes to 1,3-dienes, we 
next set out to apply this methodology. 
Phytoalexins are class of compounds produced by plants as a reply when the plants is infected. 
Polyphenols compounds are part of phytoalexins which play a role in the plant defense against 
fungal and other microbial pathogens. As a result, in recent years there is an increasing interest in 
preparation of these bioactive compounds.36  
3.4.1. Trans-resveratrol 
Resveratrol is a poly-phenol compound produce in the plant as a defence against injury or infection 
by bacteria or fungi, and is found in the skin grapes, blueberries raspberries and mulberries. 
Resveratrol is suggested to have many useful health effects, including antioxidant, anti–
inflammatory, anti–proliferative, proapoptotic, and anti–angiogenic.102 
3.4.1.1 Review recent synthesise of trans-resveratrol  
In 2017 Perin proposed a simple way to synthesis resveratrol by hydroselenation of dimethoxy 
phenyl acetylene 68 to form divinyl selenides 290 that was reacted with methoxy phenyl 
magnesium bromide in the presence of an Fe-catalyst to afford resveratrol trimethyl ether 291 in 
57% which can be deprotected of the ether groups to give the target 6 (scheme 61).103 
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Scheme 61: Synthesis of resveratrol. 
In 2015 Francisco prepared resveratrol by using Sonogashira cross coupling of dimethoxy phenyl 
acetylene 68 with 4-iodoanisole to form 292 then in three steps reduction, isomerization and 
deprotection to resveratrol 6 in 63% as overall yield  (scheme 62).104 
 
Scheme 62: Resveratrol by Sonogashira cross coupling 
In 2009 Takashi used a Heck reaction to prepared resveratrol from dimethoxy bromobenzene 294 
by cross coupling with vinylanisole 293 to form 291 in 88%, this was then deprotected to give 
resveratrol 6 (Scheme 63).105 
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 Scheme 63: Heck reaction to resveratrol 
3.4.1.2 Synthesis of trans-resveratrol 
The synthesis of trans-resveratrol from one of our 1,3-dienes 5 section (3.1.1.) by aromatization 
with iodine in methanol to give 291 (Scheme 64); 106 optimisation of this aromatization step is 
set out in Table 16. 
 
Scheme 64: Aromatization with iodine 
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Table 16: Optimizing the aromatizing condition.a 
Entry MeOH /mL Condition Temperature 
°C 
Time/h Result (isolated) 
291 
1 1.5 stirrer r.t. 4 30% 
2 1.5 stirrer r.t 3 0% 
3 1.5 reflux 68 Overnight 0% 
4 1.5 reflux 68 40 minutes 0% 
5 1 stirrer r.t. 3.5 44% 
6 1 stirrer r.t. 4.5 13% 
aThe reaction was carried out under a N2 atmosphere using 50 mg of the diene 5 with one 
equivalent of iodine. 
Table 16 shows that by using 1.5 mL of methanol and stirring for 4 hours we obtained 291 in a 
isolated yield of 30% (entry 1). We reduced the time to 3 hours and this yielded none of the desired 
compound (entry 2). In entry 3 and 4 we increased the temperature of the reaction and stirred the 
reaction overnight and for 40 minutes, but this also gave none of 291. In entry 5 and 6 we used 1.0 
mL of methanol and stir the reactions for 3.5 hour and 4.5 hour respectively, to get 44% and 13% 
yield, respectively, therefore the ideal conditions are described in entry 5. 
The proposed mechanism of the reaction107 is described in (Scheme 65);108 and shows in general 
that iodine is able to  convert the ketal group to methoxy group and aromatize the cyclohexyl ring 
due to his ability to generate hydroiodic acid in the reaction condition. 
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Scheme 65: Proposed mechanism of aromatization. 
The last step of resveratrol synthesis was deprotection of 291 by using boron tribromide in 
dichloromethane to furnish trans-resveratrol 6 in 70% yield (scheme 66), the overall yield was 
31%. 6 was characterize by 1H NMR with the data in agreement with the literature.109 
 
Scheme 66: Deprotection of the methoxy group 
3.4.2 Synthesis of Moracin M 
The same diene 5 was used to prepare moracin M in four steps starting with a singlet oxygen [2 + 
4]-addition to form the endoperoxide 7 which was characterized by 1H NMR with the three signals 
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of the diene at 6.39, 6.35 and 5.78 ppm absent and appearance of three new signals at 5.81, 5.31, 
4.77 ppm, due to respectively (scheme 67).110 
 
Scheme 67: Addition of singlet oxygen  
The next step was applying the Appel type dehydration of the endoperoxide to form the furan, that 
had been successfully optimized by our group.19 After we applied this reaction we found that the 
ketal group of compounds 7 had deprotected to reveal the ketone 303 (scheme 68). Fortunately, 
this product proved crystalline and we were able to get single crystal analysis to definitively assign 
its structure (figure 13).  
 
Scheme 68: Appel type dehydration 
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Figure 13: Crystal structure of compound 303 
The mechanism of this dehydration is described elsewhere, however its application to the 
formation of 303 is shown in (Scheme 69).19 Kornblum De LaMare rearrangement of 304 is 
promoted by -CBr3, leading to the resonance form 305. This undergoes PPh3 mediated dehydration 
giving 307, that subsequently aromatises to give 308. Unfortunately, the residual HBr promotes 
deprotection of 308, giving the benzofuran 303.  
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Scheme 69: Mechanism of Appel type reaction  
Unfortunately, all attempts to aromatise 303 using the MeOH/I2 conditions failed, presumably 
due to the presence of the ketone. Therefore, we modified the dehydration conditions by the 
introduction of NaHCO3 to neutralize the HBr generated within the Appel reaction. Using these 
condition, we were able to undertake the dehydration, and keep the acetal intake (scheme 70). 
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Scheme 70: New applied condition of Apple type reaction 
The next step was the aromatization of 310 by iodine in methanol which proceeded well, and the 
final step was the deprotection of 311 to get Moracin M (8) in 75% over these 2-steps (scheme 
71).107 The structure of moracin M was confirmed by 1H NMR spectroscopy with the data 
corresponding well with those previously reported. 
 
Scheme 71: Aromatization and deprotection 
The overall yield of moracin M was 27%, although this percentage seem to be small, but if we 
compared with previous ways mentioned in review we can found that this percentage better that 
three of these ways exactly the method of preparation in 2011 used singlet oxygen reaction 
which has overall percentage 23%. 
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3.5. Synthesis of xanthanolides 
The early demonstration of access significant amounts of precursors 130, in only 5-steps from 
commercially available sources and in high enantiomeric excess.17  
 
Scheme 72: Synthesis route  
Therefore, this part of the project was to complete the synthesis of xanthantin using the approach 
described below (Scheme 73). the intended to use 130 to deliver the key enone 313; this was to be 
achieved by base mediated elimination of OTBS, or by mesylation of the OH group and 
elimination with base to from 130.111 Once in-hand, 313 should be conveniently transformed into 
the methyl appended exo-methylene enone 315 using two complementary procedures (Scheme 
73). Simple treatment of 313 with a methyl cuprate equivalent should deliver 314, with ab initio 
calculations suggesting that the predominant product should be the diastereoisomer indicated, and 
subsequent treatment of 314 under the conditions of Connell112 delivering the exocyclic enone 315. 
Alternatively, a Morita-Bayliss-Hillman reaction performed on 313 with formaldehyde,113 
followed by treatment of the product with acetic anhydride should was expected give the acetate 
316, with subsequent treatment with methyl cuprate using the conditions of Yamamoto114 giving 
the enone 315. Unlike previous approaches to this class of compounds our conjugate addition 
methodology for the introduction of this methyl group allows for other groups (ethyl, propyl, etc.) 
to be installed therefore allowing the ability to systematically vary this functionality. With enone 
315 in hand we could then utilise our existing reported approach to installing the side chain namely, 
1,2-reduction under modified Luche reduction conditions giving the allylic alcohol, and treatment 
with trimethyl giving the ester 317 via a Claisen rearrangement.115 
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Scheme 73: Furnish a side chain at C1. 
A total synthesis of xanthatin was to be accomplished via functional group manipulation of ester 
317, and installation of the exo-methylene using existing protocols115 whereas, xanthanosin should 
be obtained via FGI of ester 317 (scheme 74). Alternatively, ester 317 would be transformed into 
diversifolide via chain truncation and a FGI (317→ diversifolide) - Target 133. We also planned 
also use methyl ester 317 to access other members of this family of natural products. Previous 
work by the Evans, Shindo, and Tang groups have identified diene target 134 (R = H) also (figure 
11) as a key intermediate for synthesising many of the xanthanolide family members.74,70 
Conversion of methyl ester 317 to the 318 can be accomplished by selective reduction, alkylation 
with allyl bromide generating the relay cross metathesis precursor. Treatment of 318 under 
ruthenium catalysed metathesis conditions will then give the ruthenium alkylidene intermediate, 
which in the presence of an external alkene will deliver the cross-metathesis products (319 and 
where R = H) - Targets 318 and 319.72,116 
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Scheme 74: Target products synthesis 
3.5.1 Preparation of Cycloendoperoxide : 
The approach to the trans-xanthanolides required a cyclic 1,3-diene, and with the identified from 
previous work that three plausible starting 1,3-dienes could be used 322, 323, and 324 (figure 14). 
1,3-cyclooctadiene 322 is commercially available (and relatively inexpensive) and could be used 
as a trial substrate; while 323 and 324 can be obtained from relatively cheap tropone. 
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Figure 14: Required 1,3-dienes  
To access 325 for the photo oxidation tropone was reduced to 1,3 diene 323 in methanol with 
NaBH4 (Scheme 75).
117 
 
Scheme 75: Reduction of tropone 
The mechanism of tropone reduction is described in scheme 74 and utilizes sodium borohydride. 
Tropone undergoes conjugate reduction to give the ketone 328, this undergoes further reduction 
to give the required 1,3-diene 323.107  
 
Scheme 76: mechanism of tropone reduction 
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At this point we kept some of 323 to investigate the preparation of endoperoxide, while the 
remainder was protected as its TBS-ether using TBSCl, imidazole and DMF to get 324 in 88% 
(scheme 75). The product was identified by 1H NMR spectra for the two-double bond protons at δ 
4.12- 4.01 ppm, respectively and the signals belonging to TBS group at δ 0.09 ppm and 0.07 ppm, 
respectively.118 
 
Scheme 75: protection reaction 
All three cyclic 1,3-dienes readily underwent [4+2]-addition using singlet oxygen. The 
endoperoxide products were formed in good to excellent yields giving 331, 332, and 333, 
respectively. They were identified by 1H NMR spectroscopy by the appearance of the alkene peaks 
at δ 6.33 ppm and 6.15 ppm, respectively (scheme 76).119 
 
Scheme 76: Preparing endoperoxide 
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3.5.2 Asymmetric Synthesis of trans-Fused Butyrolactones 
Attention now turned to the desymmetrisation of our endoperoxides to deliver the core trans-
xanthanolide skeleton shown in (scheme 72). Previous work within the group had delivered a novel 
desymmetrisation of these cyclicendoperoxides, to give enantioenriched trans-fused lactones. This 
work was based on a previous report by Toste and co-workers,120 who had used chichona 
organocatalysts (A and B)17 (Scheme 77) to achieve a desymmetrisation of a range of cyclic 
endoperoxides, furnishing γ-hydroxyenones in high enantionmeric excesses. Our own group were 
then able to demonstrate that in the presence of a malonate nucleophile, these enones could be 
converted into their trans-lactones in very high yield and acceptable enantiomeric excesses. 
Accordingly, endoperoxides 331, 332 and 333 were each exposed to catalysts A or B (previously 
prepared within the group) and sodium diethylmalonate, and this gave enantioenriched trans-fused 
lactones 334, 335, and 336 in good isolated yields (scheme 77). The absolute stereochemistry was 
assigned via comparison with our previously disclosed work.17 The lactones (334 – 336), were 
identified by 1H NMR signals of the proton of the lactone ring at around δ 3.30 ppm and by infrared 
spectra by the specific absorption belong to carbonyl group of esters at 1735 cm-1; additionally, 
the physical data matched that already reported.17  
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Scheme 77: Synthesis of Butyrolactone  
Scheme 78 shows the general mechanism of butyrolactone synthesis. Endoperoxide 332 was 
desymmetrised via Kornblum DeLaMare rearrangement with the cinchona alkaloid to give the 
hydroxy-enone 337, the diethyl malonate anion added anti to the hydroxyl group to form 340 
which was reversible in protic solvent with 342. The anion 342 then cyclizes to give 343 and 
finally, the trans –fused endoperoxide (+)-335 was formed by protonation upon work-up.18 
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Scheme 78: Mechanism of Butyrolactone Synthesis  
To confirm that that the reaction was proceeding through the γ-hydroxy enones we also 
desymmetrised endoperoxide 333, in the absence of sodium diethylmalonate (scheme 79). This 
gave γ-hydroxy enone 344 exclusively, and in high ee. Additionally, 344 proved to be crystalline 
and suitable crystals for X-ray analysis were obtained, and the structure is shown in (figure 15). 
Figure 15a clearly shows the structure of 344 and the relative configuration of the two-chiral 
centers; figure 15b shows the hydrogen bonding of the molecule.   
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Scheme 79: Desymmetrisation of meso-compound 333 
 
 
figure 15: Crystal structure of compound (344) 
104 | P a g e  
 
 
At this point we had three butyrolactones to investigate the total synthesis of the target 
xanthanolides. Initial work, to establish a viable synthetic route, would be undertaken with 336 
due to ease of synthesis, and scalability. 
3.5.3 α-Methylation and Decarboxylation of γ- Butyrolactones  
After preparation of fused butyrolactone 336 two reactions are needed to give the desired 
xanthanolides skeleton. Firstly, a methyl group on α-position of the lactone ring is required, and 
this could be introduced by simple alkyation using methyl iodide with sodium ethoxide in THF. 
Accordingly, 336 was treated with methyl iodide and sodium methoxide, and this gave 345, which 
was subsequently decarboxylated to lactone 346 by saponification of the ester group and then 
thermal decarboxylation (scheme 80). Unfortunately, the percentage yield of 346 was modest at 
best, giving 346 in only 30% isolated yield. Additionally, direct Krapcho decarboxylation121 
conditions were applied to 336 giving 347 in 71% isolated yield. The structure of 346 was 
confirmed by 1H NMR spectroscopy with a methyl group signal at δ 1.30 ppm, whereas compound 
347 lacks the signal at δ 3.30 ppm belonging to proton of the lactone ring. 
 
Scheme 80: Decarboxylation of butyrolactone 
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The mechanism of methylation involved two steps starting with deprotonation of 336 by ethoxide 
anion to form anion 348, which is subsequently alkylated with methyl iodide to form 345 (scheme 
81). 
 
Scheme 81: mechanism of methylation 
The mechanism of Krapcho decarboxylation 121 involves direct nucleophilic attack of the ethyl 
group of the ester with chloride ion, followed by decarboxylation  to form 350 and finally 347 after 
protonation (scheme 82). 
 
Scheme 82: Mechanism of Krapcho decarboxylation 
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3.5.4 Synthesis of butyrolactone α, β-unsaturated ketone. 
The introduction of the methyl group at C-1, would be accomplished via conjugate addition to an 
enone; and therefore, we needed to prepare an α, β-unsaturated ketone (again we used lactone 346 
as is was a readily accessible test substrate). We envisaged this could be introduced by a Saegusa 
oxidation122 on a silyl enol ether derived from 346. Accordingly, 346 was treated under standard 
enol ether conditions, and this generated the silyl enol ether 351 that was used without purification 
in the next step (scheme 83).123 
 
Scheme 83: Formation of enol ether 
With 351 in hand it was exposed to Saegusa oxidation122 conditions, the mechanism of which is 
shown below in (scheme 84). The mechanism of the Saegusa oxidation involves coordination of 
palladium to the enol olefin 353 followed by loss of the silyl group and formation of an oxoallyl-
palladium complex (354 - 356). β-hydride elimination to furnish the resultant 357 in 62% over 
two steps. 
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Scheme 84: Mechanism of Saegusa oxidation  
Using these conditions, we were able to obtain 357 in 62% isolated yield, and the product was 
confirmed by the 1H NMR spectroscopy with enone signals for the new double bond group at δ 
6.38 and 6.03 ppm.   
As shown in the synthesis plan of xanthanolides in section 2; ideally, we required an exocyclic 
enone to introduce the side chain at C1. This could, in principle, be introduced via a SN2’ reaction 
of a methyl equivalent to 359, which in turn can be obtained via a Morita-Baylis-Hillman reaction 
on enone 357. Consequently, treatment of enone 357  with formaldehyde in presence of DMAP124 
furnished 358 which was subsequently acetylated to give ester 359 in 37% (scheme 85); 125,126 The 
structure of 359 was confirmed by the 1H NMR spectra with the appearance of a proton signal 
belonging to the double bond group at δ 5.79 ppm. Unfortunately, due to time constraints, this is 
as far as the synthesis got with the 8-membered analogue 359. 
 
Scheme 85: Baylis Hillman reaction 
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Scheme 86 describes the mechanism of BH-reaction124 which starts by the Michael addition of the 
amine to β-position of the α,β-unsaturated ketone 357 to form zwitterionic enolate 360 which 
subsequently reacts with the formaldehyde to form another zwitterion 361. This then subsequently 
deprotonates to form 362, which then can eliminate the amine, followed by proton transfer to give 
358. 
 
Scheme 86: Mechanism of Baylis Hillman reaction 
In parallel to the model synthesis work with the 8-membered system, we also explored routes of 
the synthesis with the 7-membered lactones 334 and 335. Using the seven-membered OTBS 
lactone (+)-335 (scheme 87) we were able to methylate at C-11 using methyl iodide giving 368 in 
excellent isolated yield of 92%. Decarboxylation of this product was then carried out to give the 
expected butyrolactone 365 in 21% and as well as the enone 366 in 15% isolated yield. The 
formation of butyrolactone 366 is a result of base mediated elimination of the OTBS giving the 
enone. The structure of 366 were confirmed by 1H NMR by the disappearance of the ester group 
and appearance of the double bond signals at δ 6.34 and 6.09 ppm, respectively. Clearly, this result 
is significant, as it introduces the methyl group at C-11, as well as the required enone within the 
7-memberred ring.  
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Scheme 87: Synthesis of enone 366  
In addition, butyrolactone (-)-334 was converted to α,β-unsaturated ketone 368 in 75% by 
mesylating of the hydroxyl group in 334 to give 367,127 which was simply treated with DBU to 
give 368111 in good isolated yield through an E1CB mechanism. The next step was the methylation 
of 368 with methyl iodide to give 369 in 53% which could be simply decarboxylate to give 366. 
The structure of 369 was confirmed by the disappearance of the doublet signal belong to one proton 
at δ 3.35 ppm (Scheme 88). 
  
Scheme 88: Mesylating reaction 
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In summary, for the two routes for the 7-membered rings systems we found that 335, which is 
formed by three steps in 80% yield, could be converted to 366, but in a poor 15%, isolated yield. 
Clearly, this needs further optimization, but does demonstrate that this is a feasible route to deliver 
the required enone. Alternatively, mesylation and elimination on 334, does provide the required 
enone 369, but further optimization is required to install the methyl group at C-11. Pleasingly, the 
Bayliss-Hilmann approach for the installation of the methyl group at C-10 looks promising when 
performed on the 8-membered model system (scheme 85), and it is envisaged this will applied to 
the 7-membered system once an optimized method has been developed for accessing the desired 
enone. 
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4. Conclusion and Future work  
In conclusion, a novel approach to construct new and valuable 1,3-dienes from propargyl 
alcohols using readily available boronic acids in presence of Pd(PPh3)4 as a catalysis via base-
free Suzuki-Miyaura coupling reaction was diveloped. The reaction involves two-steps, firstly 
the formation of intermediary allene, that is subsequently rearranged via a novel Pd(II)-OB(OH)2 
complex to give 1,3-dienes.  In addition, we optimized a new condition to rearrange unactivated 
allenes to 1,3-dienes by used of a novel Pd(II)-OB(OH)2. The mechanism of the reactions was 
proposed that a palladium hydride complex derived from simple Pd(PPh3)4 and boric acid can 
rearrange allene to their corresponding 1,3-dienes, and to support this mechanistic hypothesis we 
proved the existence a key intermediate π-allylpalladium complexes via direct sample loop and 
flow injection analysis by ESI-HRMS. 
We prepared 25 1,3-dienes via this approach which will increase the store of chemical prepared 
compounds and it could play an important role in preparation of new compound in the future. 
Additionally, in-line with the original aims of the thesis, we applied one of our prepared 1,3-diene 
in a singlet oxygen reaction to synthesise moracin M in only 4-steps. 
With reference of the mechanism in (scheme 56)100 and (scheme 60)95 we easily found that both 
of intermediate allenes were terminal or there are no alpha hydrogen and both of them have π-
allylpalladium complex. This led us to conclude that the condition of the both reaction are suitable 
to produce 1,3 diene  if we use used another alkyne that can allowed to form 1,3 diene with boric 
acid, without using alcohol, to let the elimination of β allyl hydropalladium happen instead of 
coupling reaction in (scheme 60). This conclusion can be used as a future work to optimize a new 
condition of forming 1,3 dienes from alkynes (Scheme 89). 
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Scheme 89: possible rearrangement reaction 
Boronic acid with Pd0 will form palladium hydride complex H-PdII-OB(OH)2, which is add to 
alkyne 370 then eliminate to form allene 371 which is easily rearrange to diene 372 under our 
optimized condition.101 
This procedure could also be undertaken in a bi-directional fashion (Scheme 90). Formation of 
bis-propargyl alcohol 374 from 373, followed by treatment with an appropriate arylboronic acid 
under our conditions, which should readily aromatize to 376. Similarly, treatment of bis 
arylboronic acids such as 377, with two equivalents of a propargyl alcohol 378 will yield 379. 
Systems such as those depicted below could have very useful physical properties as novel 
conjugated materials.81 
 
Scheme 90: Suggested future work 
In addition, we could investigate use metals other than palladium, for example nickel or platinum, 
to perform this allene to 1,3-diene rearrangement as they can also to generate the vital metal-
hydride species with boronic acids (or boric acid).  
The 1,3-dienes synthesized in section 3.1.1, could also be used to access analogues of resveratrol, 
as well be used in the total synthesis of other members of the moracin family of natural products. 
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For example, 1,3-dienes 158 and 159 could be used, via same previous route of synthesis (scheme 
91). 
 
Scheme 91: Future starting material 
We have also made progress on the total synthesis of the xanthanolides. Having accessed key 
intermediate 369 using the endoperoxide derived from 323, it is only 6-steps to complete the 
synthesis. We have demonstrated that the Bayliss-Hilmann approach can be applied to the 8-
membered analogue, and this will now be applied to 369 or analogues. 
 
Scheme 92: Future work for xanthatin 
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5. Experimental  
5.1. General 
All reagent chemicals were purchased from Sigma-Aldrich Chemical Company Ltd. and Lancaster 
Chemical Synthesis Ltd. Commercially available reagents were used and without further 
purification. The palladium reagents were obtained from Sigma-Aldrich Chemical Company Ltd 
and were handled under argon. 
All solvents were directly used commercially except tetrahydrofuran (THF) was distilled from 
sodium and benzophenone prior to use. Et2O was purchased dry from commercial suppliers. 
Petroleum ether refers to the fractions with a boiling point between 40-60°C. Air-sensitive 
reactions were carried out using oven-dried glassware under nitrogen atmosphere.  
IR spectra were recorded using a Perkin Elmer FTIR spectrometer (Paragon 100) using CH2Cl2 as 
a solvent, unless otherwise stated. Proton magnetic resonance spectra (1H NMR) and carbon 
magnetic resonance spectra (13C NMR) were recorded at 400MHz and 100MHz respectively using 
a Bruker Avance 400MHz spectrometer as solutions in deuterated CDCl3. Coupling constants are 
measured in hertz (Hz) and chemical shifts are quoted as parts per million (ppm).  
Thin layer chromatography (TLC) was carried out on Merck Kieselgel 60 GF254 aluminium foil 
backed silica plates. Plates were visualised by Ultra Violet light (254 nm), or vanillin stain. Flash 
chromatography was carried out using Merck Kieselgel 60 H silica or Matrix silica 60, with eluent 
specified. 
High and low-resolution mass spectra were carried out on a Thermofisher exactive (orbi) 
resolution mass spectrometer. Optical rotation measurements were recorded on a polar 2001 
polarimeter using chloroform as solvent. Melting point were recorded on a Stuart Scientific 
apparatus and are uncorrected.  
All propargyl alcohols are commercially available unless mentioned.  
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5.2.Synthetic procedures 
A- General procedure to prepare propargyl alcohol compounds.128 
The corresponding ketone (34.7 mmol) in THF (20 mL) was added dropwise to a solution of 
ethynylmagnesium bromide (154 mL, 52 mmol, 0.5 M) in THF at 0 ºC. The reaction mixture was 
then stirred for 6 h at room temperature. After addition of saturated aqueous NH4Cl the mixture 
was extracted with diethyl ether (50 mL). The organic layer was dried over MgSO4, filtered and 
the solvent removed under reduce pressure. The crude residue was then purified by column 
chromatography. 
B- General procedure to prepare dienes via boronic acid.81 
Boronic acid (3.15 mmol), and alkyne (1.00 mmol) were dissolved in 1,4-dioxane (5.0 mL) and 4 
Å sieves (approx. 400 mg) was added. The resultant mixture was heated to 75 ºC under a N2 or 
argon atmosphere for 1 h. To the reaction mixture was added Pd(PPh3)4 (58 mg. 0.05 mmol, 5.0 
mol%) in one portion and the resultant yellow solution heated for a further 20 h. The reaction was 
cooled, diluted with Et2O (50 mL) and washed with NaHCO3 (50 mL). Aqueous layer was 
extracted with Et2O (50 mL) and the combined organic layers washed with brine (50 mL), dried 
over MgSO4, filtered and the solvent removed under reduce pressure. The crude residue was 
purified by column chromatography. 
77222General procedure to prepare allenes via boronic acid. -C  
Boronic acid (3.15 mmol), and alkyne (1.00 mmol) were dissolved in 1,4-dioxane (5.0 mL) and 4 
Å sieves (approx. 400 mg) added. The resultant was then heated to 70ºC under a N2 or argon 
atmosphere for 1 h. and to the reaction mixture was added Pd(PPh3)4 (58 mg. 0.05 mmol, 5.0 
mol%) in one portion and the resultant yellow solution heated for a further 4 h. After this period 
the reaction was cooled, diluted with Et2O (50 mL) and transferred to a separating funnel and 
washed with NaHCO3 (50mL). The aqueous layer was then extracted with Et2O (50 mL) and the 
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combined organic layers washed with brine (50 mL), dried with MgSO4, filtered and the solvent 
removed under reduced pressure. The crude residue was then purified by column chromatography. 
D- General procedure for allene to 1,3-diene isomerization. 
To a solution of allene (1.00 mmol) in 1,4-dioxane (5.00 mL) was added boric acid (123 mg, 2.00 
mmol) and Pd(PPh3)4 (116 mg. 0.10 mmol, 10 mol%) in one portion. The resultant reaction 
mixture was stirred and heated at 75ºC under a N2 or argon atmosphere for 24 h. After this period. 
The reaction was cooled, diluted with Et2O (50 mL) and transferred to a separating funnel and 
washed with NaHCO3 (50 mL). The aqueous layer was extracted with Et2O (50 mL), and the 
combined organic layers washed with brine (50 mL), dried over MgSO4, filtered and the solvent 
removed under reduced pressure. The crude residue was purified by column chromatography.  
5.3. Products Data 
1-Ethynylcycloheptanol. (152)129 
 
This compound was prepared according to the general procedure A, giving yellow oil (4.55 g, 
95%, Rf 0.55 in ethyl acetate /hexane : 1/4); IR (CH2Cl2) vmax 3394, 3302, 2931, 2862, 1458, 1126, 
cm-1; 1H NMR (400 MHz; CDCl3) δ 2.43 (s, 1H), 2.07 (s, 1H), 2.01-1.96 (m, 4H), 1.80 (t, J = 4 
Hz,  2H), 1.66-1.54 (m, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 88.9, 71.6, 71.3, 43.1, 28.1, 
22.1ppm.  
1-Ethynylcyclooctanol. (154)130 
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This compound was prepared according to the general procedure A, giving a white solid (4.542 g, 
86%) (Rf 0.92 in ethyl acetate /hexane : 1/4); IR (CH2Cl2) vmax 3278, 2916, 2854, 1450, 1234 cm
-
1; 1H NMR (400 MHz; CDCl3) δ 2.41 (s, 1H), 2.20 (s, 1H), 2.00-1.82 (m, 4H), 1.62 - 1.52 (m, 7H), 
1.51-1.38 (m, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 88.7, 71.1, 71.2, 38.0, 28.1, 24.7, 22.0 
ppm.  
8-Ethynyl-1,4-dioxaspiro[4.5]decan-8-ol (156)131 
 
This compound was prepared according to the general procedure A, giving a yellow oil (6.0 g, 
95%) (Rf 0.45 in ethyl acetate /hexane: 1/4); IR (CH2Cl2) vmax 3586, 3301, 2960, 2306, 1265 cm
-
1; 1H NMR (400 MHz; CDCl3) δ 3.89 (s, 4H), 2.46 (s, 1H), 2.34 (s, 1H), 2.01-1.82 (m, 4H), 1.79 - 
1.73 (m, 4H) ppm; 13C NMR (100 MHz; CDCl3) δ 107.9, 86.7, 70.0, 67.0, 64.2, 37.0, 31.0 ppm. 
(2-cyclohexylideneethenyl) benzene (136) 132 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (130 mg, 71%)  (Rf 0.45, 100% petroleum ether); IR (CH2Cl2) vmax 2926, 1952, 1459, 1446 cm
-
1; 1H NMR (400 MHz; CDCl3) δ 7.28 (d, J = 4 Hz, 4H), 7.18-7.13 (m, 1H), 6.00-5.98 (m, 1H), 
2.17-2.09 (m, 4H), 2.03-1.96 (m, 4H), 1.70-1.60 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 
199.8, 136.2, 128.6, 126.5, 126.4, 106.6, 92.4, 31.4, 27.8, 26.2 ppm; HRMS [M+H+] calculated 
for C14H17 185.1325, found 185.1321. 
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[(E)-2-(Cyclohex-1-en-1-yl) ethenyl] benzene (137).133 
 
This compound was prepared according to the general procedure B, giving a viscous colourless 
oil (142mg, 78%) (Rf 0.29, 100% petroleum ether); IR (CH2Cl2) vmax 3082, 2933, 1641, 1493, 739 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.43-7.35 (m, 2H), 7.42-7.32 (m, 2H), 7.21-7.13 (m, 1H), 6.76 
(d, J = 16.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 5.88 (t, J = 4.0 Hz, 1H), 2.30-2.22 (m, 2H), 2.21-
2.15 (m, 2H), 1.78-1.69 (m, 2H), 1.60-1.67 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 138.1, 
135.9, 132.7, 130.94, 128.8, 128.6, 127.3, 126.9, 126.2, 124.7, 26.2, 24.6, 22.6, 22.6 ppm; HRMS 
[M+H+] calculated for C14H17 185.1325, found 185.1321.  
1-[(E)-2-(Cyclohex-1-en-1-yl) ethenyl]-3-methylbenzene (138).81 
 
This compound was prepared according to the general procedure, to give a  viscous colourless oil 
(198 mg, 99%) (Rf 0.45, 100% petroleum ether); IR (CH2Cl2) vmax 3045, 2965, 1640, 732 cm-
1; H 
NMR (400 MHz; CDCl3) δ 7.15-7.24 (m, 3H), 6.99-6.97 (m, 1H), 6.75 (d, J = 16.0 Hz, 1H), 6.39 
(d, J = 16.0, Hz 1H), 5.87 (t, J = 4.0 Hz, 1H),  2.33 (s, 3H), 2.30-2.21 (m, 2H), 2.21-2.13 (m, 2H), 
1.78-1.68 (m, 2H), 1.67-1.59 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 138.1, 138.0, 136.0, 
132.5, 130.7, 128.5, 127.7, 127.0, 124.8, 123.4, 26.2, 24.6, 22.6, 22.6, 21.5 ppm; HRMS [M+H+] 
calculated for C15H19 199.1418, found 199.1487. 
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1-[(E)-2-(Cyclohex-1-en-1-yl) ethenyl]-4-methoxybenzene (139).134 
 
This compound was prepared according to the general procedure, giving a colourless oil (186 mg, 
87%) (Rf 0.52, ethyl acetate : petroleum ether / 1:10 ); IR (CH2Cl2) vmax  3054, 2986, 1683, 1512, 
739 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.32-7.30 (m, 2H), 6.89-6.85 (m, 2H), 6.65 (d, J = 16.4 
Hz, 1H), 6.39 (d, J = 16.4 Hz, 1H), 5.87 (t, J = 3.6 Hz, 1H), 3.80 (s, 3H), 2.30-2.23 (m, 2H), 2.20-
2.14 (m. 2H), 1.78-1.68 (m, 2H), 1.67-1.59 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 158.8, 
135.5, 131.1, 131.0, 129.7, 127.2, 124.1, 114.2, 55.1, 26.2, 24.5, 22.2, 22.1 ppm; HRMS [M+H+] 
calculated for C15H18O 215.1436, found 215.1448. 
1-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]-3-methoxybenzene (140).81 
 
This compound was prepared according to the general procedure, giving a viscous colourless oil 
(129 mg, 60%) (Rf 0.54, ethyl acetate : petroleum ether / 1:10); IR (CH2Cl2) vmax 3010, 2931, 1651, 
1157, 771 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.21-7.19 (m, 1H), 6.99 (d, J = 16.0 Hz, 1H), 6.92 
(s, 1H), 6.79-6.71 (m, 2H), 6.40 (d, J = 16.0 Hz, 1H), 5.89 (t, J = 4.0 Hz, 1H), 3.81 (s, 3H), 2.30-
2.21 (m, 2H), 2.21-2.15 (m. 2H), 1.78-1.68 (m, 2H), 1.67-1.59 (m, 2H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 159.9, 139.6, 135.9, 133.0, 131.2, 129.5, 124.6, 119.0, 112.6, 111.4, 55.2, 26.2, 24.6, 
22.6, 22.6 ppm; HRMS [M+H+] calculated for C15H19O 215.1430, found 215.1436. 
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1-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]naphthalene (141).81 
 
This compound was prepared according to the general procedure, giving a colourless oil (220 mg, 
94%) (Rf 0.36, 100% petroleum ether); IR (CH2Cl2) vmax 3027, 2973, 1655, 732 cm
-1; 1H NMR 
(400 MHz; CDCl3) δ 8.13-8.11 (m, 1H), 7.82-7.80 (m, 1H), 7.74-7.71 (m, 1H), 7.63-7.61 (m, 1H), 
7.53-7.39 (m, 3H), 7.19 (d, J = 15.6 Hz, 1H), 6.80 (d, J = 15.6 Hz, 1H), 5.95 (t, J = 3.6 Hz, 1H), 
2.44-2.38 (m, 2H), 2.27-2.18 (m. 2H), 1.82-1.77 (m, 2H), 1.71-1.63 (m, 2H) ppm; 13C NMR (100 
MHz; CDCl3) δ 136.3, 135.8, 135.7, 133.8, 131.4, 131.3, 128.6, 127.3, 125.9, 125.8, 125.7, 123.9, 
123.2, 121.6, 26.3, 24.8, 22.7, 22.6 ppm; HRMS [M+H+] calculated for C18H19 235.1481, found 
235.1486. 
4-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]-1,2-dimethoxybenzene (142).81 
 
This compound was prepared according to the general procedure B, giving a yellow oil (138 mg, 
57%) (Rf 0.59, ethyl acetate : petroleum ether / 15:85); IR (CH2Cl2) vmax 3035, 2944, 1589, 1234, 
756 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.95-6.86 (m, 2H), 6.80-6.78 (d, 1H), 6.62 (d, J = 16.4 
Hz, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.87 (t, J = 4.4 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 2.30-2.22 
(m, 2H), 2.12-2.12 (m. 2H), 1.78-1.68 (m, 2H), 1.67-1.58 (m, 2H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 149.1, 148.4, 135.8, 13.97, 130.1, 124.5, 120.9, 119.3, 111.4, 108.6, 56.0, 55.9, 26.2, 
24.7, 22.7, 22.6 ppm; HRMS [M+H+] calculated for C16H21O2 245.1536, found 245.1534. 
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4-(1-(Cyclohex-1-en-1-yl)vinyl)-1,2-dimethoxybenzene (143) 
 
This compound was prepared according to the general procedure B, giving a viscus yellow oil (70 
mg, 29%) (Rf 0.69, ethyl acetate:petroleum ether/15:85); IR (CH2Cl2) vmax 3045, 2931, 1658, 1249, 
758 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.81-6.78 (m, 3H), 5.67 (t, J = 4 Hz, 1H), 5.13 (s, 1H), 
4.96 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 2.30-2.21 (m, 2H), 2.15-2.06 (m, 2H), 1.75 - 1.67 (m, 2H), 
1.63-1.54 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 151.4,148.3, 148.1, 137.3, 134.8, 128.8, 
121.0, 120.9, 112.1, 110.6, 110.4, 55.9, 26.6, 25.9, 22.8, 22.2 ppm; HRMS [M+H+] calculated for 
C16H21O2 245.1536, found 245.1534. 
5-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]-1,3-dimethoxybenzene (144).81 
 
This compound was prepared according to the general procedure B, giving a yellow oil (152 mg, 
62%) (Rf 0.58, ethyl acetate : petroleum ether / 15:85); IR (CH2Cl2) vmax 2931, 2839, 1589, 1280, 
1203, 1049 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.72 (d, J = 16.4 Hz, 1H), 6.55 (s, 1H), 6.54 (s, 
1H), 6.36 (d, J = 16.0 Hz, 1H), 6.32 (m, 1H), 5.89 (m, 1H), 3.79 (s, 6H), 2.30-2.22 (m, 2H), 2.16-
2.12 (m, 2H), 1.78-1.68 (m, 2H), 1.68-1.60 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 161.0, 
140.2, 135.8, 133.2, 131.3, 128.8, 127.3, 124.7, 104.3, 99.4, 55.4, 26.2, 24.6, 22.6 ppm;  HRMS 
[M+H+] calculated for C16H21O2 245.1536, found 245.1539. 
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1-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]-4-methyl(carboxy)benzene (145).81 
 
This compound was prepared according to the general procedure B, giving a yellow oil (170 mg, 
70%) (Rf 0.36, ethyl acetate : petroleum ether / 15:85); IR (CH2Cl2) vmax 2931, 1712, 1604, 1435, 
1180, 964 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.96-7.93 (m, 2H), 7.45-7.42 (m, 2H), 6.85 (d, J = 
16.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 5.97-5.95 (m, 1H), 3.88 (s, 3H), 2.30-2.16 (m, 4H), 1.74-
1.70 (m, 2H), 1.66-1.60 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 167.1, 142.8, 135.8, 135.2, 
133.0, 132.9, 130.0, 126.0, 123.7, 52.1, 26.33, 24.5, 22.5, 22.4 ppm; HRMS [M+H+] calculated 
for C16H18O2 243.1385, found 243.1379. 
2-[(E)-2-(Cyclohex-1-en-1-yl)ethenyl]furan (146).81 
 
This compound was prepared according to the general procedure, giving a colorless oil (114 mg, 
66%) (Rf 0.86, ethyl acetate : petroleum ether / 1:10); IR (CH2Cl2) vmax 2953,1728, 1635, 1081, 
730 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.31 (d, J = 16.0 Hz, 1H), 6.78 (d, J = 16.0 Hz, 1H), 6.44-
6.42 (m, 1H), 6.20-6.18 (m, 1H), 6.19-6.17 (m, 1H), 5.88 (t, J = 3.2 Hz, 1H), 2.15-2.12 (m, 4H), 
1.69-1.60 (m, 2H), 1.59-1.55 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 153.9, 141.4, 135.5, 
131.2, 131.0, 113.0, 111.4, 106.9, 26.2, 24.2, 22.6, 22.5 ppm; HRMS [M+H+] calculated for 
C12H13O 173.0961, found 173.0981. 
(E)-1-Bromo-4-(2-(cyclohex-1-en-1-yl)vinyl)benzene (147) 
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This compound was prepared according to the general procedure B, giving a white solid (<5%,  Rf 
0.38, 100% petroleum ether); 1H NMR (400 MHz; CDCl3) δ 7.55 (d, J = 4.4 Hz, 2H), 7.41 (d, J = 
4.0 Hz, 2H), 6.73 (d, J = 16.0 Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 5.90 (t, J = 3.6 Hz, 1H), 2.22 (t, 
J = 4.0 Hz, 2H), 2.16 (s, 2H), 1.72-1.68 (m, 2H), 1.65-1.60 (m, 2H) ppm. 
 [(E)-2-(Cyclopent-1-en-1-yl)ethenyl]benzene (149).133 
 
This compound was prepared according to the general procedure, giving a colourless oil (102 mg, 
61%) (Rf 0.29, 100% petroleum ether); IR (CH2Cl2) vmax 3054, 2986, 1598, 1420, 738 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.48-7.46 (m, 2H), 7.36-7.34 (m, 2H), 7.24-7.22 (m, 1H), 6.99 (d, J = 
16.0 Hz, 1H), 6.46 (d, J = 16.0 Hz, 1H), 5.89-5.86 (m, 1H), 2.6-2.55 (m, 2H), 2.54-2.49 (m, 2H), 
2.05-1.94 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 142.9, 137.9, 132.2, 128.8, 128.6, 127.2, 
126.2, 125.9, 33.1, 31.3, 23.23 ppm; HRMS [M+H+] calculated for C13H13 169.1012, found 
169.1024. 
1-[(E)-2-(Cyclopent-1-en-1-yl)ethenyl]-4-methylbenzene (150).81 
 
This compound was prepared according to the general procedure, giving a white solid (122 mg, 
67%) (Rf 0.33, 100% petroleum ether); IR (CH2Cl2) vmax 3030, 2923, 1605, 1512, 813 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.30-7.28 (m, 2H), 7.12-7.10 (m, 2H), 6.98 (d, J = 16.0 Hz, 1H), 6.40 
(d, J = 16.0 Hz, 1H), 5.81 (t, J = 4.0 Hz, 1H), 2.59-2.50 (m, 2H), 2.49-2.43 (m, 2H), 2.35 (s, 3H), 
2.01-1.91 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 143.0, 137.0, 135.1, 131.5, 129.8, 129.4, 
128.7, 128.4, 126.2, 125.0, 33.1, 31.3, 23.3, 21.3 ppm; HRMS [M+H+] calculated for C14H16 
185.1330, found 185.1319. 
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1-[(E)-2-(Cyclopent-1-en-1-yl)ethenyl]-4-methoxybenzene (151).133 
 
This compound was prepared according to the general procedure, giving a colourless oil (155 mg, 
78%) (Rf 0.73, ethyl acetate : petroleum ether / 1:20); IR (CH2Cl2) vmax 3035, 2947, 1567, 1465, 
1172, 732 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.38-7.34 (m, 2H), 6.90 (d, J = 16.0 Hz, 1H), 6.87-
6.83 (m, 2H), 6.37 (d, J = 16.0 Hz, 1H), 5.79 (t, J = 2.0 Hz, 1H), 3.80 (s, 3H),  2.57-2.50 (m, 2H), 
2.49-2.41 (m, 2H), 2.01-1.91 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 159.0, 143.0, 130.9, 
130.7, 128.3, 127.5, 123.9, 114.1, 55.4, 33.1, 31.3, 23.3 ppm; HRMS [M+H+] calculated for 
C14H17O 201.1274, found 201.1286. 
1-[(E)-2-Phenylethenyl]cycloheptene (153).133 
 
This compound was prepared according to the general procedure, giving a colorless oil (158 mg, 
80%) (Rf 0.19, 100% petroleum ether); ; IR (CH2Cl2) vmax 3020, 2924, 1618, 1448, 694 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.40-7.38 (m, 2H), 7.30-7.28 (m, 2H), 7.16-7.13 (m, 1H), 6.74 (d, J = 
16.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 6.04 (t, J = 6.8 Hz, 1H), 2.45-2.41 (m, 2H), 2.20-2.18 (m, 
2H), 1.80-1.76 (m, 2H), 1.53-1.48 (m, 4H) ppm; 13C NMR (100 MHz; CDCl3) δ 143.2, 138.2, 
135.6, 133.4, 128.6, 126.9, 126.3, 124.8, 32.4, 28.9, 27.4, 26.9, 26.4 ppm; HRMS [M+H+] 
calculated for C15H19 199.1480, found 199.1479. 
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(1E)-1-[(E)-2-Phenylethenyl] cyclooctene (155).135 
 
This compound was prepared according to the general procedure, giving a colorless oil (159 mg, 
75%) (Rf 0.62, 100% petroleum ether); IR (CH2Cl2) vmax 3013, 2916, 1597, 1450, 745 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.44-7.42 (m, 2H), 7.31-7.28 (m, 2H), 7.20-7.17 (m, 1H), 6.74 (d, J = 
16.4 Hz, 1H), 6.49 (d, J = 16.4 Hz, 1H), 5.85 (t, J = 4.2 Hz, 1H), 2.51-2.48 (m, 2H), 2.27-2.24 (m, 
2H), 1.69-1.45 (m, 8H) ppm; 13C NMR (100 MHz; CDCl3) δ 139.4, 138.1, 133.9, 132.4, 128.7, 
126.9, 126.5, 125.3, 30.6, 28.7, 27.3, 26.9, 24.5 ppm; HRMS [M+H+] calculated for C16H21 
213.1638, found 213.1635. 
8-[(E)-2-(3,5-Dimethoxyphenyl)ethenyl]-1,4-dioxaspiro[4.5]dec-7-ene (5).81 
 
This compound was prepared according to the general procedure B with extending heating to 68 
hours, giving a colorless oil (130 mg, 43%) (Rf 0.18, diethyl ether : hexane / 3:7); IR (CH2Cl2) 
vmax 3055, 2939, 1589, 1203, 1149, 702 cm
-1; 1H NMR (400 MHz; CDCl3) δ 6.71 (d, J = 16.0 Hz, 
1H), 6.57-6.55 (m, 2H), 6.39 (d, J = 16.0 Hz, 1H), 6.35-6.31 (m, 1H), 5.78 (t, J = 4.0 Hz, 1H), 
3.98 (s, 4H), 3.78 (s, 6H), 2.50-2.47 (m, 2H), 2.44-2.41 (m, 2H), 1.85-1.83 (m, 2H) ppm; 13C NMR 
(100 MHz; CDCl3) δ 160.9, 139.9, 135.3, 131.8, 127.4, 126.2, 108.1, 104.4, 99.5, 64.6, 55.4, 36.5, 
30.9, 23.8 ppm; HRMS [M+H+] calculated for C18H23O4 303.1591, found 303.1580. 
 
(E)-8-(4-methoxystyryl)-1,4-dioxaspiro[4.5]dec-7-ene (158) 
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This compound was prepared according to the general procedure B with extending heating to 68 
hours, colorless oil, (217 mg, 80%) (Rf 0.36, Et2O:petroleum ether / 1:3); IR (CH2Cl2) vmax  2938, 
1595, 1485, 1284, 1111 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.31 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 
8.0 Hz, 2H), 6.65 (d, J = 16.0 Hz, 1H), 6.39 (d, J = 16.0 Hz, 1H), 5.72 (t, J = 4.0 Hz, 1H), 3.99 (s, 
4H), 3.79 (s, 3H), 2.49 (t, J = 5.2 Hz, 2H), 2.43 (s, 2H), 1.86 (t, J = 6.4 Hz, 2H) ppm; 13C NMR 
(100 MHz; CDCl3) δ 158.9, 135.4, 130.6, 129.3, 127.4, 125.9, 125.7, 114.0, 108.1, 64.5, 55.3, 
36.3, 30.9, 23.8 ppm; HRMS [M+H+] calculated for C17H21O3 273.1485, found 273.1477  
(E)-8-(3methoxystyryl)-1,4-dioxaspiro[4.5]dec-7-ene (159) 
 
This compound was prepared according to the general procedure B with extending heating to 72 
hours, giving a colorless oil (220 mg, 81%) (Rf 0.47, diethyl ether : hexane / 1:3); IR (CH2Cl2) 
vmax 2938, 1595, 1485, 1252, 1111, 773 cm
-1; 1H NMR (400 MHz; CDCl3) δ 7.21 (t, J = 8.0 Hz, 
1H), 6.98 (d, J = 8.0 Hz, 1H), 6.92 (t, J = 2.0 Hz, 1H), 6.78-6.74 (m, 2H), 6.42 (d, J = 16.0 Hz, 
1H), 5.78 (t, J = 4.0 Hz, 1H), 3.99 (s, 4H), 3.79 (s, 3H), 2.52-2.49 (m, 2H), 2.44 (s, 2H), 1.88-1.85 
(t, J = 3.6 Hz, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 159.8, 139.3, 135.3, 131.5, 129.5, 127.2, 
126.1, 119.0, 112.7, 111.6, 108.1, 64.5, 55.2, 36.4, 30.9, 23.8 ppm; HRMS [M+H+] calculated for 
C17H21O3 273.1485, found 273.1477. 
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[(1E)-3-Methylbuta-1,3-dien-1-yl]benzene (161).136 
 
This compound was prepared according to the general procedure B, giving a viscous colorless oil 
(122 mg, 85%) (Rf 0.31, 100% petroleum ether); IR (CH2Cl2) vmax 3025, 2968, 1645, 1493, 1265, 
739 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.45-7.43 (m, 2H), 7.37-7.35 (m, 2H), 7.27-7.24 (m, 1H), 
6.94 (d, J = 16.0 Hz, 1H), 6.55 (d, J = 16.0 Hz, 1H), 5.11 (s, 1H), 5.07 (s, 1H), 2.01 (s, 3H) ppm; 
13C NMR (100 MHz; CDCl3) δ 142.1, 137.5, 131.8, 128.8, 128.7, 127.5, 126.7, 117.4, 22.8 ppm; 
HRMS [M+H+] calculated for C11H13 145.1012, found 145.1021. 
1-Methyl-4-[(1E)-3-methylbuta-1,3-dien-1-yl]benzene (162).137 
 
This compound was prepared according to the general procedure B, giving a white solid (74 mg, 
47%) (Rf 0.39, 100% petroleum ether); IR (CH2Cl2) vmax 3051, 2986, 1603, 1513, 738 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.37-7.34 (m, 2H), 7.17-7.14 (m, 2H), 6.85 (d, J = 16.0 Hz, 1H), 6.52 
(d, J = 16.0 Hz, 1H), 5.09 (s, 1H) 5.04 (s, 1H), 2.35 (s, 3H), 1.99 (s, 3H) ppm; 13C NMR (100 
MHz; CDCl3) δ 142.3, 137.4, 134.7, 130.8, 129.4, 128.7, 126.5, 116.9, 21.3, 18.7 ppm; HRMS 
[M+H+] calculated for C12H15 159.1168, found 159.1163.  
(E)-1-methoxy-4-(3-methylbuta-1,3-dien-1-yl)benzene(163).101 
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This compound was prepared in overall yield according to the general procedure B, giving a white 
solid (170 mg, 98%) (Rf 0.78, ethyl acetate:petroleum ether / 1:10); IR (CH2Cl2) vmax 3032, 2986, 
1640, 1265, 732 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.36 (d, J = 6.8 Hz, 2H), 6.86 (d, J = 6.8 Hz, 
2H), 6.75 (d, J = 16.4 Hz, 1H), 6.48 (d, J = 16.0 Hz, 1H), 5.06 (s, 1H), 5.01 (s, 1H), 3.81 (s, 3H), 
1.96 (s, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 159.2, 142.2, 130.2, 129.7, 128.2, 127.7, 116.3, 
114.1, 55.3, 18.7 ppm; HRMS [M+H+] calculated for C11H15O 163.1117 found 163.1112. 
 [(1E)-3-Phenylbuta-1,3-dien-1-yl]benzene (165).136 
 
This compound was prepared according to the general procedure B, giving a colorless volatile oil 
that readily degraded upon standing (152 mg, 74%) (Rf 0.28, 100% petroleum ether); IR (CH2Cl2) 
vmax 3054, 2986, 1642, 1421, 739 cm
-1; 1H NMR (400 MHz; CDCl3) δ 7.45-7.23 (m, 10H), 7.11-
7.08 (m, 1H), 6.52 (m, 1H), 5.46 (s, 1H), 5.28 (s, 1H) ppm; 13C NMR (100 MHz; CDCl3) δ 148.2, 
140.2, 137.2, 132.0, 130.8, 128.9, 128.6, 128.3, 127.9, 127.8, 126.5, 117.5 ppm; HRMS [M+H+] 
calculated for C16H15 207.1168, found 207.1165. 
1-Methyl-3-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]benzene (167).81 
 
This compound was prepared according to the general procedure, giving a colorless oil (93 mg, 
55%) (Rf 0.41, 100% petroleum ether); IR (CH2Cl2) vmax 3025, 2980, 1640, 1442, 732 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.28-7.17 (m, 3H), 6.98-6.96 (m, 1H), 6.79 (d, J = 16.0 Hz, 1H), 6.38 
(d, J = 16.0, 1H), 5.68 (q,  J = 6.8 Hz, 1H), 2.31 (s, 3H), 1.81 (s, 3H), 1.78 (d, J = 6.8 Hz, 3H) 
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ppm; 13C NMR (100 MHz; CDCl3) δ 138.0, 138.4, 134.8, 133.8, 128.3, 128.0, 127.8, 127.0, 125.0, 
123.0, 21.8, 14.0, 12.0 ppm; HRMS [M+H+] calculated for C13H17 173.1325, found 173.1323. 
1-Methyl-4-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]benzene(168) 
 
This compound was prepared according to the general procedure B, giving a colorless oil (125 mg, 
73%) (Rf 0.42, 100% petroleum ether); IR (CH2Cl2) vmax 3024, 2924, 1602, 1512, 732 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.29 (d, J = 8.2 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 6.76 (d, J = 16.0 Hz, 
1H), 6.41 (d, J = 16.0 Hz, 1H), 5.68 (q, J = 7.0 Hz, 1H), 2.32 (s, 3H), 1.86-1.83 (m, 3H), 1.78 (d, 
J = 7.4 Hz, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 136.7, 135.3, 133.0, 129.5, 129.3, 127.6, 
127.0, 125.2, 21.2, 14.1, 12.1 ppm; HRMS [M+H+] calculated for C13H17 173.1325 found 
173.1317. 
(E)-10,13–Dimethyl-17-(3-methylstyryl)-1,2,6,7,8,9.10,11,12,13,14,15–dodecahydro-3H-
cyclopenta[a]phenanthren-3-one (170).81 
 
This compound was prepared according to the general procedure, to give colorless oil (220 mg, 
57%) (Rf 0.11, ethyl acetate : petroleum ether / 1:10); IR (CH2Cl2) vmax  3050, 2955, 1675, 1610, 
1450, 732 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.21-7.16 (m, 4H), 7.05-7.03 (d, J = 5.6 Hz, 1H), 
6.48 (d, J = 16.0 Hz, 1H), 6.35 (d, J = 16.0 Hz, 1H), 5.69 (s, 1H), 2.40-0.80 (m, 26H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 199.7, 171.3, 138.3, 137.0, 134.5, 128.6, 128.3, 127.8, 127.1, 124.0, 
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123.7, 84.0, 53.6, 49.8, 47.1, 38.7, 36.4, 35.7, 32.9, 23.7, 21.5, 20.7, 17.5, 14.2 ppm; HRMS 
[M+H+] calculated for C28H35O 387.2682, found 387.2677. 
 (E)-1-Methyl-2-(3-methylpent-1-ene-1-yl)denzene (172). 
 
This compound was prepared according to the general procedure B, giving a colorless oil (113 
mg, 65%) (Rf 0.42, 100% petroleum ether); IR (CH2Cl2) vmax 3068, 2969, 1485, 1459, 1412 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 7.42-7.37 (m, 2H), 7.21- 7.01 (m, 2H), 6.47 (d, J = 16.4 Hz, 1H), 
6.32 (d, J = 16.8Hz, 1H), 2.41 (s, 3H), 2.19-2.09 (m, 1H), 1.98-1.88 (m, 2H), 1.35 (d, 3H), 0.79 
(t, J = 7.2 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 141.8, 132.5, 128.7, 128.6, 127.79, 
127.7, 125.4, 124.8, 45.2, 32.44, 22.9, 19.8, 9.2; [M+H+], calculated for C13H17 173.1325, found 
173.1218. 
C. 1,1'-Buta-1,2-diene-1,3-diyldibenzene (173).95 
 
This compound was prepared according to the general procedure C, giving a colourless oil (187 
mg, 91%) (Rf  0.45, 100% petroleum ether); IR (CH2Cl2) vmax 3082, 3060, 1935, 1686, 1493 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 7.68-7.61 (m, 2H), 7.51-7.44 (m, 6H), 7.40-7.32 (m, 2H), 6.52 (q, 
J = 3.2 Hz, 1H), 2.27 (s, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 207.0, 136.5, 134.7, 128.9, 
128.6, 127.2, 127.1, 126.0, 104.7, 96.8, 16.9 ppm; HRMS [M+H+] calculated for C16H14 207.1174, 
found 207.1168. 
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1-Methyl-2-(3-phenylbuta-1,2-dien-1-yl)benzene. (226)77 
 
 This compound was prepared according to the general procedure C, giving a viscous yellow oil 
(184 mg, 84%) (Rf 0.41, 100% petroleum ether); IR (CH2Cl2) vmax 3020, 2948, 1933, 1599, 1492 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.53 (d, J = 1.6 Hz, 2H),7.52-7.35 (m, 2H), 7.32-7.25 (m, 
3H), 7.22-7.14 (m, 2H) 6.72 (t, J = 3.2 Hz, 1H), 2.46 (s, 3H), 2.21 (d, J = 2.4 Hz, 3H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 207.5, 140.4 136.5, 135.4, 128.6, 128.1, 127.2, 127.1, 126.3, 125.9, 
125.7, 102.2, 92.9, 18.6, 15.7 ppm; HRMS [M-H+] calculated for C16H15 207.1168, found 
207.1181. 
(2-Cyclohexylidene ethenyl)-benzene (136).132, 138 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (130 mg, 71%) (Rf 0.45, 100% petroleum ether); IR (CH2Cl2) vmax 2926, 1952, 1459, 1446 cm
-
1; 1H NMR (400 MHz; CDCl3) δ 7.28-7.26 (m, 4H), 7.17-7.13 (m, 1H), 5.99 (d, J = 2.0 Hz, 1H), 
2.27-2.24 (m, 2H), 2.21-1.17 (m, 2H), 1.70-1.54 (m, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 
199.8, 136.2, 128.6, 126.5, 126.4, 106.6, 92.4, 31.4, 27.8, 26.2 ppm; HRMS [M+H+] calculated 
for C14H17 185.1325, found 185.1336. 
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1-(2-cyclohexylideneethenyl)-4-methylbenzene (227).84 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (127 mg, 64%) (Rf 0.25, 100% petroleum ether); IR (CH2Cl2) vmax 2932, 1902, 1513, 1451 cm
-
1; 1H NMR (400 MHz; CDCl3) δ  7.26 (dd, J = 8.0, 8.4 Hz, 2H), 7.10 (dd, J = 8.0, 8.0 Hz, 2H), 
6.21 (t, J = 16.4 Hz, 1H), 2.32 (d, J = 5.2 Hz, 3H), 2.08-2.03 (m, 2H), 1.96-1.92 (m, 2H), 1.63-
1.52 (m, 4H) 1.44-1.38 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 138.8, 136.6, 129.2, 127.5, 
126.8, 126.0, 36.6, 26.4, 22.7, 21.2 ppm; HRMS [M+H+] calculated for C15H19, 199.1481 found 
199.1479. 
1-(2-Cyclohexylideneethenyl)-2-methylbenzene (228). 
 
 This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (119 mg, 60%) (Rf 0.44, 100% petroleum ether); IR (CH2Cl2) vmax 3060, 2926, 1951, 1600, 
1452 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.34-7.18 (m, 4H),  6.26 (m, 1H), 2.44 (s, 3H), 2.20-
2.10, (m, 4H), 1.80-1.70 (m, 4H), 0.97-0.94 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 200.6, 
141.6, 135.8, 129.8, 129.6, 127.4, 125.2, 105.0, 89.9, 31.4, 29.4, 26.5, 19.8 ppm; HRMS [M+H+] 
calculated for C15H19 199.1481, found 199.1494. 
(2-Cyclohexylidene ethenyl)-3-methoxybenzene (229).101 
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This compound was prepared according to the general procedure C, giving viscous colourless oil 
(135 mg, 63%) (Rf  0.89, ethyl acetate : petroleum / 5 : 95); IR (CH2Cl2) vmax 2924, 1951, 1459, 
1442, 1149 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.19 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 
6.84 (t, J = 8.0 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 5.96 (t, J = 2.0 Hz, 1H), 3.79 (s, 3H), 2.27-2.24 
(m, 2H), 2.20-1.17 (m, 2H), 1.70-1.58 (m, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 199.8, 159.9, 
137.8, 129.5, 119.3, 112.0, 111.8, 106.7, 92.4, 55.2, 31.4, 27.8, 26.2 ppm; HRMS [M+H+] 
calculated for C15H19O 215.1430, found 215.1434. 
 (2-Cyclohexylidene ethenyl)-3-methylbenzene (230).101 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (89 mg, 45%) (Rf 0.39, 100% petroleum ether); IR (CH2Cl2) vmax 2924, 1951, 1604, 1442, 1226 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.17 (d, J = 7.6 Hz, 2H), 7.09 (d, J = 2.8 Hz, 2H), 6.98 (d, J 
= 6.8 Hz, 1H), 5.96 (d, J = 2.0 Hz, 1H), 2.34, (s, 3H), 2.32-2.24 (m, 2H), 2.21-2.18 (m, 2H), 1.70-
1.56 (m, 6H) ppm; 13C NMR (100 MHz; CDCl3) 199.7, 138.1, 136.1, 128.5, 127.8, 127.2, 123.7, 
106.4, 92.4, 31.4, 27.8, 26.2, 21.5 ppm; HRMS [M+H+] calculated for C15H19 199.1481, found 
199.1694. 
1-Bromo-4-(2-cyclohexylidenevinyl)benzene (231). 
 
This compound was prepared according to the general procedure, giving a viscous oil (50 mg, 
19%) (Rf  0.38, 100% petroleum ether); 
1H NMR (400 MHz; CDCl3) δ 7.37 (d, J = 8.4 Hz, 2H), 
7.12 (d, J = 6.4 Hz, 2H), 5.91 (t, J = 2 Hz, 1H), 2.23-2.16 (m, 2H), 1.68-1.56 (m, 2H), 1.34-1.17 
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(m, 4H) 0.88-0.84 (m, 2H) ppm; HRMS [M+H+] calculated for C14H16Br 263.0430, found 
263.0466. 
(2-Cyclohexylidene ethenyl)-naphthalene (232).101 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (159 mg, 68%) (Rf 0.44, 100% petroleum ether); IR (CH2Cl2) vmax 3055, 2924, 2854, 1951, 
1265, 964 cm-1; 1H NMR (400 MHz; CDCl3) δ 8.28 (dd, J = 1.6, 9.2 Hz, 1H), 7.86-7.82 (m, 2H), 
7.69 (d, J = 8.4 Hz, 1H), 7.53-7.40 (m, 4H), 6.67 (t, J = 2.4 Hz, 1H), 2.36-2.29 (m, 4H), 1.72-1.54 
(m, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 201.5, 134.0, 132.4, 128.7, 128.0, 126.9,125.9, 
125.8, 125.7, 125.6, 125.2, 123.9, 105.0, 89.2, 31.5, 27.5, 26.2 ppm; HRMS [M+H+] calculated 
for C18H18 235.1487, found 235.1492. 
1-(2-cyclopentylideneethenyl)-2-methylbenzene (233) . 
 
This compound was prepared according to the general procedure C, giving a viscous yellow oil 
(79 mg, 43%) (Rf 0.45, 100% petroleum ether); IR (CH2Cl2) vmax 3019, 2958, 1949, 1601, 1478 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.38 (d, J = 4 Hz, 1H), 7.37-7.23 (m, 1H), 7.20-7.09 (m, 2H),  
6.33-6.29 (m, 1H), 2.60-2.50 (m, 4H), 2.40 (s, 3H), 1.83-1.77 (m, 4H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 198.6, 141.5, 135.8, 129.8, 129.2, 127.1, 125.5, 106.0, 92.3, 31.4, 27.2, 19.4 ppm; HRMS 
[M+H+] calculated for C14H17 185.1325, found 185.1337. 
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(2-Cyclopentylidene ethenyl)-benzene (234).139 
 
This compound was prepared according to the general procedure C, giving a viscous oil colorless 
(93 mg, 55%) (Rf   0.87, 100% petroleum ether); IR (CH2Cl2) vmax 3032, 2924, 1951, 1597, 1442 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.31-7.28 (m, 4H), 7.18-7.14 (m, 1H), 6.00 (d, J = 2.4 Hz, 
1H), 2.28-2.26, (m, 2H), 2.22-2.18 (m, 2H), 1.83-1.66 (m, 4H) ppm; 13C NMR (100 MHz; CDCl3) 
δ 199.8, 136.2, 128.7, 126.60, 126.4, 106.6, 92.4, 31.4, 27.8 ppm; HRMS [M+H+] calculated for 
C13H15 171.1168, found 171.1172. 
1-(Buta-1,2-dien-1-yl)naphthalene. (236) 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (79 mg, 44%) (Rf 0.45, 100% petroleum ether); IR (CH2Cl2) vmax 3054, 2986, 2055, 1422, 1265 
cm-1; 1H NMR (400 MHz; CDCl3) δ 8.24 (d, J = 8 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 
7.2 Hz, 1H), 7.52-7.42 (m, 4H),  6.81-6.77 (m, 1H), 5.62-5.55 (m, 1H), 1.85 (dd, J = 2.8, 3.6 Hz, 
3H) ppm; 13C NMR (100 MHz; CDCl3) δ 207.5, 133.5, 128.7, 127.9, 127.3, 126.0, 125.9, 125.7, 
125.7, 125.3, 123.7, 90.6, 88.6, 14.2 ppm; HRMS [M-H+] calculated for C14H11 179.0855, found 
179.0865. 
1-Methyl-2-(3-methylbuta-1,2-dien-1-yl)benzene. (237)77 
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 This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (95 mg, 60%) (Rf 0.47, 100% petroleum ether); IR (CH2Cl2) vmax  3063, 2980, 1952, 1601, 
1460 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.37 (d, J = 4 Hz, 1H), 7.20-7.10 (m, 3H),  6.21 (m, 1H), 
2.41 (s, 3H), 1.87 (s, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 203.9, 134.8, 133..9, 132.0, 127.2, 
126.2, 129.2, 97.8, 89.9, 20.0, 19.7 ppm; HRMS [M+H+] calculated for C11H13 145.1012, found 
145.1021. 
(3-Methylbuta-1,2-dien-1-yl)benzene. (238)84 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (90 mg, 68%) (Rf 0.46, 100% petroleum ether); IR (CH2Cl2) vmax 3028, 1954, 1598, 1496, 1454. 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.31-7.27 (m, 5H), 6.03-6.00 (m, 1H), 1.86 (s, 6H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 203.1, 142.0, 131.6, 126.4, 126.3, 99.1, 92.5, 20.2 ppm; HRMS 
[M+H+] calculated for C11H13 145.1012, found 145.1007. 
 (3-Methyl-1,2-butadien-1-yl)-3-methoxybenzene (239).101 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (66 mg, 38%) (Rf 0.56, ethyl acetate : hexane / 5 : 95); IR (neat) 2931, 1950, 1702, 1596, 1259 
cm-1; 1H NMR (400 MHz; CDCl3) δ 6.87 (d, J = 2.0 Hz, 1H), 6.82 (s, 1H), 6.72 (dd, J = 2.0, 2.4 
Hz, 1H), 5.98-5.93 (m, 1H) 3.81 (s, 3H),1.82 (s, 3H), 1.81 (s, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 203.3, 159.9, 137.6, 129.5, 119.4, 112.2, 112.0, 99.3, 92.6, 55.3, 20.4 ppm; HRMS 
[M+H+] calculated for C12H15O 175.1117, found 175.1119. 
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(3-Methyl-1,2-butadien-1-yl)-3,5-dimethylbenzene (240).101 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (55 mg, 32%) (Rf 0.58, 100% petroleum ether); IR (CH2Cl2) vmax 2979, 2912, 1954, 1598, 1215 
cm-1; 1HNMR (400 MHz; CDCl3) δ 6.87 (s, 2H), 6.80 (s, 1H), 5.93-5.89 (m, 1H), 2.28 (s, 6H), 
1.81 (s, 3H), 1.79 (s, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 203.1, 138.1, 135.9, 128.3, 124.5, 
98.9, 92.5, 21.3, 20.4 ppm; HRMS [M+H+] calculated for C13H17 173.1336, found 173.1325. 
(E)-1-methoxy-4-(3-methylbuta-1,3-dien-1-yl)benzene (241). 
 
This compound was prepared according to the general procedure C, giving a colourless oil (96 mg, 
55%) (Rf  0.55, / ethyl acetate:petroleum ether/5:95); IR (CH2Cl2) vmax 3057, 3019, 1949, 1494, 
1450; 1HNMR (400 MHz; CDCl3) δ 7.21-7.18 (m, 2H), 6.86-6.81 (m, 2H), 5.95 (q, J = 2.9 Hz, 
1H), 3.79 (s, 3H), 1.81 (d, J = 2.9 Hz, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 202.4, 158.4, 
130.2, 127.7, 114.1, 99.1, 92.0, 55.3, 20.5, 18.7 ppm. 
(3-Methyl-1,2-butadien-1-yl)-4-methylbenzene (242).84 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (113 mg, 72%) (Rf  0.59, 100% petroleum ether); IR (CH2Cl2) vmax 2964, 2918, 1951, 1512, 
1454 cm-1;  1H NMR (400 MHz; CDCl3) δ 7.17 (d, J = 8.0 Hz, 2H), 7.10 (d, J= 7.6 Hz,2H), 5.98-
5.95 (m, 1H), 2.33 (s, 3H), 1.82 (s, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 202.9, 136.2, 
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133.1,129.3, 126.6, 99.1, 92.4, 21.3, 20.5 ppm; HRMS [M+H+] calculated for C12H15 159.1168, 
found 159.1170. 
(3-Methyl-1,2-butadien-1-yl)-3-methylbenzene (243).101 
 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (55 mg, 35%) (Rf 0.58, 100% petroleum ether); IR (CH2Cl2) vmax 3023, 2964, 1944, 1598, 1492 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.16 (t, J = 7.2 Hz, 1H), 7.05 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 
7.2 Hz, 1H), 5.98-5.93 (m, 1H), 2.32 (s, 3H), 1.81 (s, 3H), 1.80 (s, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 203.2, 138.1, 136.0, 128.5, 127.3, 127.3, 123.9, 99.1, 92.6, 21.5, 20.4 ppm; HRMS 
[M+H+] calculated for C12H15 159.1168, found 159.1171. 
Methyl (3-Methyl-1,2-butadien-1-yl)-4-carboxybenzene (244).101 
 
This compound was prepared according to the general procedure C, giving a viscous colorless oil 
(48 mg, 24%) (Rf 0.63, ethyl acetate:petroleum ether / 5:95); IR (CH2Cl2) vmax 3019, 2950, 1952, 
1715, 1605, 1453 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.94 (d, J = 3.6 Hz, 2H),7.29 (d, J = 6.0 
Hz, 2H), 6.01-5.99 (m, 1H), 3.90 (s, 3H), 1.87 (s, 6H), 1.85 (s, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 204.5, 167.2, 141.2, 130.0, 129.9, 126.4, 99.8, 92.3, 52.1, 20.2 ppm; HRMS [M+H+] 
calculated for C13H13O2 203.1067, found 203.1062. 
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1-Methyl-4-(3-methylpenta-1,2-dien-1-yl)benzene (245). 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (100 mg, 58%) (Rf 0.7, 100% petroleum ether); IR: 3073, 1949, 1601, 1496, 1150. cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 7.18 (d, J = 4.4 Hz, 2H), 7.03 (d, J = 7.6 Hz, 2H), 6.08-6.06 (m, 1H), 
2.33 (s, 3H), 2.12-2.05 (m, 2H), 1.81 (s, 3H), 1.06 (t, J = 7.6 Hz, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 202.0, 136.1, 133.2, 129.3, 126.4, 105.4, 94.3, 27.3, 21.2, 18.9, 12.4 ppm; HRMS 
[M+H+] calculated for C13H17 173.1325, found 173.1318.  
1-Methyl-2-(3-methylpenta-1,2-dien-1-yl)benzene.(246) 
 
 
This compound was prepared according to the general procedure C, giving a colourless oil (107 
mg, 62%) (Rf 0.67, 100% petroleum ether); IR (CH2Cl2) vmax 3046, 2967, 1951, 1513, 1177 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 7.19 (d, J = 4.8 Hz, 2H), 7.10 (d, J = 7.6 Hz, 2H), 6.09-6.05 (m, 
1H), 2.32 (s, 3H), 2.13-2.06 (m, 2H), 1.81 (d, J = 2.4 Hz, 3H), 1.06 (t, J = 7.2 Hz, 3H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 202.0, 136.1, 133.2, 129.4, 129.3,  126.1, 105.4, 94.3, 27.3, 21.2, 18.9, 
12.3 ppm; HRMS [M+H+] calculated for C13H17 173.1325, found 173.1317. 
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 (3-Methyl-1,2-pentadien-1-yl)-3-methylbenzene (247).101 
 
This compound was prepared according to the general procedure, giving a viscous colorless oil 
(124 mg, 72%) (Rf 0.73, 100% petroleum ether); IR (CH2Cl2) vmax 2575, 2916, 1951, 1604, 1450 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.21-7.19 (m, 1H), 7.13-7.11 (m, 2H), 7.01-7.00 (m 1H), 
6.12-6.07 (m, 1H), 2.32 (s, 3H), 2.20 - 2.05 (m, 2H), 1.85 (s, 3H), 1.10 - 1.11 (t, J = 4.2 Hz, 3H) 
ppm; 13C NMR (100 MHz; CDCl3) δ 202.4, 138.2, 136.2, 128.5, 127.3, 123.7, 105.4, 94.6, 27.3, 
21.5, 19.0, 15.4, 12.4 ppm; HRMS [M+H+] calculated for C13H17 173.1325, found 173.1326. 
 1,3-dimethyl-5-(3-methylpenta-1,2-dien-1-)benzene (248). 
 
This compound was prepared according to the general procedure, giving a viscous colourless oil 
(59 mg, 32%) (Rf 0.58, 100% petroleum ether); IR (CH2Cl2) vmax 2979, 2912, 1954, 1598, 1215 
cm-1; 1H NMR (400 MHz; CDCl3) δ 6.91 (s, 2H), 6.84 (s, 1H), 6.05-6.04 (m, 1H), 2.31 (s, 6H), 
2.14-2.09 (m, 1H), 1.84 (d, J = 3.2 Hz, 3H), 1.08 (t, J = 7.6 Hz, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 2.203, 138.1, 136.1, 128.3, 124.4, 105.3, 94.5, 27.3, 21.4, 19.0, 12.4 ppm; HRMS 
[M+H+] calculated for C14H19 187.1487, found 187.1483.  
 (2-Cycloheptylidene ethenyl)-3-methylbenzene (249).101 
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This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (95 mg, 45%) (Rf 0.48, 100% petroleum ether); IR (neat) 3066, 2924, 1951, 1605, 1458 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 7.16 (t, J = 4.0 Hz, 2H), 7.08 (s, 1H), 6.95 (d, J = 6.8 Hz, 1H), 5.94 
(m, J = 2.4 Hz, 1H), 2.37-2.29, (m, 7H), 1.69-1.61 (m, 8H) ppm; 13C NMR (100 MHz; CDCl3) δ 
203.4, 138.1, 136.1, 128.5, 127.3, 127.2, 123.7, 108.4, 92.3, 32.3, 29.5, 28.8, 21.5 ppm; HRMS 
[M+H+] calculated for C16H21 213.1638, found 213.1643. 
 (2-Cyclooctylidene ethenyl)-3-methylbenzene (250).101 
 
This compound was prepared according to the general procedure C, giving a viscous colourless 
oil (126 mg, 56%) (Rf 0.56, 100% petroleum ether); IR (neat) 3025, 2920, 1941, 1603, 1443, 1219 
cm-1; 1H NMR (400 MHz; CDCl3) δ 7.15 (t, J = 7.6 Hz, 2H), 7.08 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 
7.6 Hz, 1H), 5.97 (d, J = 2.0 Hz, 1H), 2.32-2.26, (m, 7H), 1.79-1.54 (m, 10H) ppm; 13C NMR (100 
MHz; CDCl3) δ 203.6, 138.1, 136.3, 128.5, 127.8, 127.4, 127.2, 123.8, 108.3, 93.0, 31.7, 27.1, 
27.1, 26.9, 26.2, 21.5 ppm; HRMS [M-H+] calculated for C17H23 225.1638, found 225.1654. 
2-Methyl-4-phenylbut-3-yn-2-ol (251)140 
 
In small mortar was added anhydrous acetone (1.16 g, 20 mmol), ethynyl benzene (2.09 g, 20.00 
mmol) and potassium t-butoxide (2.21 g, 20.00 mmol) then use the pestle to mix the mixture for 
ten minutes after that, the components were left for 30 minutes at room temperature. in 50 ml 
beaker was added to the mixture 15 ml of 10% aqueous sodium chloride and extracted with 
dichloromethane then dry the organic layer over MgSO4, filtered and remove the solvent under 
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reduce pressure to give a colorless crystal (2.80 g, 87%); 1H NMR (400 MHz; CDCl3) δ 7.63-7.45 
(m, 5H), 5.43 (s, 1H), 1.56 (s, 6H) ppm. 
 (3-Methyl-1,2-butadien-1-yl)-1-phenyl-1-methylbenzene (252).101 
 
This compound was prepared according to the general procedure C, giving a viscous colorless oil 
(215 mg, 92%) (Rf 0.35, 100% petroleum ether); IR (neat) 3025, 2917, 1944, 1601, 1443, 880 cm
-
1; 1H NMR (400 MHz; CDCl3) δ 7.34-7.08 (m, 9H), 2.36 (s, 3H), 1.91-1.90 (m, 6H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 203.8, 143.4, 142.7, 141.7, 137.7, 130.4, 128.2, 128.0, 119.2, 98.4, 
22.2, 22.1, 21.6, 20.6 ppm; HRMS [M+H+] calculated for C18H19 235.1481, found 235.1477. 
1-[(E)-2-(Cyclohept-1-en-1-yl)ethenyl]-3-methylbenzene (256).101 
 
This compound was prepared according to the general procedure D, giving a colourless oil (206 
mg, 98%) (Rf  0.46, 100% petroleum ether); IR (CH2Cl2) vmax 3028, 2921, 1603, 1444, 1264   cm
-
1; 1H NMR (CDCl3, 400 MHz) δ 7.21-7.17 (m, 3H), 7.00-6.98 (m, 1H), 6.74 (d, J = 16.0 Hz, 1H), 
6.44 (d, J = 16.0 Hz, 1H), 6.04-6.01 (m, 1H), 2.44-2.41 (m, 2H), 2.33 (s, 3H), 2.30-2.23 (m, 2H), 
1.83-1.76 (m, 2H), 1.57-1.50 (m, 4H) ppm; 13C NMR (CDCl3, 100 MHz) δ 143.3, 138.1, 135.4, 
133.2, 128.5, 127.7, 127.0, 124.9, 123.4, 32.4, 28.8, 27.3, 26.9, 26.4, 21.5 ppm; HRMS [M+H+] 
calculated for C16H20 213.1643, found 2213.1640. 
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1-[(E)-2-(Cycloocta-1-en-1-yl)ethenyl]-3-methylbenzene (257).101 
 
This compound was prepared according to the general procedure D, giving a colourless oil (200 
mg, 89%) (Rf  0.46, 100% petroleum ether); IR (CH2Cl2) vmax 3024, 2919, 1702, 1601, 1444 cm
-
1; 1H NMR (CDCl3, 400 MHz) δ 7.23-7.17 (m, 3H), 7.01-6.99 (m, 1H), 6.74 (d, J = 16.4 Hz, 1H), 
6.45 (d, J = 16.0 Hz, 1H), 5.86 (t, J = 8.8 Hz, 1H), 2.52-2.49 (m, 2H), 2.33 (s, 3H), 2.26-2.23 (m, 
2H), 1.62-1.47 (m, 8H) ppm; 13C NMR (CDCl3, 100 MHz) δ 139.5, 138.1, 138.1, 133.7, 132.1, 
128.5, 128.0, 127.0, 125.3, 123.1, 30.6, 28.5, 27.5, 27.1, 26.4, 24.4, 21.5 ppm; HRMS [M+H+] 
calculated for C17H22 227.1800, found 227.1788. 
 [(1E)-3-Methylbuta-1,3-dien-1-yl]-3-methoxybenzene (258).101 
 
This compound was prepared according to the general procedure D, giving a colourless oil (88 
mg, 51%) (Rf  0.55, ethyl acetate : petroleum ether / 5 : 95); IR (CH2Cl2) vmax 2939, 1603, 1464, 
1156 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.25-7.21 (m, 1H), 7.04-7.02 (m, 1H), 6.96-6.94 (m, 
1H), 6.85 (d, J =16.4 Hz, 1H), 6.78-6.76 (m, 1H), 6.49 (d, J = 16.4 Hz, 1H), 5.11 (s, 1H), 5.07 (s, 
1H), 3.81 (s, 3H), 1.96 (s, 3H) ppm; 13C NMR (CDCl3, 100 MHz) δ 159.9, 142.1, 138.9, 132.1, 
129.6, 128.7, 119.3, 117.6, 113.3, 111.7, 55.3, 18.7 ppm; HRMS [M+H+] calculated for C12H14O 
175.1123, found: 175.1114. 
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 [(1E)-3-Methylbuta-1,3-dien-1-yl]-3,5-dimethylbenzene (260).101 
 
This compound was yield according to the general procedure D, giving a colourless oil (144 mg, 
84%) (Rf 0.56, 100% petroleum ether); IR (neat) 2916, 1598, 1445, 1162, 840 cm
-1; 1H NMR 
(CDCl3, 400 MHz) δ 7.05 (s, 2H), 6.88 (s, 1H) 6.85 (d, J = 16.0 Hz, 2H), 6.48(d, J = 16.0 Hz, 1H), 
5.10 (s, 1H), 5.04 (s, 1H), 2.30 (s, 6H), 1.95 (s, 3H) ppm; 13C NMR (CDCl3, 100 MHz) δ 142.3, 
138.1, 137.4, 131.4, 129.3, 128.9, 124.6, 124.5, 117.1, 21.4, 20.4, 18.7 ppm; HRMS [M+H+] 
calculated for C13H16 173.1330, found 173.1328. 
 [(1E)-3-Methylbuta-1,3-dien-1-yl]-3-methylbenzene (259).101 
 
This compound was prepared according to the general procedure D, giving a colourless oil (138 
mg, 88%) (Rf 0.56, 100% petroleum ether); IR (CH2Cl2) vmax 3022, 2919, 1605, 1449, 1264 cm
-1; 
1H NMR (CDCl3, 400 MHz) δ 7.26-7.21 (m, 3H), 7.06-7.05 (m, 1H), 6.87 (d, J = 16.0 Hz, 1H), 
6.50 (d, J = 16.0 Hz, 1H), 5.11 (s, 1H), 5.06 (s, 1H), 2.33 (s, 3H), 1.99 (s, 3H) ppm; 13C NMR 
(CDCl3, 100 MHz) δ 202.4, 138.1, 136.1, 128.3, 124.4, 105.3, 94.5, 27.3, 21.4, 19.0, 12.4 ppm; 
HRMS [M+H+] calculated for C12H14 159.1174, found 159.1171. 
Methyl-[(1E)-3-methylbuta-1,3-dien-1-yl]-4-carboxybenzene (261).101 
 
145 | P a g e  
 
 
This compound was prepared according to the general procedure D, giving a colourless oil (198 
mg, 98% M.P. = 94.5 – 95.5 °C) (Rf  0.61, ethyl acetate:petroleum ether / 5 : 95); IR (CH2Cl2) vmax 
2947, 1708, 1600, 1455, 1275 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.98 (d, J = 6.4 Hz, 2H), 7.47 
(d, J = 8.4 Hz, 2H), 6.96 (d, J = 16.0 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 5.18 (s, 1H), 5.12 (s, 1H), 
3.89 (s, 3H), 1.97 (s, 3H) ppm; 13C NMR (CDCl3, 100 MHz) δ 167.0, 142.0, 141.8, 134.2, 130.0, 
128.8, 127.7, 126.4, 119.1, 52.2, 18.6 ppm; HRMS [M+H+] calculated for C13H14O2 203.1072, 
found 203.1065. 
 (3-Methylbuta-1,3-dien-1-yl)-1-phenyl-1-(4-methylbenzene) (262).101 
 
This compound was prepared as an approx. 1:1 of E/Z isomers according to the general procedure 
D, giving a colourless oil (156 mg, 67%) (Rf  0.37, 100% petroleum ether); IR (CH2Cl2) vmax 3021, 
2914, 1599, 1489, 1180, 883 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.42-7.01 (m, 9H), 6.67 (s, 1H), 
5.04-4.98 (m, 2H), 2.44 (s, 3H), 2.36 (d, J = 14 Hz, 3H) ppm; 13C NMR (CDCl3, 100 MHz) δ 
141.7, 141.4, 138.3, 131.0, 130.4, 128.6, 128.2, 128.1, 128.0, 127.8, 127.2, 124.8, 124.3, 119.1, 
22.1, 21.6 ppm; HRMS [M+H+] calculated for C18H18 235.1487, found 235.1486. 
 [(2E, 4E)-3-Methylpenta-2,4-dien-1-yl]-3-methylbenzene (167).101 
 
This compound was prepared according to the general procedure D, giving a colourless oil (100 
mg, 58%) (Rf 0.39, 100% petroleum ether); IR (CH2Cl2) vmax 3025, 2980, 1640, 1442, 732 cm
-1; 
1H NMR (CDCl3, 400 MHz) δ 7.24-7.18 (m, 3H), 7.01 (d, J = 6 Hz, 1H), 6.81 (d, J = 16.4 Hz, 
1H), 6.43  (d, J = 16.0 Hz, 1H), 5.71 (m, 1H), 2.35 (s, 3H), 1.85 (s, 3H), 1.78 (d, J = 6.0 Hz, 3H) 
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ppm; 13C NMR (CDCl3, 100 MHz) δ 138.0,138.0, 133.8, 128.3, 128.0, 127.8, 127.0, 125.0, 123.0, 
21.8, 14.0, 12.0 ppm; HRMS [M+H+] calculated for C13H17 173.1325, found 173.1323. 
 [(1E)-3-Ethylbuta-1,3-dien-1-yl]-3-methylbenzene (263) and [(2Z, 4E)-3-methylpenta-2,4-
dien-1-yl]-3-methylbenzene (264).101 
 
These compounds 263 and 264 were isolated as an inseparable mixture in (60 mg, 35%) yield 
prepared according to general procedure D.  
IR (CH2Cl2) vmax 3025, 2980, 1640, 1442, 732 cm
-1; 
263 1H NMR (CDCl3, 400 MHz) δ 7.26-7.19 (m, 3H), 7.03 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 16.0 
Hz, 1H), 6.56  (d, J = 16.0 Hz, 1H), 5.10 (d, J = 2.0 Hz, 2H), 2.36 (q, J = 6.8 Hz, 2H), 2.38 (s, 3H), 
1.16 (m, 3H) ppm; 13C NMR (CDCl3, 100 MHz) δ 147.8, 139.9, 128.5, 128.1, 127.1, 125.9, 123.6, 
115.0, 24.8, 21.5, 18.8 ppm; 
264 1H NMR (CDCl3, 400 MHz) δ 7.26 - 7.19 (m, 3H), 7.03 (d, J = 8.0 Hz, 1H), (d, J = 8.0 Hz, 
1H), 6.52 (d, J =12.0 Hz, 1H), 5.54 (m, 1H), 2.36 (s, 3H), 1.91 (s, 3H), 1.84 (d, J = 6.8 Hz, 3H) 
ppm; 13C NMR (CDCl3, 100 MHz) δ 138.2, 133.0, 131.2, 128.1, 127.1, 125.6, 123.6, 22.7, 13.3 
ppm;  
HRMS [M+H+] calculated for C13H17 173.1325, found: 173.1322. 
 (E)-1,3-Dimethyl-5-(3-methylenepent-1-en-1-yl)benzene (265). 
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Compound 248 was isomerized to three dienes in 97% overall yield according to the general 
procedure D, this compound isolated from the total result to give a colorless oil (97 mg, 52%) (Rf  
0.68, 100% petroleum ether).  
= J = 16.0 Hz, 1H), 6.52 (d, J 1H), 6.80 (d,  ) δ 6.88 (s, 2H), 6.80 (s,3H NMR (400 MHz; CDCl1
16 Hz, 1H), 5.11 (s, 1H), 5.07 (s, 1H), 2.35 (s, 6H), 1.92 (t, J = 1.2 Hz, 3H), 1.84 (dd, J = 1.2, 1.2 
) δ 147.9, 138.0, 138.0, 135.9, 133.6, 128.2, 125.5, 3C NMR (100 MHz; CDCl13Hz, 2H) ppm; 
187.1481, found 187.1477. 19H14]  calculated for C
+[M+H 114.9, 27.2, 21.3, 14.1 ppm;124.1,  
1,3-dimethyl-5-((1E,3E)-3-methylpenta-1.3-dien-1-yl)benzene (266) and 1,3-dimethyl-5-
((1E,3Z)-3-methylpnta-1.3-dien-1-yl)benzene (267). 
           
 266 and 267 compounds were isomerized in (45 mg, 24%) and (39 mg, 21%) respectively 
overall yield according to the general procedure, giving a colorless oil (Rf  0.66, 100% petroleum 
ether). 266 1H NMR (400 MHz; CDCl3) δ 7.03 (s, 1H), 7.01 (s, 2H), 6.78 (d, J = 16.0 Hz, 1H), 
6.38 (d, J = 16.0 Hz, 1H), 5.72-5.66 (m, 1H), 2.31 (s, 6H), 1.84 (s, 3H), 1.79 (d, 3H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 138.0, 134.8, 133.6, 132.9, 129.1, 127.8, 124.3, 124.1, 21.4, 13.8, 
12.1 ppm; 
283 1H NMR (400 MHz; CDCl3) δ 7.20 (d, J = 10 Hz, 1H), 6.87 (s, 1H), 6.84 (s, 2H), 6.49 (d, J 
= 16.0 Hz, 1H),  5.52-5.50 (m, 1H), 2.38 (d, J = 4, 3H), 2.31 (s, 6H), 1.91 (s, 3H), ppm; 13C 
NMR (100 MHz; CDCl3) δ 138.0, 134.8, 133.6, 132.9, 128.7, 125.7, 125.1, 124.1, 21.3, 14.1, 
12.8 ppm; HRMS [M+H+] calculated for C14H19 187.1481, found 187.1477. 
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(E)-1,3-Dimethoxy-5-(4-methoxystyryl) benzene (291). 
 
To the solution of diene 5 (0.30 g, 1.00 mmol) in anhydrous methanol (3.00 mL) was added iodine 
(0.25 g, 1.00 mmol) and the reaction mixture stirred at room temperature for (3.5h). To the solution 
was added of sat. thiosulfate solution (2.00 mL) and the aqueous layer extracted with ethyl acetate 
(5 mL). The organic extracts were dried over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified by silica gel column chromatography (pet. ether : CH2Cl2 : Et2O 
/ 5:4:1) to furnish 291 (20 mg, 44%) as a yellow solid (MP 55.0-57.0 ᵒC); 1H NMR (400 MHz; 
CDCl3) δ 7.45-7.42 (d, J = 12.0 Hz, 2H), 7.05 (d, J = 16.0 Hz, 1H), 6.91-6.87 (m, 3H), 6.64 (s, 
2H), 6.37 (s, 1H), 3.82 (s, 9H) ppm; 13C NMR (100 MHz; CDCl3) δ 161.0, 159.5, 139.8, 130.0, 
128.8, 127.9, 126.6, 114.2, 104.4, 99.7, 55.5 ppm; HRMS [M+H+] calculated for C17H19O3 
271.1329, found 271.1328. 
Resveratrol (6). 
 
To a solution of compound 291 (20 mg, 0.087 mmol) in CH2Cl2 (2.00 mL) was added a solution 
of BBr3 in CH2Cl2 (8.00 mL, 1.0 M, 0.78 mmol) drop wise at 0 
ᵒC over 30 min. The reaction 
mixture was stirred at room temperature for 3 h. H2O (10 mL) was added and the aqueous layer 
extracted with CH2Cl2 (10 mL) and the organic layer combined and dried (MgSO4), filtered the 
solvent removed under reduced pressure. The residue was purified by silica gel column 
chromatography (Rf 0.7, ethyl acetate:hexane/3:1) to furnish 6 as a yellow solid (12 mg, 70%, MP 
240-242 ᵒC); IR (CH2Cl2) vmax 3565, 3058, 1415, 1091, 756 cm
-1; 1H NMR (400 MHz; d6-DMSO) 
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δ 7.35 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 16.0 Hz, 1H), 6.78 (d, J = 16.0 Hz, 1H), 6.71-6.69 (d, J = 
8.0 Hz, 2H), 6.33 (s, 2H), 6.06 (s, 1H) ppm; 13C NMR (100 MHz; d6-DMSO) δ 159.0, 157.7, 
139.8, 128.6, 128.4, 126.1, 116.0, 104.8, 102.3 ppm; HRMS [M+H+] calculated for C14H13O3 
229.0870, found 229.0861. 
3-(3,5-Dimethoxyphenyl)-5,6,8,8a-tetrahydro-3H-spiro[benzo[c]dioxine-7,2’-[1,3]dioxolane] 
12 (7).141 
 
To a solution of compound 5 (151 mg, 0.5 mmol) in CH2Cl2 (100 mL) was added methylene blue 
(50 mg, 0.16 mmol) and the reaction mixture exposed to a slow stream of O2, and then irradiated 
with visible light for 3.5 h. The solvent was evaporated under reduce pressure and the residue was 
purified by flash chromatography (Rf  0.35, ethyl acetate:hexane/1:9) to give 7 as a colorless oil 
(90 mg, 54%); 1H NMR (400 MHz; CDCl3) δ 6.54 (s, 2H), 6.41 (s, 1H), 5.81 (s, 1H), 5.31 (s, 1H), 
4.78-4.74 (m, 1H), 3.99-3.66 (m, 4H), 3.79 (s, 6H), 2.42 (d, J = 8.0 Hz, 2H), 2.12 (m, 1H), 1.83 
(m, 1H), 1.61 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 160.8, 141.1, 137.4, 118.6, 108.8, 
106.4, 100.3, 79.9, 64.7, 64.5, 55.4, 38.5, 35.4, 28.2 ppm; HRMS [M+Na+] calculated for C18H22O6  
357.1309, found 357.1308. 
2-(3,5-Dimethoxyphenyl)-4,7-dihydrobenzofuran-6(5H)-one (303).19 
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To a solution of CBr4 (0.092 g, 0.27 mmol) in CH2Cl2 (1.0 mL) at 0 °C was added PPh3 (0.073 g, 
0.27 mmol). The resulting mixture was stirred for 15 min, and then a solution of 7 (75 mg, 0.22 
mmol) in CH2Cl2 (1.0 mL) was added. The reaction mixture was brought to room temperature and 
stirred for a further 17 h. After this period, the solvent was removed in vacuo and the crude product 
purified by column chromatography (Rf = 0.56, pet. ether:CH2Cl2:Et2O/5:4:1) to give the furan 
(303) as a white crystalline solid (37 mg, 60%, MP = 146–148 ᵒC); IR (CH2Cl2) vmax 3019, 1713, 
1597, 1216 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.77 (s, 2H), 6.52 (s, 1H), 6.37 (s, 1H,), 3.82 (s, 
6H), 3.58 (s, 2H), 2.77 (t, J = 6.4 Hz, 2H,), 2.66 (t, J = 6.4 Hz, 2H,) ppm; 13C NMR (100 MHz; 
CDCl3) δ 207.1, 161.1, 153.8, 146.1, 132.5, 118.7, 105.8, 101.6, 99.8, 64.8, 55.5, 39.4, 19.8 ppm; 
HRMS [M+H+] calculated for C16H17O4 273.1121, found 273.1131. 
2-(3,5-Dimethoxyphenyl)-4,7-dihydro-5H-spiro[benzofuran-6,2’-[1,3]dioxolane] (310). 
 
To a solution of CBr4 (0.092 g, 0.27 mmol) in CH2Cl2 (1.0 mL) cooled to 0 °C was added PPh3 
(0.073 g, 0.27 mmol). The resulting mixture was stirred for 15 min. followed by a solution of 
NaHCO3 (0.022 g, 0.27 mmol), then a solution of 7 (0.075 g, 0.22 mmol in CH2Cl2 (1.0 mL) was 
added. The solution was brought to RT and stirred for a further 72h. After this period, solvents 
were removed in vacuo and the crude product purified by column chromatography (Rf 0.58, pet. 
ether:CH2Cl2:Et2O/5:4:1) to give the furan 310 as a colourless oil (211 mg, 67%); 
1H NMR (400 
MHz; CDCl3) δ: 6.75 (d, J = 2.4 Hz, 2H), 6.46 (s, 1H), 6.33 (t, J = 4.0 Hz, 1H), 4.04 – 4.01 (m, 
4H), 3.80 (s, 6H), 2.92 (s, 2H), 2.58 (t, J = 6.0 Hz, 2H), 1.91 (t, J = 6.0 Hz, 2H) ppm; 13C NMR 
(100 MHz; CDCl3) δ 161.0, 152.9, 148.0, 133.0, 118.1, 109.0, 106.1, 101.7, 99.4, 64.8, 55.4, 34.9, 
32.2, 19.3 ppm; HRMS [M+H+] calculated for C18H21O5  17.1384, found 317.1394. 
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Moracin M (8).107 
 
To the solution of compound 310 (25 mg, 0.08 mmol) in anhydrous methanol (1.00 mL) was added 
iodine (20 mg, 0.08 mmol) and the reaction mixture stirred at room temperature until the starting 
material was consumed (3.5h). To the solution was added (2.00 mL) of sat. soln. of sodium 
thiosulfate pentahydrate and the aqueous layer extracted with ethyl acetate (5 mL) The organic 
extracts were then dried with magnesium sulfate, filtered and concentrated under reduced pressure. 
The residue crude (24 mg) was directly entered to the next step by dissolving in CH2Cl2 (2 mL) 
and a solution of BBr3 in CH2Cl2 (8 mL, 1.0 M, 0.80 mmol) added drop wise at 0ᵒC over 30 min 
under N2. The reaction mixture was then stirred at room temperature for 3 hours. After this period 
H2O (10 mL) was added and the aqueous layer extracted with CH2Cl2 (10 mL) and the organic 
layer combined and dried with magnesium sulfate, filtered the solvent removed under reduced 
pressure. Purification by silica gel column chromatography (Rf  0.31, hexane:ethyl acetate/1:1) 
gave moracin M (8) as a white solid (17 mg, 90%) yield over 2-steps, m.p. 280-282 ᵒC (lit. 271-
271 ᵒC); 1H NMR (400 MHz; d6-DMSO) δ 7.34 (d, J = 8.0 Hz, 1H), 7.04 (s, 1H), 6.89 (s, 1H), 
6.70 (d, J = 8.0 Hz, 1H), 6.65 (s, 2H), 6.18 (s, 1H) ppm; 13C NMR (100 MHz; d6-DMSO) δ 159.3, 
156.2, 155.7, 154.4, 132.2, 121.6, 121.3, 112.9, 103.1, 102.8, 102.1, 97.9 ppm; 1H NMR (400 
MHz; d4-methanol) δ: 7.33 (d, J = 8.0 Hz, 1H), 6.89 (s, 2H), 6.76 (s, 2H), 6.73 (d, J = 8.0 Hz, 1H), 
6.26 (s, 1H) ppm; 13C NMR (100 MHz; d4-methanol) δ 158.5, 155.8, 155.3, 154.7, 132.5, 121.7, 
120.8, 111.9, 102.7, 102.2, 101.0, 97.2 ppm; HRMS [M+H+] calculated for C14H11O4  243.0652, 
found 243.0661. 
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3,5-Heptadienol (323).117 
 
To a solution of (1.00 g, 10.0 mmol) of tropone in methanol 20 mL was added sodium borohydride 
(0.50 g, 13.2 mmol). The mixture was stirred overnight at room temperature. The solvent was 
removed under reduced pressure, and diethyl ether 25 mL was added to the crude and washed with 
water (10 mL) and brine (2 x 10mL). The organic layer was extracted, dried over MgSO4, filtered 
and the solvent was removed under reduce pressure, gave 323 as a yellow oil (0.85 g, 77%). (Rf 
0.6, 1:1/EtOAc:hexane) IR (CH2Cl2) vmax 3325, 2915, 1430 cm
-1; 1H NMR (400 MHz; CDCl3) δ 
5.71-5.67 (m, 2H), 5.61-5.57 (m, 2H), 4.33 (s, 1H), 3.85-3.80 (m, 1H), 2.46-2.38 (m, 2H), 2.28-
2.19 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 128.8, 126.1, 69.4, 40.6 ppm. 
 
((tButyldimethylsily)oxy)-l,3-cycloheptadiene(324).118 
 
 
A mixture of dimethylformamide (4 mL), 3,5-cycloheptadienol 323, (850 mg, 7.7 mmol), tert-
butyldimethylsilyl chloride (1.5 g, 10 mmol), and imidazole (1.3 g, 15.8 mmol) was stirred for 20 
h at room temperature. The reaction mixture was then decanted into dichloromethane (35 mL) and 
was washed with water (5 mL), saturated ammonium chloride (5 mL) and then with brine (2 x 5 
mL). The organic layers were dried with MgSO4, filtered and evaporated. The crude oil was 
purified by column chromatography (hexane), to give 324 as a yellow oil (1.28 mg, 75%) (Rf 0.9, 
hexane); IR (CH2Cl2) vmax 3054, 1680, 1422, 1259, 1084 cm
-1; 1H NMR (400 MHz; CDCl3) δ 5.77 
(t, J = 8.4 Hz, 2 H), 5.66-5.62 (m, 2 H), 4.06-4.00 (m, 1H), 2.51-2.39 (m, 4 H), 0.87 (s, 9 H), 0.05 
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(s, 6 H) ppm; 13C NMR (100 MHz; CDCl3) δ 128.0, 126.0, 71.4, 41.0, 25.7, -2.8 ppm; HRMS 
[M+H+] calculated for C13H25OSi 225.1669, found 225.1662. 
E. General synthesis of endoperoxide.142 To a stirred solution diene (14 mmol) in CCl4 80 mL  
was added rose Bengal (R.B.) 35 mg. The resulting mixture was irradiated with a projection lamp 
(500 W) while oxygen was passed through the solution and the mixture was stirred at room 
temperature for 24 h.. The solvent was removed under pressure (30˚C, 20 mmHg), giving an oil, 
which was purified by a silica gel column chromatography (ethyl acetate:hexane/2:3). 
 
6,7-Dioxabicyclo[3.2.2]non-8-en-3-ol (331). 
 
This compound was prepared according to the general procedure E, giving a colorless oil (1.41 g, 
71%) (Rf 0.31, ethyl  acetate:hexane/1:9); IR (CH2Cl2) vmax 3599, 3055, 2987, 1668, 1262cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 6.35 (dd, J = 3.2, 3.6 Hz, 2H), 4.99 (q, J = 4.0 Hz, 2H), 3.74-3.65 (m, 
1H), 2.56 (s, 1H), 2.33-2.26 (m, 2H), 1.99-1.93 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 
128.7, 73.5, 65.7, 40.6 ppm; HRMS [M+Na+] calculated for C7H10O3Na 165.0533, found 
165.0533. 
 ((6,7-Dioxabicyclo[3.2.2]non-8-en-3-yl)oxy)(tert-butyl)dimrthylsilane (332).117 
 
This compound was prepared according to the general procedure E, giving a white solid (2.94 g, 
82%, MP 75-77 0C) (Rf 0.24, ethyl acetate:hexane/5:95); IR (CH2Cl2) vmax 3054, 2968, 1471, 1264, 
1145 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.37 (dd, J = 2.0, 3.2 Hz. 2H), 4.64 (t, J = 3.6 Hz, 2H), 
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3.73-3.68 (m, 1H), 2.22-2.15 (m, 2H), 2.07-2.01 (m, 2H) 0.84 (s, 9H), 0.00 (s, 6H) ppm; HRMS 
[M+Na+] calculated for C13H24SiO3Na 279.1387, found 279.1387. 
7,8-Dioxabicyclo[4.2.2]dec-9-ene (333)143 
 
This compound was prepared according to the general procedure E, giving a white solid powder 
(1.86 g, 95%, MP 55-56 0C (literature143 53-55 0C)) (Rf 0.68, diethyl ether:hexane/2:3); IR 
(CH2Cl2) vmax 2953, 1463, 1271 cm
-1; 1H NMR (400 MHz; CDCl3) δ 6.14 (dd, J = 2.0, 2.0 Hz, 
2H), 4.77-4.72 (m, 2H), 2.13-2.06 (m, 2H), 1.89-1.80 (m, 2H), 1.78-1.69 (m, 2H), 1.62-1.55 (m, 
2H) ppm; 13C NMR (100 MHz; CDCl3) δ 128.2, 76.6, 33.2, 24.0 ppm; HRMS [M+H+] calculated 
for C8H13O2 141.0910, found 141.0909. 
F. General procedure of enantio-enrich lactone formation. 119 
 To a solution of the endoperoxide (1.0 mmol) in dry THF (5 mL) was added (0.1 mmol) catalyst 
a or b. The resultant mixture was stirred for 16 h. at room temperature After this period a solution 
of ethyl malonate (1.0 mmol) [prepared in THF (3.0 mL) by the addition of NaOEt (2.2 mL, 0.5 
M, 1.1 mmol) to the malonate (1.0 mmol)] was added dropwise at 0 °C, and the resultant solution 
allowed to warm to room temperature and stirred. After 1-2 h an additional tetrahydrofuran (15 
mL) was added to help the solubility then the reaction kept stirred 24 h.   The reaction mixture 
was then cooled to 0 °C and quenched by the addition of 1 M HCl (10 mL) after which it was 
partitioned between ethyl acetate (50 mL) and H2O (50 mL), and the aqueous layer was extracted 
with further portions of ethyl acetate (2 × 20 mL). The organic layers were then combined, washed 
with brine, dried (Na2SO4), and filtered, and the solvent was removed under pressure. The crude 
products were then purified by chromatography column eluting with (hexane:ethyl acetate/2:3). 
The following products were obtained. 
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 (Z)-4-Hydroxycyclooct-2-en-1-one (344)143 
 
This compound was isolated through the lactonization formation general procedure F using the 
b catalyst before added the malonate giving a white solid crystal (133 mg, 95%, MP 107 – 109 
0C(in literature143 93-94 0C)) (Rf 0.53, ethyl acetate:hexane/2:3); 
1H NMR (400 MHz; CDCl3) δ 
6.00 (dd, J = 2.0, 2.0 Hz, 1H), 5.78 (d, J = 5.6 Hz, 1H), 4.98 (d, J = 6.8 Hz, 1H), 2.73 (s, 1H), 
2.00-1.85 (m, 2H), 1.69-1.50 (m, 4H), 1.48-1.44 (m, 2H) ppm; 13C NMR (100 MHz; CDCl3) δ 
134.5, 132.6, 11.4, 81.6, 39.0, 33.5, 23.8, 23.0 ppm; HRMS [M+H+] calculated for C8H13O2 
141.0910, found 141.0911. 
(-)Ethyl(3R,3aS,7S,8aR)-7-Hydroxy-2,5-dioxooctahydro-2H-cyclohepta[b]furan-3-
carboxylate (334). 
 
This compound was prepared according to the general procedure F using the a catalyst, giving a 
colourless oil (210 mg, 82%) (Rf 0.17, petroleum ether:ethyl acetate/1:1); [α]24D = -29.0 (c 1.00, 
CH2Cl2); IR (CH2Cl2) vmax 3596, 3055, 1788, 1736, 1709, 1180 cm
-1; 1H NMR (400 MHz; 
CDCl3) δ 4.30-4.24 (m, 2H), 3.93 (ddd, J = 2.8, 2.4, 1.6 Hz, 1H), 3.34 (d, J = 12.4 Hz, 1H), 3.23-
3.16 (m, 1H), 3.06 (t, J = 11.6 Hz, 1H), 2.87 (dd, J = 5.4, 4.8 Hz, 1H), 2.80-2.71 (m, 2H), 2.32 
(dd, J = 11.6, 11.6 Hz, 1H), 1.98-1.89 (m, 1H), 1.31 (t, J = 6.8 Hz, 3H) ppm; 13C NMR (100 
MHz; CDCl3) δ 205.7, 169.6, 166.4, 78.9, 65.4, 62.7, 53.1, 53.1, 44.4, 43.0, 41.7, 14.1 ppm; 
HRMS [M+Na+] calculated for C12H16O6Na 279.0836, found 279.0839. 
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(+)-ethyl(3S,3aR,7R,8aS)-7-((tert-butyldimethylsilyl)oxy)-2,5-dioxooctahydro-2H-
cyclohepta[b]furan-3-carboxylate (335).17 
 
This compound was prepared according to the general procedure F using the b catalyst , giving 
a yellow viscous oil (296 mg, 80%) (Rf 0.55, hexane:ethyl acetate/3:2); [α]22D = +7.4 (c 1.00, 
CH2Cl2); IR (CH2Cl2) vmax 3054, 2987, 1787, 1737, 1709, 1256 cm
-1; 1H NMR (400 MHz; 
CDCl3) δ 4.23 (dq, J = 2.0, 2.4 Hz, 2H), 4.17-4.10 (m, 1H), 3.89-3.83 (m, 1H), 3.30 (t, J = 6.4 
Hz, 1H), 3.19-3.15 (m, 1H), 2.99 (dd, J = 10.8, 10.8 Hz, 1H), 2.80 (dd, J = 5.2, 4.8 Hz, 1H), 2.62-
2.57 (m, 2H), 2.27 (dd, J = 11.4, 12 Hz, 1H), 1.98-1.89 (m, 1H), 1.26 (t, J = 7.2 Hz, 3H), 0.82 (s, 
9H), 0.03 (s, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 205.8, 169.6, 166.4, 79.0, 66.0, 62.5, 53.2, 
44.7, 43.7, 41.4, 25.8, 25.6, 17.9, 14.0, -4.8 ppm; HRMS [M+Na+] calculated for C18H30O6SiNa 
393.1704, found 393.1693. 
(+) Ethyl (3S,3aR,9as)-2,5-dioxodecahydrocycloota[b]furan-3-carboxylate(336).17 
 
This compound was prepared according to the general procedure F catalyst b, giving a viscous 
colorless oil (175 mg, 69%) (Rf 0.50, 6:4 hexane : ethyl acetate); [α]22D = +65 (c 1.00, CH2Cl2); 
1H NMR (400 MHz; CDCl3) δ 4.33-4.20 (m, 2H), 4.19-4.10 (m, 1H), 3.37 (d, J = 12.4 Hz, 1H), 
3.23-3.10 (m, 1H), 2.78-2.67 (m, 2H), 2.42 (dd, J = 14.4, 11.5 Hz, 1H), 2.33 (dt, J = 12.7, 5.6 
Hz, 1H), 2.24-2.12 (m, 1H), 1.92-1.69 (m, 4H), 1.50-1.37 (m, 1H), 1.35-1.27 (m, 3H) ppm; 13C 
NMR (100 MHz; CDCl3) δ 211.6, 169.4, 166.6, 84.1, 62.5, 53.9, 45.5, 43.9, 39.0, 31.1, 26.0, 
22.1, 14.1 ppm; HRMS [M-H+] calculated for C13H17O5 253.1071 found 253.1066. 
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E-  G. General procedure of α-Methylation of Lactone.119                                                              
To a solution of sodium ethoxide in ethanol (0.5 M, 2.2 mL) and THF (4 mL) was added lactone 
(1.00 mmol) while holding the reaction under N2. After 10 min. of stirring the mixture became a 
sludge. At this period, methyl iodide (149 mg,1.05 mmol) was added and the reaction mixture 
stirred overnight (16 h) at room temperature. The reaction was quenched by the addition of 1 M 
HCl (2 mL) and the mixture partitioned between dichloromethane (50 mL) and 1 M HCl (50 
mL). The aqueous layer was then extracted, the subsequent organic layers were (MgSO4) dried 
and filtered, and the solvent was removed under reduced pressure. The TLC test gives one spot 
of the crude (Rf=0.61 hexane: ethyl acetate 6:4) and this was it used without further purification 
due to one spot in tlc. 
 (+)-ethyl (3R,3aR,9aS)-3-methyl-2,5-dioxodecahydrocycloocta[b]furan-3-carboxylate 
17).45(3 
 
This compound was prepared according to the general procedure G, giving a viscose colorless oil 
(255 mg, 95%); IR (CH2Cl2) vmax 3054, 2987, 1780, 1739, 1707, 1265 cm
-1; 1H NMR (400 MHz; 
CDCl3) δ 4.29-4.22 (m, 2H), 4.22-4.17 (m, 1H), 3.26-3.16 (m, 1H), 2.70-2.60 (m, 1H), 2.52-2.43 
(m, 1H), 2.42-2.32 (m, 2H), 2.13 (dtd, J = 15.2, 5.6, 2.7 Hz, 1H), 1.91-1.71 (m, 4H), 1.58-1.48 (m, 
1H), 1.40-1.37 (s, 3H), 1.29 (t, J = 7.1, 2.6 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 212.1, 
173.9, 169.7, 82.6, 62.5, 55.1, 47.7, 40.8, 40.1, 30.8, 26.1, 22.7, 14.1, 13.9 ppm; HRMS [M+Na+] 
calculated for C14H20O5Na 291.1203 found 291.1203. 
 119H.  General hydrolysis Decarboxylation of the lactones. 
To a solution of KOH (2 M, 15 mL) and ethanol (15 mL) was added the lactone (1.4 mmol) and 
the reaction miture stirred for 16 h. at room temperature. After this period, the mixture was 
acidified, the aqueous layer extracted with dichloromethane (2 x 20 mL), the resultant organic 
layer dried with MgSO4 and filtered, and the solvent removed under pressure. The residue was 
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then dissolved in toluene (10 mL) and refluxed overnight. The toluene was then removed under 
pressure and the residue purified by silica column chromatography eluting with hexane:ethyl 
acetate 3:2.  
 (3R,3a,9aS)-3-Methylhexahydrocycloocta[b]furan-2,5(3H,4H)-dione(346).17 
 
This compound was prepared according to the general procedure H, giving a viscous colorless oil 
(59 mg, 30%) (Rf 0.22, hexane:ethyl acetate/3:2); IR (CH2Cl2) vmax 3055, 2986, 1765, 1703, 996 
cm-1; 1H NMR (400 MHz; CDCl3) δ 4.14 (dt, J = 3.2, 3.2, 2.8 Hz, 1H), 2.64-2.55 (m, 2H), 2.46-
2.26 (m, 3H), 2.23-2.09 (m, 2H), 1.91-1.65 (m, 3H), 1.64-1.51 (m, 1H), 1.50-1.37 (m, 1H), 1.20 
(d, J = 6.9 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 212.7, 177.0, 83.9, 48.9, 45.2, 42.6, 39.8, 
31.4, 25.7, 22.9, 12.8 ppm; HRMS [M+H+] calculated for C11H17O3 197.1172, found 197.1172. 
 (3aR,9aS)-Hexahydrocycloocta[b]furan-2,5(3H,4H)-dione (347)17,121  
 
In a round flask was placed lactone (348) (0.254 g, 1.00 mmol), LiCl (0.084g, 2.00 mmol), H20 
(0.036g, 2.00 mmol), and 5 mL of anhydrous DMSO. After refluxed the mixture at 135ºC under 
nitrogen atmosphere for 20 h, the reaction mixture was cooled to room temperature and quenched 
with (20 mL) of water and extracted with (50 mL) of ethyl acetate, washed with brine, dried with 
MgSO4 then filtered. The solvent was removed under reduce pressure. The resultant crude purified 
with silica column chromatography eluting with (petroleum ether:ethyl acetate/3:2), giving a white 
solid (130 mg, 71%) (Rf 0.2, petroleum ether:ethyl acetate/3:2). 
1H NMR (400 MHz; CDCl3) δ 
4.18 (td, J = 9.1, 3.1 Hz, 1H), 2.77-2.57 (m, 4H), 2.45 (dd, J = 13.9, 11.3 Hz, 1H), 2.41-2.29 (m, 
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2H), 2.25-2.14 (m, 1H), 1.94-1.69 (m, 3H), 1.68-1.57 (m, 1H), 1.52-1.39 (m, 1H) ppm; 13C NMR 
(100 MHz; CDCl3) δ 212.4, 174.4, 86.0, 46.4, 41.1, 39.7, 37.1, 31.6, 25.7, 22.8 ppm. 
 (3R,3aR,9aS,Z)-3-Methyl-3a,8,9,9a-tetrahydrocycloota[b]furan-2,5(3H,4H)-dione 
145,144).57(3 
 
In a suitable flask lactone 346 (1.17 g, 5.0 mmol) was mixed with (900 mg, 6 mmol) of pre-dried 
sodium iodide in (5 ml) acetonitrile. After this period triethylamine, (607 mg, 0.85 mL, 6 mmol) 
was added followed by TMSCl, (652 mg, 0.77 mL, 6 mmol) drop wise. The reaction mixture left 
overnight. At this point (10 mL) of cold hexane then (10 mL) of cold water were added. The 
resultant mixture extracted with dichloromethane (2 X 10 mL). The combined organic layers dried 
with MgSO4, filtered and the solvent removed under reduced pressure to give the (1.25 g) which 
was proceed to the next step without further purification. The crude product was dissolved in 
DMSO (100 mL) then, Pd(OAc)2 (112 mg, 0.5 mmol) was added and the reaction mixture stirred 
vigorously at 80 0C under oxygen atmosphere for 42 h. After NaHCO3(50 mL) was added and the 
resultant solution extract with diethyl ether (3 X 100 mL). The combined organic layers dried over 
MgSO4, filtered and the solvent removed under reduced pressure. The resultant crude was purified 
by flash column chromatography (ethylacetate : petroleum ether/4:1, Rf 0.57), to give a colorless 
oil (602 mg, 62%); IR (CH2Cl2) vmax 3055, 2985, 1776, 1705, 1665 cm
-1; 1H NMR (400 MHz; 
CDCl3) δ 6.47-6.31 (m, 1H), 6.00 (t, J = 12.6 Hz, 1H), 4.17 (td, J = 10.2, 5.1 Hz, 1H), 2.91 (dd, J 
= 15.7, 4.9 Hz, 1H), 2.73-2.62 (m, 2H), 2.27-2.19 (m, 2H), 1.96-1.85 (m, 1H), 1.85-1.72 (m, 2H), 
1.25 (t, J = 2.5 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 177.1, 177.0, 139.8, 132.7, 84.0, 
45.3, 42.7, 39.9, 31.5, 25.8, 12.8 ppm; HRMS [M+Na+] calculated for C11H14O3Na 217.0835, 
found 217.0833. 
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((3R.3aR,9aS,Z)-3-Methyl-2,5-dioxo-2,3,3a,4,5,8,9,9a-octahydrocycloota[b]furan-6-
yl)methyl acetate (359).125,113 
 
To a solution on lactone 357 (291 mg, 1.5 mmol) in THF (0.75 mL) was added (0.3 mL) 
formaldehyde in water 37% and DMAP (30 mg, 0.24 mmol). The resultant mixture stirred slowly 
for 10 days at room temperature, after this period the mixture quenched with (5 mL) of 5% HCl at 
00C then, the mixture extracted with dichloromethane (2 X 10 mL). The combined organic layers 
were dried with MgSO4, filtered and the solvent removed under reduced pressure. The resultant 
crude product was purified by flash column chromatography with (ethyl acetate:hexane/1:1) (Rf 
0.57), giving a colorless oil (147 mg, 62%); IR (CH2Cl2) vmax 3054, 2987, 1776, 1743, 1708 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 5.79 (d, J = 3.6 Hz, 1H), 4.39 (t, J = 9.6 Hz, 1H), 4.32 (t, J = 5.8 
Hz, 1H), 4.25 -4.14 (m, 1H), 4.10-3.99 (m, 1H), 2.92-2.72 (m, 2H), 2.64-2.43 (m, 2H), 2.41-2.27 
(m, 2H), 2.06 (s, 3H), 1.40-1.36 (m, 1H), 1.26 (d, J = 7.2 Hz, 3H) ppm; 13C NMR (100 MHz; 
CDCl3) δ 210.8, 177.0, 170.5, 130.9, 130.2, 82.0, 63.8, 46.9, 41.4, 40.8, 26.1, 23.1, 21.1, 12.6 ppm; 
HRMS [M+Na+] calculated for C14H18O5Na 289.1046 found 289.1044. 
Ethyl(3R,3aR,7R,8aS)-7-((tert-butyldimethylsilyl)oxy)-3-methyl-2,5-dioxootahydro-2H-
cyclohepta[b]furan-3-carboxylate (354). 
 
This compound was prepared according to the general procedure G, giving a viscous colorless oil 
(353 mg, 92%) (Rf 0.69, petroleum ether:ethyl acetate/1:1); IR (CH2Cl2) vmax 3054, 2987, 1781, 
1738, 1708, 1157 cm-1; 1H NMR (400 MHz; CDCl3) δ 4.22 (q, J = 2.5 Hz, 2H), 3.95-3.82 (m, 1H), 
3.35 - 3.21 (m, 1H), 3.15-3.05 (m, 1H), 2.99 (dd, J = 12.4, 10.7 Hz, 1H), 2.37-2.24 (m, 1H), 2.04-
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1.89 (m, 1H), 1.90-1.79 (m, 1H), 1.60 (d, J = 11.9 Hz, 3H), 1.36 (d, J = 9.1 Hz, 2H), 1.26 (t, J = 
7.2 Hz, 3H), 0.84 (s, 9H), 0.05 (s, 6H) ppm; 13C NMR (100 MHz; CDCl3) δ 205.8, 174.3, 171.0, 
79.3, 62.5, 53.3, 45.2, 41.6, 40.5, 39.2, 25.6, 14.0, 13.8, -4.8 ppm; HRMS [M+Na+] calculated for 
C19H32O6NaSi 407.1860, found 407.1861. 
 (3R,3aR,7R,8aS)-7-((tert-Butyldimethylsilyl)oxy)-3-methylhexahydro-2H-
cyclohepta[b]furan-2,5(3H)-dione (365). 
 
This compound was prepared according to the general procedure H, giving a colorless oil (66 mg, 
21%) (Rf 0.54, hexane:ethyl acetate/1:1); IR (CH2Cl2) vmax 3054, 2987, 1778, 1707, 1186 cm
-1; 1H 
NMR (400 MHz; CDCl3) δ 4.47-4.38 (m, 1H), 4.34 (dd, J = 6.6, 4.9 Hz, 1H), 2.87-2.76 (m, 2H), 
2.70 (dd, J = 18.3, 2.7 Hz, 1H), 2.62 (td, J = 8.9, 4.4 Hz, 1H), 2.39-2.24 (m, 2H), 2.20-2.08 (m, 
1H), 1.82 - 1.71 (m, 1H), 1.28-1.23 (3H), 0.83 (d, J = 2.9 Hz, 9H), 0.06 (d, J = 2.5 Hz, 6H) ppm; 
13C NMR (100 MHz; CDCl3) δ 207.3, 177.7, 80.4, 65.4, 51.0, 46.5, 42.9, 41.8, 25.8, 18.0, 12.7, -
5.0 ppm; HRMS [M+Na+] calculated for C16H28O4NaSi 335.1649, found 335.1650. 
(3R,3a,8aS)-3-methyl-3a,4,8,8a-tetrahydro-2H-cyclohepta[b]furan-2,5(3H)-dione (366). 
  
This compound was prepared according to the general procedure H, giving a yellow oil (27 mg, 
15%) (Rf 0.53, hexane:ethyl acetate/1:1); IR (CH2Cl2) vmax 3054, 2986, 1777, 1706, 1660 cm
-1; 
1H NMR (400 MHz; CDCl3) δ 6.34 (q, J = 3.0 Hz, 1H), 6.09 (d, J = 2.9 Hz, 1H), 4.39 (q, J = 5.2 
Hz, 1H), 3.60-3.41 (m, 1H), 3.26-3.10 (m, 2H), 2.94-2.89 (m, 1H), 2.26-2.15 (m, 2H), 1.28 (d, J 
= 7.0 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 198.7, 177.3, 137.7, 132.5, 80.4, 44.8, 43.4, 
42.1, 37.0, 12.8 ppm; HRMS [M+H+] calculated for C10H13O3 181.0859,found 181.0855. 
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Ethyl((3R,3aS,8aR)-2,5-dioxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-3-
carboxylate (368).111 
 
The lactone 334 (256 mg, 1mmol) was dissolved in (5 mL) of dry dichloromethane then triethyl 
amine was added (0.35 mL, 2 mmol). The resultant reaction mixture was cooled in ice bath to 0 
0C and MsCl (0.15 mL, 1.5 mmol) added dropwise with stirring. After 1 hour the reaction mixture 
was warmed to RT and stirred overnight until all starting material was consumed indicated by TLC 
plate. At this point the mixture was cooled to 0 0C then DBU (0.21 mL, 2 mmol) was added wisely 
and after one hour leaved to stirred at room temperature for overnight. The reaction mixture diluted 
with dichloromethane and (10 mL), water (10 mL), the organic layer was separated, and the 
aqueous layer extracted with dichloromethane (2 X 10 mL). The combined organic layers dried 
with MgSO4, filtered and the solvent removed under reduced pressure. The resultant crude purified 
by flash column chromatography with (ethyl acetate:hexane/3:7 to 6:4) (Rf 0.71), giving a colorless 
oil (178mg, 75%); IR (CH2Cl2) vmax 3054, 2987, 1784, 1737, 1708, 1604 cm
-1; 1H NMR (400 
MHz; CDCl3) δ 6.35-6.25 (m, 1H), 6.06 (dd, J = 13.2, 2.9 Hz, 1H), 5.04 (td, J = 10.4, 4.7 Hz, 1H), 
4.41-4.32 (m, 2H), 3.69-3.60 (1H), 3.27-3.22 (m, 1H), 3.22-3.15 (m, 1H), 2.60-2.48 (m, 1H), 1.33 
(t, J = 7.2 Hz, 3H) ppm; 13C NMR (100 MHz; CDCl3) δ 197.3, 165.3, 161.7, 136.4, 132.6, 80.6, 
64.6, 44.5, 42.2, 38.7, 36.8, 13.8 ppm; HRMS [M+H+] calculated for C12H15O5 239.0914, found 
139.0914. 
Ethyl(3S, 3aS, 8aR)-3-methyl-2,5-dioxo-3, 3a, 4, 5, 8, 8a-hexahydro-2H-cyclohepta[b]furan-
3-carboxylate (369). 
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This compound was prepared according to the general procedure G, giving a viscous colorless oil 
(134 mg, 53%) (Rf 0.26, petroleum ether:ethyl acetate/1:1); IR (CH2Cl2) vmax 3054, 2987, 1783, 
1738, 1710, 1661, 1185 cm-1; 1H NMR (400 MHz; CDCl3) δ 6.32 (qd, J = 6.6, 2.9 Hz, 1H), 6.11-
6.02 (m, 1H), 4.48 (td, J = 10.3, 4.5 Hz, 1H), 4.30-4.17 (m, 2H), 3.23-3.09 (m, 2H), 2.71-2.58 (m, 
2H), 2.51 (dd, J = 17.5, 13.0 Hz, 1H), 1.42 (s, 3H), 1.27 (t, J = 7.2, Hz, 3H) ppm; 13C NMR (100 
MHz; CDCl3) δ 198.1, 174.1, 169.4, 137.4, 132.5, 79.4, 62.6, 43.6, 40.2, 39.5, 36.7, 14.3, 14.0 
ppm; HRMS [M+Na+] calculated for C13H16O5Na 275.0890, found 275.0890. 
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7. Appendix: 
2-(3,5-Dimethoxyphenyl)-4,7-dihydrobenzofuran-6(5H)-one (303) X-Ray data 
Formula. 
C16H16O4. One molecule in the asymmetric unit. The ring C(2) > C(7) is distorted with C(4)–O(2) lying out 
of the plane as might be expected with a significant aliphatic proportion in the ring. 
Disorder & Solvent of Crystallisation. 
No disorder or solvent of crystallisation. 
Packing. 
Molecules pack in layers with some weak (aliphatic)C–H∙∙∙O intermolecular interactions within sheets. 
Only van der Waals forces between layers. 
Author for all publications, posters, etc.: Dr. Mark R.J. Elsegood. 
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Crystal data 
C16H16O4 Z = 2 
Mr = 272.29 F(000) = 288 
Triclinic, P¯1 Dx = 1.416 Mg m-3 
a = 7.48034 (16) Å Cu K radiation,  = 1.54184 Å 
b = 8.57141 (19) Å Cell parameters from 7623 reflections 
c = 10.4014 (2) Å  = 4.3–70.3° 
 = 90.8603 (17)°  = 0.83 mm-1 
 = 94.6762 (18)° T = 100 K 
 = 105.8774 (19)° Block, colourless 
V = 638.84 (2) Å3 0.13 × 0.08 × 0.04 mm3 
 
Data collection 
Rigaku 007HF equipped with Varimax confocal 
mirrors and an AFC11 goniometer and HyPix 
6000 detector diffractometer. 
2324 independent reflections 
Radiation source: Rotating anode 2143 reflections with I > 2(I) 
Detector resolution: 10 pixels mm-1 Rint = 0.031 
profile data from –scans max = 68.2°, min = 4.3° 
Absorption correction: multi-scan  
CrysAlis PRO 1.171.39.34b (Rigaku Oxford 
h = -8→8 
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Diffraction, 2017) Empirical absorption 
correction using spherical harmonics, 
implemented in SCALE3 ABSPACK scaling 
algorithm. 
Tmin = 0.806, Tmax = 1.000 k = -10→10 
11720 measured reflections l = -12→12 
 
Refinement 
Refinement on F2 Primary atom site location: iterative 
Least-squares matrix: full Hydrogen site location: difference Fourier map 
R[F2 > 2(F2)] = 0.032 All H-atom parameters refined 
wR(F2) = 0.085 w = 1/[2(Fo2) + (0.0388P)2 + 0.2134P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.07 (/)max = 0.001 
2324 reflections max = 0.22 e Å-3 
245 parameters min = -0.19 e Å-3 
0 restraints  
 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
for (mck40) 
 x y z Uiso*/Ueq 
C1 0.74475 (17) 0.63752 (14) 0.63340 (11) 0.0227 (3) 
O1 0.68007 (12) 0.47270 (10) 0.65125 (8) 0.0235 (2) 
C2 0.69736 (17) 0.39693 (14) 0.53759 (11) 0.0229 (3) 
C3 0.64839 (19) 0.21786 (15) 0.52724 (12) 0.0265 (3) 
H3A 0.695 (2) 0.1750 (18) 0.6040 (15) 0.033 (4)* 
H3B 0.509 (2) 0.1700 (19) 0.5121 (15) 0.036 (4)* 
C4 0.73635 (17) 0.16745 (14) 0.41293 (11) 0.0238 (3) 
O2 0.78693 (13) 0.04451 (10) 0.41461 (8) 0.0294 (2) 
C5 0.74718 (19) 0.27102 (15) 0.29558 (12) 0.0258 (3) 
H5A 0.820 (2) 0.2344 (17) 0.2376 (14) 0.028 (4)* 
H5B 0.617 (2) 0.2425 (18) 0.2547 (15) 0.034 (4)* 
C6 0.81535 (19) 0.45662 (15) 0.32061 (11) 0.0245 (3) 
H6A 0.954 (2) 0.4945 (18) 0.3155 (14) 0.030 (4)* 
H6B 0.761 (2) 0.5069 (17) 0.2533 (14) 0.026 (3)* 
C7 0.76920 (16) 0.50602 (14) 0.45032 (11) 0.0222 (3) 
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C8 0.79919 (17) 0.66262 (15) 0.51211 (11) 0.0231 (3) 
H8 0.852 (2) 0.7694 (18) 0.4763 (14) 0.029 (4)* 
C9 0.74438 (16) 0.74355 (14) 0.74436 (11) 0.0227 (3) 
C10 0.81133 (17) 0.91158 (14) 0.73493 (11) 0.0241 (3) 
H10 0.860 (2) 0.9570 (17) 0.6573 (14) 0.029 (4)* 
C11 0.80990 (17) 1.01267 (14) 0.83991 (12) 0.0242 (3) 
C12 0.74471 (17) 0.95067 (15) 0.95574 (12) 0.0247 (3) 
H12 0.7476 (18) 1.0213 (17) 1.0256 (14) 0.024 (3)* 
C13 0.68003 (17) 0.78257 (15) 0.96373 (11) 0.0238 (3) 
C14 0.67830 (17) 0.67856 (15) 0.85960 (12) 0.0238 (3) 
H14 0.633 (2) 0.5644 (19) 0.8694 (14) 0.030 (4)* 
O3 0.87717 (13) 1.17582 (10) 0.82132 (8) 0.0294 (2) 
C15 0.8749 (2) 1.28634 (16) 0.92497 (13) 0.0290 (3) 
H15A 0.750 (2) 1.2772 (18) 0.9497 (15) 0.035 (4)* 
H15B 0.957 (2) 1.2731 (18) 1.0008 (16) 0.033 (4)* 
H15C 0.923 (2) 1.392 (2) 0.8914 (15) 0.041 (4)* 
O4 0.61433 (13) 0.70844 (10) 1.07288 (8) 0.0288 (2) 
C16 0.6394 (2) 0.80924 (16) 1.18787 (12) 0.0280 (3) 
H16A 0.594 (2) 0.7364 (18) 1.2551 (14) 0.028 (4)* 
H16B 0.565 (2) 0.8867 (17) 1.1789 (13) 0.027 (3)* 
H16C 0.775 (2) 0.8673 (19) 1.2087 (15) 0.036 (4)* 
 
Geometric parameters (Å, º) for (mck40) 
C1—C8 1.3593 (17) C9—C10 1.3973 (17) 
C1—O1 1.3830 (14) C9—C14 1.3991 (17) 
C1—C9 1.4589 (16) C10—C11 1.3863 (17) 
O1—C2 1.3725 (14) C10—H10 0.957 (15) 
C2—C7 1.3481 (17) C11—O3 1.3730 (14) 
C2—C3 1.4773 (17) C11—C12 1.3946 (17) 
C3—C4 1.5169 (16) C12—C13 1.3950 (17) 
C3—H3A 0.964 (16) C12—H12 0.934 (14) 
C3—H3B 1.007 (16) C13—O4 1.3696 (14) 
C4—O2 1.2131 (15) C13—C14 1.3894 (17) 
C4—C5 1.5145 (17) C14—H14 0.954 (15) 
C5—C6 1.5430 (17) O3—C15 1.4288 (15) 
C5—H5A 0.949 (15) C15—H15A 0.969 (16) 
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C5—H5B 0.997 (16) C15—H15B 0.985 (16) 
C6—C7 1.5025 (16) C15—H15C 0.959 (17) 
C6—H6A 1.006 (15) O4—C16 1.4339 (15) 
C6—H6B 0.950 (15) C16—H16A 0.965 (15) 
C7—C8 1.4322 (17) C16—H16B 0.980 (14) 
C8—H8 0.984 (15) C16—H16C 1.005 (17) 
    
C8—C1—O1 109.66 (10) C7—C8—H8 127.7 (8) 
C8—C1—C9 134.41 (11) C10—C9—C14 119.95 (11) 
O1—C1—C9 115.91 (10) C10—C9—C1 119.38 (11) 
C2—O1—C1 106.14 (9) C14—C9—C1 120.67 (11) 
C7—C2—O1 111.13 (10) C11—C10—C9 119.50 (11) 
C7—C2—C3 129.13 (11) C11—C10—H10 119.9 (9) 
O1—C2—C3 119.66 (10) C9—C10—H10 120.5 (9) 
C2—C3—C4 108.89 (10) O3—C11—C10 115.34 (10) 
C2—C3—H3A 110.8 (9) O3—C11—C12 123.10 (11) 
C4—C3—H3A 108.4 (9) C10—C11—C12 121.56 (11) 
C2—C3—H3B 110.9 (9) C11—C12—C13 118.11 (11) 
C4—C3—H3B 107.9 (9) C11—C12—H12 119.9 (9) 
H3A—C3—H3B 109.8 (13) C13—C12—H12 122.0 (8) 
O2—C4—C5 122.11 (11) O4—C13—C14 115.40 (11) 
O2—C4—C3 120.54 (11) O4—C13—C12 123.10 (11) 
C5—C4—C3 117.25 (10) C14—C13—C12 121.50 (11) 
C4—C5—C6 116.74 (10) C13—C14—C9 119.36 (11) 
C4—C5—H5A 107.7 (9) C13—C14—H14 118.7 (9) 
C6—C5—H5A 111.8 (9) C9—C14—H14 122.0 (9) 
C4—C5—H5B 104.3 (9) C11—O3—C15 117.95 (9) 
C6—C5—H5B 108.5 (9) O3—C15—H15A 113.0 (9) 
H5A—C5—H5B 107.2 (12) O3—C15—H15B 111.3 (9) 
C7—C6—C5 111.70 (10) H15A—C15—H15B 109.8 (12) 
C7—C6—H6A 109.5 (8) O3—C15—H15C 104.5 (10) 
C5—C6—H6A 109.4 (8) H15A—C15—H15C 108.4 (13) 
C7—C6—H6B 111.0 (8) H15B—C15—H15C 109.6 (13) 
C5—C6—H6B 108.5 (9) C13—O4—C16 117.03 (10) 
H6A—C6—H6B 106.6 (12) O4—C16—H16A 105.6 (9) 
C2—C7—C8 106.09 (10) O4—C16—H16B 110.9 (8) 
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C2—C7—C6 122.43 (11) H16A—C16—H16B 108.6 (12) 
C8—C7—C6 131.33 (11) O4—C16—H16C 110.3 (9) 
C1—C8—C7 106.97 (11) H16A—C16—H16C 110.6 (12) 
C1—C8—H8 125.3 (8) H16B—C16—H16C 110.8 (12) 
    
C8—C1—O1—C2 0.37 (13) C8—C1—C9—C10 0.3 (2) 
C9—C1—O1—C2 -178.38 (10) O1—C1—C9—C10 178.66 (10) 
C1—O1—C2—C7 -0.03 (13) C8—C1—C9—C14 -179.53 (13) 
C1—O1—C2—C3 176.91 (11) O1—C1—C9—C14 -1.18 (17) 
C7—C2—C3—C4 14.46 (19) C14—C9—C10—C11 -0.62 (18) 
O1—C2—C3—C4 -161.85 (10) C1—C9—C10—C11 179.54 (11) 
C2—C3—C4—O2 147.96 (12) C9—C10—C11—O3 -179.58 (11) 
C2—C3—C4—C5 -35.51 (15) C9—C10—C11—C12 0.63 (19) 
O2—C4—C5—C6 -138.11 (13) O3—C11—C12—C13 -179.81 (11) 
C3—C4—C5—C6 45.42 (16) C10—C11—C12—C13 -0.04 (19) 
C4—C5—C6—C7 -28.67 (16) C11—C12—C13—O4 179.47 (11) 
O1—C2—C7—C8 -0.30 (14) C11—C12—C13—C14 -0.57 (19) 
C3—C2—C7—C8 -176.87 (13) O4—C13—C14—C9 -179.46 (11) 
O1—C2—C7—C6 175.72 (10) C12—C13—C14—C9 0.57 (19) 
C3—C2—C7—C6 -0.8 (2) C10—C9—C14—C13 0.03 (18) 
C5—C6—C7—C2 7.35 (17) C1—C9—C14—C13 179.87 (11) 
C5—C6—C7—C8 -177.74 (12) C10—C11—O3—C15 178.45 (11) 
O1—C1—C8—C7 -0.55 (14) C12—C11—O3—C15 -1.77 (18) 
C9—C1—C8—C7 177.88 (13) C14—C13—O4—C16 170.94 (11) 
C2—C7—C8—C1 0.52 (14) C12—C13—O4—C16 -9.10 (18) 
C6—C7—C8—C1 -175.01 (13)   
 
Document origin: publCIF [Westrip, S. P. (2010). J. Apply. Cryst., 43, 920-925]. 
Computing details 
Data collection: CrysAlis PRO 1.171.39.34b (Rigaku OD, 2017); cell refinement: CrysAlis PRO 
1.171.39.34b (Rigaku OD, 2017); data reduction: CrysAlis PRO 1.171.39.34b (Rigaku OD, 2017); 
program(s) used to solve structure: SHELXT 2014/5 (Sheldrick, 2014); program(s) used to refine 
structure: SHELXL2018/1 (Sheldrick, 2018); molecular graphics: Bruker SHELXTL; software used to 
prepare material for publication: Bruker SHELXTL. 
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Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   are estimated 
using the full covariance matrix.  The cell esds are taken   into account individually in the 
estimation of esds in distances, angles   and torsion angles; correlations between esds in cell 
parameters are only   used when they are defined by crystal symmetry.  An approximate 
(isotropic)   treatment of cell esds is used for estimating esds involving l.s. planes. 
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Table 1 
Experimental details 
Crystal data 
Chemical formula C16H16O4 
Mr 272.29 
Crystal system, space group Triclinic, P¯1 
Temperature (K) 100 
a, b, c (Å) 7.48034 (16), 8.57141 (19), 10.4014 (2) 
, ,  (°) 90.8603 (17), 94.6762 (18), 105.8774 (19) 
V (Å3) 638.84 (2) 
Z 2 
Radiation type Cu K 
 (mm-1) 0.83 
Crystal size (mm3) 0.13 × 0.08 × 0.04 
 
Data collection 
Diffractometer Rigaku 007HF equipped with Varimax confocal 
mirrors and an AFC11 goniometer and HyPix 
6000 detector diffractometer. 
Absorption correction Multi-scan CrysAlis PRO 1.171.39.34b (Rigaku 
Oxford Diffraction, 2017) Empirical absorption 
correction using spherical harmonics, 
implemented in SCALE3 ABSPACK scaling 
algorithm. 
Tmin, Tmax 0.806, 1.000 
No. of measured, independent and 
observed [I > 2(I)] reflections 
11720, 2324, 2143  
Rint 0.031 
(sin /)max (Å-1) 0.602 
 
Refinement 
R[F2 > 2(F2)], wR(F2), S 0.032,  0.085,  1.07 
No. of reflections 2324 
No. of parameters 245 
H-atom treatment All H-atom parameters refined 
max, min (e Å-3) 0.22, -0.19 
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Computer programs: CrysAlis PRO 1.171.39.34b (Rigaku OD, 2017), SHELXT 2014/5 (Sheldrick, 
2014), SHELXL2018/1 (Sheldrick, 2018), Bruker SHELXTL. 
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(Z)-4-Hydroxycyclooct-2-en-1-one (344) X-Ray Data  
MCKALS8 Figures & Description. 
Data collected at the ALS synchrotron. Note authors and acknowledgement below. 
Formula. 
C8H12O2. One molecule in the asymmetric unit. 
Disorder & Solvent of Crystallisation. 
No disorder or solvent of crystallisation. 
Packing. 
Molecules pack via strong O(2)–H(2)∙∙∙O(2) H-bonds into spiral chains along the 4-fold c axis 
via the hydroxyl groups. There are also weaker C(3)–H(3)∙∙∙O(1) H-bonds in this direction. See 
tables for H-bond geometry. 
Authors for all publications, posters, etc.: Dr. Mark R.J. Elsegood & Dr. Simon J. Teat. 
ALS Acknowledgement, which MUST be used in all publications, seminars, poster, etc.: 
This research used resources of the Advanced Light Source, which is a DOE Office of Science 
User Facility under contract no. DE-AC02-05CH11231. 
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Crystal data 
C8H12O2 Dx = 1.325 Mg m-3 
Mr = 140.18 Synchrotron radiation,  = 0.7749 Å 
Tetragonal, P41 Cell parameters from 9079 reflections 
a = 11.1057 (7) Å  = 2.8–30.7° 
c = 5.6962 (4) Å  = 0.11 mm-1 
V = 702.55 (10) Å3 T = 100 K 
Z = 4 Needle, colourless 
F(000) = 304 0.30 × 0.01 × 0.01 mm3 
 
Data collection 
Bruker D8 with PHOTON 100 detector  
diffractometer 
1679 independent reflections 
Radiation source: Advanced Light Source 
station 11.3.1 
1603 reflections with I > 2(I) 
Silicon 111 monochromator Rint = 0.051 
Detector resolution: 10.42 pixels mm-1 max = 30.7°, min = 2.0° 
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/ shutterless scans h = -14→14 
Absorption correction: multi-scan  
SADABS v2016/2, Sheldrick, G.M., (2012) 
k = -14→14 
Tmin = 0.967, Tmax = 0.999 l = -7→7 
9782 measured reflections  
 
Refinement 
Refinement on F2 All H-atom parameters refined 
Least-squares matrix: full w = 1/[2(Fo2) + (0.0323P)2 + 0.1154P]   
where P = (Fo2 + 2Fc2)/3 
R[F2 > 2(F2)] = 0.029 (/)max < 0.001 
wR(F2) = 0.069 max = 0.22 e Å-3 
S = 1.06 min = -0.18 e Å-3 
1679 reflections Extinction correction: SHELXL2017/1 
(Sheldrick 2017), 
Fc*=kFc[1+0.001xFc23/sin(2)]-1/4 
140 parameters Extinction coefficient: 0.041 (10) 
1 restraint Absolute structure: Flack x determined using 
689 quotients [(I+)-(I-)]/[(I+)+(I-)] (Parsons, 
Flack and Wagner, Acta Cryst. B69 (2013) 249-
259). 
Primary atom site location: iterative Absolute structure parameter: -0.2 (4) 
Hydrogen site location: difference Fourier map  
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
for (mckals8) 
 x y z Uiso*/Ueq 
O1 0.55573 (10) 0.84379 (10) 0.34622 (19) 0.0124 (3) 
C1 0.61513 (14) 0.73031 (14) 0.3807 (3) 0.0124 (3) 
O2 0.55209 (10) 0.64158 (10) 0.2532 (2) 0.0138 (3) 
H2 0.488 (3) 0.620 (2) 0.326 (6) 0.038 (7)* 
C2 0.60777 (14) 0.71150 (15) 0.6421 (3) 0.0139 (3) 
H2A 0.628 (2) 0.630 (2) 0.709 (4) 0.021 (6)* 
C3 0.57195 (15) 0.81162 (15) 0.7465 (3) 0.0149 (3) 
H3 0.5638 (18) 0.826 (2) 0.907 (5) 0.017 (5)* 
C4 0.56012 (14) 0.90902 (14) 0.5650 (3) 0.0135 (3) 
H4 0.4852 (17) 0.9565 (16) 0.580 (4) 0.010 (4)* 
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C5 0.66936 (15) 0.99339 (15) 0.5667 (3) 0.0169 (4) 
H5A 0.656 (2) 1.056 (2) 0.442 (4) 0.023 (6)* 
H5B 0.6709 (18) 1.0329 (19) 0.716 (4) 0.016 (5)* 
C6 0.78970 (15) 0.92867 (15) 0.5305 (4) 0.0183 (4) 
H6A 0.8516 (17) 0.9922 (18) 0.541 (4) 0.016 (5)* 
H6B 0.804 (2) 0.873 (2) 0.661 (4) 0.022 (6)* 
C7 0.80068 (15) 0.86186 (15) 0.2962 (4) 0.0185 (4) 
H7A 0.765 (2) 0.912 (2) 0.172 (4) 0.019 (6)* 
H7B 0.890 (2) 0.853 (2) 0.253 (5) 0.030 (6)* 
C8 0.74392 (14) 0.73626 (14) 0.2838 (3) 0.0153 (3) 
H8A 0.743 (2) 0.709 (2) 0.114 (5) 0.024 (6)* 
H8B 0.7934 (18) 0.6774 (19) 0.366 (4) 0.016 (5)* 
 
Geometric parameters (Å, º) for (mckals8) 
O1—C1 1.4360 (18) C5—C6 1.531 (2) 
O1—C4 1.442 (2) C5—H5A 1.01 (2) 
C1—O2 1.4103 (19) C5—H5B 0.96 (2) 
C1—C2 1.506 (2) C6—C7 1.532 (3) 
C1—C8 1.535 (2) C6—H6A 0.99 (2) 
O2—H2 0.86 (3) C6—H6B 0.98 (2) 
C2—C3 1.322 (2) C7—C8 1.532 (2) 
C2—H2A 1.01 (2) C7—H7A 0.98 (2) 
C3—C4 1.502 (2) C7—H7B 1.03 (2) 
C3—H3 0.93 (3) C8—H8A 1.01 (3) 
C4—C5 1.533 (2) C8—H8B 0.97 (2) 
C4—H4 0.989 (19)   
    
C1—O1—C4 107.89 (12) C4—C5—H5A 107.8 (13) 
O2—C1—O1 108.34 (12) C6—C5—H5B 108.6 (12) 
O2—C1—C2 112.67 (13) C4—C5—H5B 107.5 (13) 
O1—C1—C2 103.42 (13) H5A—C5—H5B 108.2 (17) 
O2—C1—C8 107.91 (13) C5—C6—C7 114.46 (14) 
O1—C1—C8 109.95 (13) C5—C6—H6A 105.3 (11) 
C2—C1—C8 114.35 (14) C7—C6—H6A 110.0 (13) 
C1—O2—H2 111.1 (19) C5—C6—H6B 109.3 (14) 
C3—C2—C1 110.15 (15) C7—C6—H6B 110.2 (13) 
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C3—C2—H2A 131.0 (13) H6A—C6—H6B 107 (2) 
C1—C2—H2A 118.9 (13) C6—C7—C8 116.63 (15) 
C2—C3—C4 108.79 (16) C6—C7—H7A 108.6 (13) 
C2—C3—H3 127.6 (14) C8—C7—H7A 108.6 (13) 
C4—C3—H3 123.2 (14) C6—C7—H7B 109.4 (15) 
O1—C4—C3 103.66 (13) C8—C7—H7B 107.3 (13) 
O1—C4—C5 109.85 (13) H7A—C7—H7B 105.8 (19) 
C3—C4—C5 111.49 (14) C7—C8—C1 113.95 (13) 
O1—C4—H4 108.4 (12) C7—C8—H8A 108.7 (13) 
C3—C4—H4 113.3 (12) C1—C8—H8A 108.9 (13) 
C5—C4—H4 109.9 (10) C7—C8—H8B 110.9 (12) 
C6—C5—C4 113.76 (13) C1—C8—H8B 109.0 (13) 
C6—C5—H5A 110.8 (13) H8A—C8—H8B 105 (2) 
    
C4—O1—C1—O2 142.45 (13) C2—C3—C4—C5 -100.52 (17) 
C4—O1—C1—C2 22.68 (16) O1—C4—C5—C6 -57.75 (19) 
C4—O1—C1—C8 -99.85 (15) C3—C4—C5—C6 56.57 (19) 
O2—C1—C2—C3 -128.32 (15) C4—C5—C6—C7 60.9 (2) 
O1—C1—C2—C3 -11.56 (18) C5—C6—C7—C8 -82.15 (19) 
C8—C1—C2—C3 107.98 (16) C6—C7—C8—C1 47.8 (2) 
C1—C2—C3—C4 -3.76 (19) O2—C1—C8—C7 148.22 (14) 
C1—O1—C4—C3 -24.90 (15) O1—C1—C8—C7 30.2 (2) 
C1—O1—C4—C5 94.33 (14) C2—C1—C8—C7 -85.57 (18) 
C2—C3—C4—O1 17.58 (17)   
 
Hydrogen-bond geometry (Å, º) for (mckals8) 
 D—H···A D—H H···A D···A D—H···A 
O2—H2···O2i 0.86 (3) 1.91 (3) 2.7644 (14) 172 (3) 
C2—H2A···O2ii 1.01 (2) 2.63 (2) 3.597 (2) 160.4 (18) 
C3—H3···O1iii 0.93 (3) 2.51 (3) 3.439 (2) 174.0 (19) 
 
Symmetry codes:  (i) -y+1, x, z+1/4;  (ii) y, -x+1, z+3/4;  (iii) x, y, z+1. 
Document origin: publCIF [Westrip, S. P. (2010). J. Apply. Cryst., 43, 920-925]. 
Computing details 
Data collection: Bruker APEX 2; cell refinement: Bruker SAINT v8.38a; data reduction: Bruker SAINT 
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v8.38a; program(s) used to solve structure: SHELXT 2014/5 (Sheldrick, 2014); program(s) used to refine 
structure: SHELXL2017/1 (Sheldrick, 2017); molecular graphics: Bruker SHELXTL; software used to 
prepare material for publication: Bruker SHELXTL. 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   are estimated 
using the full covariance matrix.  The cell esds are taken   into account individually in the 
estimation of esds in distances, angles   and torsion angles; correlations between esds in cell 
parameters are only   used when they are defined by crystal symmetry.  An approximate 
(isotropic)   treatment of cell esds is used for estimating esds involving l.s. planes. 
 
Table 1 
Experimental details 
Crystal data 
Chemical formula C8H12O2 
Mr 140.18 
Crystal system, space group Tetragonal, P41 
Temperature (K) 100 
a, c (Å) 11.1057 (7),  5.6962 (4) 
V (Å3) 702.55 (10) 
Z 4 
Radiation type Synchrotron,  = 0.7749 Å 
 (mm-1) 0.11 
Crystal size (mm3) 0.30 × 0.01 × 0.01 
 
Data collection 
Diffractometer Bruker D8 with PHOTON 100 detector  
diffractometer 
Absorption correction Multi-scan  
SADABS v2016/2, Sheldrick, G.M., (2012) 
Tmin, Tmax 0.967, 0.999 
No. of measured, independent and 
observed [I > 2(I)] reflections 
9782, 1679, 1603   
Rint 0.051 
(sin /)max (Å-1) 0.658 
 
Refinement 
R[F2 > 2(F2)], wR(F2), S 0.029,  0.069,  1.06 
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No. of reflections 1679 
No. of parameters 140 
No. of restraints 1 
H-atom treatment All H-atom parameters refined 
max, min (e Å-3) 0.22, -0.18 
Absolute structure Flack x determined using 689 quotients [(I+)-(I-
)]/[(I+)+(I-)] (Parsons, Flack and Wagner, Acta 
Cryst. B69 (2013) 249-259). 
Absolute structure parameter -0.2 (4) 
 
Computer programs: Bruker APEX 2, Bruker SAINT v8.38a, SHELXT 2014/5 (Sheldrick, 2014), 
SHELXL2017/1 (Sheldrick, 2017), Bruker SHELXTL. 
Table 2 
Hydrogen-bond geometry (Å, º) for (mckals8) 
 D—H···A D—H H···A D···A D—H···A 
O2—H2···O2i 0.86 (3) 1.91 (3) 2.7644 (14) 172 (3) 
C2—H2A···O2ii 1.01 (2) 2.63 (2) 3.597 (2) 160.4 (18) 
C3—H3···O1iii 0.93 (3) 2.51 (3) 3.439 (2) 174.0 (19) 
 
Symmetry codes:  (i) -y+1, x, z+1/4;  (ii) y, -x+1, z+3/4;  (iii) x, y, z+1. 
 
